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Abstract 
Background 
The 7-valent pneumococcal conjugate vaccine (PCV7) was introduced routinely in the 
UK in September 2006 and replaced by PCV13 from April 2010. 
Aims 
To evaluate the impact of PCV7 on the incidence of all-cause community-acquired 
pneumonia (CAP) in children. Also to investigate the aetiology of CAP before and after 
the introduction of PCV as well as serotype the pneumococcal infections. 
Methods 
Enrolled children were from North East England (excluding Cumbria) who were aged 
0–16 years and presented with clinical and radiological features suggestive of 
pneumonia. Epidemiology survey was prospectively undertaken in 2008–2009 at 11 
hospitals in North East England. Data were compared to those from a similar survey 
undertaken in the same hospitals in 2001–2002. Aetiology studies were prospectively 
conducted in 2001–2002 (pre-vaccine) and 2009–2011 (post-vaccine) in Newcastle and 
Middlesbrough. Investigations included culture, serology, immunofluorescence 
antibody, urinary pneumococcal antigen and PCR assays.   
Epidemiology Results 
A total of 542 children were enrolled, of which 74% were aged <5 years. PCV7 uptake 
was 90.7%. The annual incidence of pneumonia was 11.8/10 000 (95% CI 10.9–12.9), 
and the hospitalisation rate was 9.9/10 000 (95% CI 9.0–10.9). Compared to 2001, there 
was a 19% (95% CI 8–29) reduction in the annual rate of CAP in those aged <5 years, 
and in those <2 years a 33.1% (95% CI 20–45) reduction in the annual incidence of 
 xvi 
 
CAP and 38.1% (95% CI 24–50) reduction in hospitalisation rates. However, for those 
unvaccinated aged ≥5 years, there was no difference in the annual incidence of CAP and 
hospitalisation rate between both surveys. Since 2001, the overall reduction in annual 
incidence was 17.7% (95% CI 8–26) and for hospitalisation 18.5% (95% CI 8–28). 
Aetiology Results 
A total of 401 children were enrolled; 241 and 160 respectively in the pre- and post-
vaccine studies (73% aged <5 years), for whom at least one diagnostic investigation had 
been performed. Identification of a definite pathogen was higher post-vaccine (61%) 
than pre-vaccine (48.5%) [p=0.019]. Rates of bacterial infections were not different 
between post- and pre-vaccine (17.5% versus 24%, p=0.258). Viral (31%) and mixed 
infections (12.5%) found more often post-vaccine than pre-vaccine (19.5% [p=0.021] 
and 5% [p=0.015] respectively). Pneumococcal detection post-vaccine was substantially 
improved when PCR assays were used compared to culture (21.6% versus 6%, 
p=0.0004). A serotype was identified in 75% (18/24) post-vaccine including serotypes 1 
(44.4%), 3 (27.8%), 19A (22.2%) and 7A/F (5.6%). 
Conclusions 
PCV7 has reduced both the annual incidence and rate of hospitalisation of pneumonia in 
children, particularly those aged <2 years. Pneumococcal serotypes which are included 
in PCV13 but not PCV7 predominated. This suggests that the replacement with PCV13 
likely to be associated with a reduction in the incidence of pneumococcal-related 
pneumonia. Continued surveillance is required to monitor for emerging serotypes. 
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Chapter 1 Introduction            
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1.1 Outline of the thesis 
The thesis contains eight chapters that cover three themes on community-acquired 
pneumonia in children following the introduction of the national pneumococcal 
conjugate vaccination programme with PCV7 in 2006 which was replaced by PCV13 in 
2010. Data were compared with findings from similar study undertaken in the North 
East of England in 2001–2002. Themes include the epidemiology and aetiology of 
pneumonia and the issues surrounding the radiological diagnosis of pneumonia. 
Appendices provide information on the ethical approvals, standard study questionnaire 
used for data collection including all variables and outcomes, study information sheets 
for parents and age-appropriate for children with consent and assent forms, and list and 
copies of publications that were generated from this research as well as presentations of 
data at scientific meetings.  
 
With the use of literature review in chapter one and study methods in chapters two, all 
chapters were written for publications and manuscripts are either published, being in 
press or under peer review as outlined below: 
1. Chapter one covers the literature review on the epidemiology and aetiology of 
pneumonia in children during the era of pneumococcal conjugate vaccination 
programme and also brings in the discussion the implementation of national 
management recommendations of childhood pneumonia from the British 
Thoracic Society which were published during the period between the two 
studies in 2002. It also discusses the increasing role of PCR-based assays in 
establishing the causes of pneumonia. Another important section discusses the 
application and limitations of WHO criteria to diagnose pneumonia in children 
and the recognised continuing inter-observer variability in the interpretation of 
chest radiographs. It includes the study hypotheses and aims. 
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2. Chapter two outlines the study methods for the epidemiology survey, aetiology 
and radiological studies. It covers the study designs and populations, processes 
of data collection and validation, laboratory procedures including the steps I 
followed to develop a sequential multiplex pneumococcal serotype-specific 
PCR locally for the purpose of the aetiology study. 
3. Chapter three presents and discusses the results of the epidemiology survey 
which were compared with data from 2001–2002 survey in terms of annual 
disease incidence rates, hospitalisation rates and risk factors for the 
development of severe pneumonia. The findings suggest that PCV7 from this 
prospective survey outside the trial settings was effective in reducing both the 
annual incidence of childhood pneumonia seen in hospital and annual rates of 
hospitalisation in one population within the UK when compared with 
randomised trials evaluated the impact of pneumococcal conjugate vaccination 
on the incidence of pneumonia. 
 Published in Epidemiology and Infection 
4. Chapter four presents and discusses data on the clinical presenting features and 
management of pneumonia in children seen in hospital. This survey completes 
the audit cycle started with a similar prior to the publication of the national 
management guidelines of childhood pneumonia. The findings showed that 
there has been a positive change in the management practices of childhood 
pneumonia reflected by reduced number of overall investigations performed 
and an increased preference for oral antibiotic use. 
 In peer review with Journal of Evaluation in Clinical Practice  
5. Chapter five presents and discusses the results of the first study to describe the 
aetiology of pneumonia in UK children prior to and following the introduction 
of the pneumococcal conjugate vaccination programme. The findings showed 
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that although viruses are the most common cause of pneumonia, around one 
fifth of children had bacterial infections. The combined use of culture, serology 
and PCR-based diagnostic tests significantly improved the identification of 
causative pathogens in childhood pneumonia.  
 Published in European Respiratory Journal 
6. Chapter six presents and discusses the results of diagnostic approaches to 
pneumococcal infections and provides the first information on serotype 
distribution of pneumococcal CAP in UK children after the introduction of the 
pneumococcal conjugate vaccination programme. The findings showed that 
non-PCV7 but PCV13 serotypes were the major contributor to the aetiology of 
pneumococcal pneumonia in UK children. Therefore continued surveillance is 
required to monitor for the emergence of serotype replacement. 
 Published in Diagnostic Microbiology and Infectious Disease 
7. Chapter seven presents and discusses the substantially observed inter-observer 
variability in the interpretation of chest radiographs for the diagnosis of 
paediatric pneumonia. These findings add to the recognized variability in the 
literature demonstrating that there may be a need for evaluation of the WHO 
categorization of radiological pneumonia in children to improve the validity 
and encourage widespread adoption of the criteria. 
 In peer review with Pediatric Pulmonology 
8. Chapter eight summarises the overall study outcomes, strengths and limitations 
and conclusions. It also highlights the impacts of this research and areas for 
future studies.     
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1.2 Epidemiology of childhood pneumonia 
Community-acquired pneumonia (CAP) is a common childhood infection and an 
important cause for hospital admission.[1-3] The course of illness has a variable 
severity ranging from mild to severe, and can be complicated by systemic disease and 
death.[4-6] It is a major public health problem and causes approximately 20% (two 
million) of annual global childhood morbidity and mortality mostly among those aged 
under five years, of which 70% occurs in resource limited countries.[7-10] The range of 
implicated pathogens is wide and includes viruses, bacteria or co-infection with 
both.[11-15] Different laboratory diagnostic techniques with an increasing application 
of PCR-based assays over the last decade are used to establish the aetiology of CAP in 
children.[16-18] Laboratory diagnostic approaches carry variable sensitivity and 
specificity.[19, 20] Causative pathogens in young children are predominately viruses or 
co-infection with bacteria compared to older children over five years where bacterial 
pathogens are more common.[16, 21] All of these factors could relate to potential 
causative pathogens for different age groups, hence variable disease incidence rates of 
CAP.[22-26]     
 
Streptococcus pneumoniae is thought to be the leading bacterial cause of pneumonia 
among young children.[27] In the UK, pneumococcal infection was identified in nearly 
10% of CAP in children,[28, 29] compared to 15.5% from a previous local aetiological 
study in the North East of England. Studies in the USA and Finland suggested that 
among children aged under two years, S. pneumoniae causes up to 45% of pneumonia 
seen in hospital.[11, 12, 30] This is likely to be an underestimation of the true burden of 
pneumococcal disease, given the relative imprecision of microbiological diagnosis of 
pneumonia in children.[1] It has been estimated that the annual incidence of childhood 
CAP in Europe is 2.5 million.[31] Studies of incidence and mortality of CAP before the 
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era of the 7-valent pneumococcal conjugate vaccine (PCV7) estimated a variable annual 
incidence of approximately 40/1000 for children under five years of age, and 15/1000 
for those aged 5–14 years.[5, 32, 33]  This variation in incidence rates of all-cause 
pneumonia has been related to age, causative pathogens including viruses and bacteria, 
severity assessment, admission criteria and referral pathways, clinical and radiological 
definitions of pneumonia, and seasonal and geographical changes.[1, 2, 11, 34-44] The 
observed variable annual incidence rates of overall IPD across the world likely reflect 
poor case ascertainment and may be underestimated.[1, 2, 4, 35, 45-47] This is because 
the diagnosis is usually made by culturing of clinical biological samples, which needs 
the presence of viable pathogens.[48-50]  
 
Pneumococcal serotype surveillance is monitored by serological capsular identification 
of clinical isolates after culture.[51, 52] The recovery rate of S. pneumoniae from 
culturing of blood and pleural fluids is approximately 10%.[53, 54] Sensitive and 
specific serotype monitoring require a wide range of sera to cover the prevailing 
types.[46] This technique has cost implications and can be limited by inconclusive 
results due to the occurrence of auto-agglutination.[55] Therefore in developed 
countries usually typing is limited to the serotypes contained in the 23-valent 
pneumococcal polysaccharide vaccine.[56] Vergison and colleagues actively surveyed 
98.5% of paediatric units in Belgium to prospectively establish the annual incidence of 
IPD in children aged under five years to investigate the problem of underestimation of 
the disease burden.[46] They showed a twofold increase in the incidence of IPD (59.5 
cases per 10 000 children per year) between 2002 and 2003 when compared with 
previous passive epidemiologic surveillance. Variations in the adapted epidemiologic 
surveillance methods in terms of logistic and laboratory approaches as well as lack of 
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use culture-negative techniques in resource limited countries contribute considerably in 
the differences in annual incidence rates of overall IPD.[4, 35, 46, 50] 
 
Identifying the aetiology of CAP in children is challenging with a large number of 
potential pathogens, some of which may also be carried as commensal organisms, which 
can complicate the interpretation of the results of testing nasopharyngeal samples.[57] 
Conventional methods such as blood culture and serology often have limited sensitivity 
due to inadequate sample volume or lack of convalescent sera.[1] Molecular diagnostics 
are now routinely used in the assessment of viral respiratory infections and similar 
techniques have been developed for the detection of bacterial respiratory infections.[17, 
20] Resti and colleagues demonstrated a significant improvement in the identification of 
pneumococcal pneumonia in children by PCR on blood samples (15.4%) when applied 
simultaneously with blood culture (3.8%).[18] In a recent study of Italian children aged 
under five years, overall bacteremic pneumococcal pneumonia was identified in 14.3%, 
which was established by PCR in 92%, blood culture 1% and both in 7%.[58]     
 
The annual incidence of childhood CAP seen in hospitals in the North East of England 
was evaluated prospectively in 2001–2002.[59] At that time the annual incidence of 
childhood pneumonia was 14.4/10 000 (95% CI 13.4–15.4) and 33.8/10 000 (95% CI 
31.1–36.7) for those aged under five years.[59] The annual incidence of pneumonia was 
higher in boys and children aged under five years with a ratio of 1.3 and 4 respectively. 
There was a positive association between the severity of illness and young age (under 
five years old) and prematurity (24–28 weeks gestation). Although there was variation 
in the incidence by county of residence,[59] it was not possible to ascertain the actual 
reasons behind this.[11, 34] An extensive work by the WHO with accumulating 
evidence over the years from different continents showed that the risk factors for 
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development of acute lower respiratory infections in children particularly those aged 
under five years either related to host or environment.[4, 8, 60-64] These include a 
likely risk factors such as poor nutritional status, low birth weight (<2.5 kg), suboptimal 
breast feeding during the first half year of life, inadequate immunisation, household 
crowding, air pollution and parental smoking, low socioeconomic status, zinc 
deficiency, young mother’s age, and presence of comorbidity and other infections.[4, 
65-75] Other potential factors include attendance at day-care centres, nasopharyngeal 
carriage of viruses and bacteria, low maternal education, vitamin A deficiency, and cold 
and humid weather as well as environmental pollution.[4, 76]  
 
In the USA, PCV7 was licensed for use in February 2000, and in February 2001 in the 
European Union for active immunisation of children for prevention of invasive 
pneumococcal disease (IPD).[77] The introduction of PCV7 against S. pneumoniae, 
which is highly effective against invasive bacteraemia and meningitis in young children, 
was found to decrease the annual incidence of lobar pneumonia by up to 35% in the 
USA and Canada.[78, 79] It has been associated with a considerable reduction in 
IPD,[80-86] and vaccine serotype pneumococcal nasopharyngeal carriage in 
children.[87] Among young children aged under two years, IPD caused by vaccine and 
non-vaccine-related serotypes significantly reduced by approximately 80% and 50% 
respectively.[80] There has been also significant reduction of IPD in the non-vaccinated 
population resulting from herd immunity (accurately herd effect).[88-91] The term 
‘herd immunity’ means the proportion of immunised individuals in a given population, 
whereas indirect protection 'herd effect' refers to the reduction in the incidence of 
infection in the unimmunised individuals due to the presence of immunised part of the 
community.[92-94] 
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However, there has been a substantial global increase in childhood empyema thoracis 
over the last 15 years particularly between 2000 and 2005 compared with the previous 
data.[95-101] Pneumococcal, staphylococcal and group A streptococcal infections are 
being the common bacterial causative pathogens of empyema in children.[102-107] A 
worldwide rising trend in empyema thoracis due to pneumococcal pneumonia, typically 
following infection with S. pneumoniae serotype 1 has been reported.[102, 108, 109] 
PCV7 does not contain antigen against this serotype, and there is some evidence from 
the USA that the introduction of this vaccine into the routine immunisation schedule 
was associated with emergence of empyema related to other non-vaccine pneumococcal 
serotypes, particularly 1, 19A, 3, 6A and 7F.[86, 96, 108]  
 
There is much interest in exploring the increase in empyema thoracis which has been 
observed in the recent years.[110] The incidence of empyema has increased rapidly in 
the UK over the last decade, and it is known from PCR and serotype-specific ELISA 
studies that this mostly related to infection with S. pneumoniae serotype 1.[102, 111] 
Rees and colleagues first reported a sevenfold increase in the number of cases of 
empyema managed at the regional respiratory unit for the West Midlands in the UK 
between 1995/1996 compared with the previous three years.[112] In England, annual 
admission rates for empyema in children aged under 15 years from 14 per million 
population in 1995/1996 to 26 per million in 2002/2003 (p=0.003), and 14 per million 
to 46 per million (p<0.001) among those aged under five years over the same 
period.[113] Similarly, study of Scottish children aged under 15 years showed that 
annual admission rates of empyema increased from <10 per million population in 1998 
to 37 per million in 2005.[114] This increase was more among those aged under five 
years, from 6.5 per million annually between 1981 and 1998 to 66 per million in 2005. 
Instead overall annual admission rates for pneumonia remained unchanged among those 
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aged under five years where gradually rose by an average of 50 per million annually 
between 1981 and 2005.[114] Using HES data, Koshy and colleagues recently reported 
a 22% decrease between 2006 and 2008 in admissions of empyema in children after the 
routine introduction of PCV7 in England.[115] Whereas in England and Wales,[116] 
IPD caused by PCV7 serotypes was reduced by 98% in children aged under two years 
between 2000–2006 period and 2009/2010. On the other hand non-PCV7 serotypes IPD 
increased by 68%, giving an overall reduction in IPD of 56% in this age group.[116] 
 
Most invasive pneumococcal infection is thought to arise as a consequence of previous 
colonisation of the nasopharynx.[117-119] S. pneumoniae serotype 1 does not normally 
colonise the nasopharynx, and the mechanism by which the organism is transmitted 
between individuals and the subsequent pathogenesis of invasive infection is 
uncertain.[118, 120, 121] It is unclear whether the reported increase in the annual 
incidence of empyema is a reflection of an increase in the percentage of cases of 
pneumonia which are due to pneumococcal serotype 1, or whether there has been an 
increase in the relative number of patients with pneumonia progressing to 
empyema.[110] In a recent small school outbreak of pneumococcal serotype 1 
pneumonia, one adult was found to have a positive nasopharyngeal culture with this 
organism raising the possible theoretical hypothesis that adult to child transmission may 
be an important factor.[122] 
 
In September 2006, PCV7 including antigen for serotypes 4, 6B, 9V, 14, 18C, 19F, and 
23F was added routinely to the UK immunisation programme.[123, 124] The vaccine 
schedule is three doses administered at 2, 4 and 13 months of age. When introduced, 
those over and under one year of age received one and two doses respectively as part of 
a catch up programme for children aged under two years. Subsequently this was 
 11 
 
replaced by PCV13 from April 2010, which also includes antigen for the additional 
serotypes 1, 3, 5, 6A, 7F, and 19A.[125] Previous studies in the UK anticipated that the 
vaccine coverage for the included serotypes to be approximately 76%.[126, 127] Based 
on estimates of serotype coverage, and vaccine efficacy and uptake, the potential 
reduction in IPD among children aged under five years is approximately 67% with a 
predicted vaccine uptake to reach 90% in those aged one year.[127] Vaccine coverage is 
a complex process and requires combined strategies such as improvement in 
socioeconomic and nutritional status and education of people in poor communities to 
achieve better availability and affordability with sustainable delivery and uptake of the 
immunisation programme.[128-132] These measures in return facilitate making it cost-
effective intervention.[133-135]  
 
Following the introduction of PCV7 routinely in most of European countries, there was 
a substantial reduction in the incidence of overall IPD caused by PCV7 serotypes,[136] 
but associated with counter increase of IPD related to serotypes included in PCV13; 1, 
19A, 3, 6A, and 7F.[86, 137] In England and Wales, non-PCV7 serotypes are now 
associated with IPD [116] and an increase in pneumococcal serotype 19A is associated 
with complicated pneumonia with empyema.[138] The observed increase in detection of 
pneumococci in this study is presumably related to both improved molecular techniques 
and continued pneumococcal disease due to replacement with non-PCV7 serotypes. 
Similar findings were reported from the USA on children with empyema, where 98% 
were non-PCV7 serotypes.[108] Gorton and colleagues showed a 90% (95% CI 61–99) 
reduction of IPD caused by PCV7 serotypes in children aged under five years in the 
North East of England between 2006/2007 and 2009/2010.[139] They also showed a 
non-significant increase in IPD caused by non-PCV7 serotypes in this age group of 88% 
(95% CI -10 to 312) which was mainly caused by serotypes 7F, 19A and 22F.[139] This 
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suggests that PCV13 could substantially reduce IPD.[125, 140] Recent data following 
the introduction of PCV13 in the USA showed that there were marginal increase in IPD 
caused by non-PCV13 serotypes; 33F, 22F, 12, 15B, 15C, 23A and 11.[141] 
 
The efficacy of pneumococcal conjugate vaccines in preventing radiological pneumonia 
has been shown to be up to 37% in randomized controlled trials.[142-146] Koshy and 
colleagues reported a 19% reduction in both annual incidence of childhood pneumonia 
and hospitalisation rate in England between 2006 and 2008 by using hospital episodes 
statistics (HES) data.[115] There was a 13% reduction in the annual rate of 
hospitalisation in the under five age group following the introduction of PCV7 in 
Canada.[79] Estimates from other studies of PCV11 in the Philippines [147] and PCV7 
in the USA [144] reported decreases in the annual incidence of all-cause pneumonia by 
approximately 22%. This is compared to 25% reduction against radiological pneumonia 
reported in a randomized controlled trial of PCV9 in South Africa [142] and 30% in the 
USA [148]. This may be a reflection of the differences in pneumococcal disease 
between populations.[50, 149] Furthermore, variable vaccine efficacies between these 
trials might be related to different valency of the vaccines used, variations in disease 
incidence rates between countries and pneumococcal serotype distribution, missed to 
follow up of some enrolled cases, definitions of radiological pneumonia and primary 
outcomes, presence of other chronic diseases and concurrent acute infections such as 
human immunodeficiency virus (HIV), tuberculosis, measles and gastroenteritis, and 
poor socioeconomic and nutritional status.[4, 35, 145, 146] 
 
Studies and randomised-controlled trials of the pneumococcal conjugate vaccine used 
the same WHO criteria for radiological classification of pneumonia in children in 
epidemiological studies which are applied in the present research.[150, 151] These trials 
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are individually summarised here. Immunisation with PCV7 of American Indian 
children aged under two years in a setting with high rates of IPD in the Navajo and 
White Mountain Apache Indian reservations, the vaccine efficacy was 76.8% in 
reducing the disease incidence.[152] In the USA, PCV7 was given to infants at 2, 4, 6 
and 12 to 15 months of age.[144] It was found to be more effective in reducing 
pneumonia in children aged under a year (32.2%) than that of 23.4% and 9.1% among 
those aged under or over two years respectively.[144] Three doses of PCV9 were given 
to infants aged 6–51 weeks at an interval of 25 days between doses in the Gambian 
trial.[143] The vaccine demonstrated an efficacy of 37% and 7% against first episode of 
radiological and clinical pneumonia respectively. It also had 77% VE against IPD 
caused by PCV7 serotypes.[143] Infants in South Africa were immunised in the PCV9 
trial with doses given at 6, 10, and 14 weeks of age.[142] It resulted in VE of 83% in 
reducing first episode IPD among those without HIV infection compared to 65% among 
those with HIV infection. Among children without HIV infection, the VE was 20% 
against the incidence of first episodes of radiological pneumonia.[142] In a trial of 
PCV11 in The Philippines, three doses were given at four weeks apart for infants aged 
between six weeks and six months.[147] It had 22.9% (p=0.06) VE against radiological 
pneumonia for children aged 3 to 23 months old, whereas subgroup analysis showed VE 
of 34% (p=0.02) and 2.7% (p=0.88) for those aged 3 to 11 months and 12 to 23 months 
old respectively. There was no significant VE against clinical pneumonia (p=0.99).[147] 
 
Interestingly, the major reduction in pneumonia admissions was observed in those aged 
under two years by approximately 40% in the USA,[153, 154] but lesser (15%) during 
the PCV9 trial in the Gambia.[143] A decrease in the admission rate among those aged 
2–4 years was observed in 17%.[153] There was marked reduction in the disease 
incidence in the under two age group of up to 37% from the pneumococcal conjugate 
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vaccination trials and pooled review data.[143, 145, 146] However, prospective 
epidemiological studies are valuable in establishing the impact of vaccines in 
populations’ outside trial settings.[155, 156] Furthermore, childhood CAP is a frequent 
cause of admission to hospital.[1, 6] Clinical features of pneumonia are often non-
specific in young children.[157, 158] Management decisions are generally based on a 
combination of clinical signs, symptoms and radiological changes.[157, 159] The 
clinical features and management outcomes of pneumonia in children were previously 
described in a survey conducted in hospitals in the North East of England in 2001–
2002.[157] National UK clinical guidelines for childhood CAP were published in 2002 
[160] and updated in 2011 [1]. They synthesized evidence and expert opinion to 
produce best practice national standards, which included statements on investigations 
and antibiotics use as outlined below:[160]  
1. Blood cultures should be performed in all children suspected of having bacterial 
pneumonia. 
2. Nasopharyngeal aspirates from all children under the age of 18 months should 
be sent for viral antigen detection with or without viral culture. 
3. Acute phase reactants should not be measured routinely. 
4. Amoxicillin is first choice for oral antibiotic therapy in children under the age of 
five years and macrolide antibiotics may be used as first line empirical treatment 
in children aged five and above. 
5. Antibiotics administered orally are safe and effective for children presenting 
with CAP. 
6. Intravenous antibiotics should be used in the treatment of pneumonia in children 
when the child is unable to absorb oral antibiotics (for example, because of 
vomiting) or presents with severe signs and symptoms. 
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7. Appropriate intravenous antibiotics for severe pneumonia include Co-amoxiclav, 
Cefuroxime, and Cefotaxime. 
8. If clinical or microbiological data suggest that S. pneumoniae is the causative 
organism, Amoxicillin, Ampicillin, or Penicillin alone may be used. 
 
Evidence for the safety and efficacy of oral antibiotics even in severe pneumonia in 
children accumulated over the six years period between surveys, including a Cochrane 
review in 2006 [161] and the PIVOT trial in 2007 [162]. Recent review of data sets 
from four studies of the management outcomes of severe pneumonia in children aged 
under three years in the community was associated with few complications, supporting 
the management of such cases with oral antibiotics in primary care settings.[163] 
Antibiotic stewardship programs and management guidelines have been shown to 
improve the selection of appropriate investigations and antibiotics for management of 
infections in children.[164-167] These measures allow better use of health resources and 
reduction of antibiotic drug resistance which are becoming global challenges.[168-173]   
 
Therefore the initiatives of pneumococcal conjugate vaccination programme and BTS 
management guidelines of pneumonia mean that now is an ideal time to review the 
incidence, epidemiology and management of pneumonia presenting to hospital using the 
only population in the UK where this has previously been established, in order to 
explore the impact of PCV7 on the prevention of all-cause pneumonia the influence of 
the national guidelines on management of CAP in children. Such data are essential for 
plans for future public health preventative strategies and newer vaccine generation.   
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1.3 Aetiology of childhood pneumonia 
The range of implicated pathogens is wide and includes viruses, bacteria or co-infection 
with both.[6, 174] S. pneumoniae is the leading bacterial cause of this infection 
particularly in resource limited countries.[4] Pathogens can be difficult to identify in 
children with pneumonia.[1, 2] Studies of pneumonia frequently report low levels of 
pathogen identification although improved knowledge of pneumonia aetiology is 
essential for development of targeted management and effective public health strategies 
and assessment of interventions such as vaccination.[1, 175] Depending on the 
diagnostic methods adopted, causative pathogens can be identified in 40–85% of 
childhood CAP.[11-13, 15, 176-178] Bacterial pathogens are identified in 
approximately 50%, where as viral and mixed viral-bacterial infections are implicated 
respectively in up to two-thirds and a third of CAP in children.[11, 13, 15]  
 
The three previous UK studies investigating the aetiology of pneumonia in children 
prior to the introduction of the conjugate pneumococcal vaccination were able to 
identify the aetiology of pneumonia in between 24% and 54% of cases.[28, 29, 176] 
One tested blood for S. pneumoniae, Mycoplasma and Chlamydophila using PCR and 
identified 8% of children with pneumococcal pneumonia.[28] Another study identified 
6% pneumococcal infection using pneumolysin ELISA on blood.[29] However, none of 
these studies investigated bacterial aetiology or evaluated the serotypes involved in 
pneumococcal pneumonia in a comprehensive manner or evaluated the serotypes 
involved in pneumococcal pneumonia.  
 
S. pneumonia causes a range of life-threatening diseases including pneumonia, 
septicaemia and meningitis which lead to a substantial global childhood morbidity and 
mortality.[7, 149, 179] It is a gram positive bacterium normally colonised in the 
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nasopharynx.[180] The polysaccharide capsule forms the main virulent antiphagocytic 
component, and is the target of serotype-specific vaccines for prevention of invasive 
pneumococcal disease.[181] Immunochemistry of the capsular serotype facilitated the 
identification of 91 serotypes and classification of immunologically similar serotypes 
into 46 serogroups.[51, 180, 182] Data before the era of PCV7 showed that most of IPD 
is caused by approximately 15 common serotypes with a relative large geographical 
variation worldwide.[110, 149, 183] In Europe the commonly prevalent serogroups 
among young children ranked in decreasing order include: 14, 6, 19, 18, 23, 9, 1, 7, 4, 5, 
3, 24, 15, 33 and 10,[149] whereas in Britain particularly serotypes 14, 6 (B/A), 19 
(F/A), 18 (C/B/A/F), 23 (F/A/B), 9 (V/N/A), 7 (F/A), 4, 5 and 3 are responsible for the 
majority of IPD.[126, 149, 184] Since the introduction of PCV7 in Europe, there has 
been a decrease in annual incidence of IPD, antibiotics resistance and vaccine 
serotypes.[86] But worryingly a replacement with new prevailing non-vaccine serotypes 
has been observed including 1, 19A, 3, 6A, and 7F.[86, 116, 138] 
  
The observed variable annual incidence of IPD across the world likely reflects poor 
ascertainment and may be underestimated.[45] This is because the diagnosis is usually 
made by culturing of clinical biological samples, which needs the presence of viable 
pathogens.[48] Serotype surveillance is monitored by serological capsular identification 
of clinical isolates after culture.[51, 52] The recovery rate of S. pneumoniae from 
culturing of blood and pleural fluids is approximately 10%.[53, 54] Sensitive and 
specific serotype monitoring require a wide range of sera to cover the prevailing types. 
This technique has cost implications and sometimes constrained by inconclusive results 
due to the occurrence of auto-agglutination.[55] Therefore, in developed countries 
usually typing is limited to the serotypes contained in the 23-valent pneumococcal 
polysaccharide vaccine.[56]  
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Identifying the aetiology of CAP in children is challenging with a large number of 
potential pathogens, some of which may also be carried as commensal organisms, which 
can complicate the interpretation of the results of testing nasopharyngeal samples.[57] 
Conventional laboratory methods such as blood culture and serology often have limited 
sensitivity due to inadequate sample volume, minimal presence of bacteremia and lack 
of convalescent sera.[1, 13, 185-187] Children are not usually able to produce sputum, 
and direct sampling of the lung using percutaneous aspiration or bronchoalveolar lavage 
is not a routine practice in the UK.[160] Pathogens are difficult to identify in children 
with pneumonia, with blood culture and serological testing often negative due to 
minimal presence of bacteremia.[186, 187] This paucity of S. pneumoniae isolation 
makes examining pneumococcal serotype distribution in childhood CAP difficult, with 
no UK, and little worldwide, data. Using non-culture techniques including 
pneumococcal detection by PCR in blood [18] and pleural fluid [188], pneumococcal 
antigen detection in urine [189] and pneumococcal serotype detection by PCR [18, 58], 
there was an improved insight into the contribution of S. pneumoniae and specific 
serotypes to the aetiology of CAP in children.  
 
Many patients have received antibiotics prior to hospitalisation which can affect the 
isolation of bacterial pathogens.[190] The rate of positive blood culture in children with 
pneumonia is about 5%.[13] In order to address these issues various antigenic assays 
have been developed.[191, 192] However, the significance of a positive pneumococcal 
antigen test in urine is rendered difficult to interpret because of the high frequency of 
nasopharyngeal pneumococcal carriage in normal children which generates a false 
positive antigen signal.[193-197] As S. pneumoniae serotype 1 does not normally 
colonise the nasopharynx,[118, 120, 121] it would not be expected that a healthy 
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uninfected children would have positive urinary antigen test for this specific serotype. 
Although urinary pneumococcal antigen detection by Binax Now has limited specificity 
(56%), it has good sensitivity (100%) in children with suspected IPD,[189] but is 
confounded as a diagnostic test by nasopharyngeal carriage where up to 21% may be 
positive.[196] Urinary antigen may also be positive in 4% healthy nasopharyngeal 
culture-negative children,[196] although given the increased sensitivity of PCR 
compared to culture, it is likely that nasopharyngeal culture-negative children would 
have pneumococcal carriage if tested by PCR.[198] Thus, a positive urinary antigen in a 
child with pneumonia and no pneumococcal nasopharyngeal carriage by PCR is likely 
to reflect invasive pneumococcal infections. 
 
Molecular diagnostics are now routinely used in the assessment of viral respiratory 
infections and similar techniques have been developed for the detection of bacterial 
respiratory infections.[17, 20, 199] Resti and colleagues demonstrated a significant 
improvement in the identification of pneumococcal pneumonia in children by PCR 
assay on blood samples (15.4%) when applied simultaneously with blood culture 
(3.8%).[18] In a recent study of Italian children aged under five years, overall 
bacteremic pneumococcal pneumonia was identified in 14.3%, which was established 
by PCR assay in 92%, blood culture 1% and both in 7%.[58] A molecular-based method 
using sequential multiplex PCR assay to specifically identify the capsular serotype-
specific sequences provides a practical and cost-effective tool for the surveillance of 
IPD.[200, 201] The test has been developed at the Centres for Disease Control and 
Prevention (CDC) in the USA.[200] Molecular pneumococcal serotyping has been 
found effective when performed either on culture-positive samples,[200, 202] or 
directly on clinical biological samples.[48] Pai and colleagues studied 29 primer pairs to 
target the prevalent pneumococcal serotypes in the USA.[200] The primers were 
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grouped into seven multiplex reactions. Of the 29 primers, 18 were fully specific for the 
targeted serotypes; 1, 3, 4, 5, 8, 10A, 14, 15A, 15B/C, 16F, 17F, 19A, 19F, 20, 23F, 31, 
34, and 35B. Serotyping was established in 95% of isolates (54% fully specific and 41% 
cross-reactive with minor serotypes). The same 29 primers were studied by an Italian 
group.[48] The molecular diagnosis was carried out directly on clinical biological 
samples by real-time PCR and confirmed by sequential multiplex PCR. These PCR 
assays confirmed the serotypes in 86% of those with S. pneumoniae infection.  
 
The changes in the prevailing serotypes of S. pneumoniae in children with pneumonia 
and empyema are important to monitor with the introduction of conjugate 
pneumococcal vaccination.[86, 203, 204] S. pneumoniae is rarely identified in these 
children, and the development of a molecular model for serotype specific detection 
informs essential epidemiological and aetiological surveillance required for evaluation 
of the effectiveness of currently available pneumococcal vaccines and development of 
new vaccines.[86, 205, 206] The national Respiratory and Systemic Infection 
Laboratory at the Health Protection Agency (HPA) in London have developed a 
multiplexed immunoassay using xMAP beads for detection of serotype-specific S. 
pneumoniae antigens.[207] This assay can identify all of the serotypes included in 
PCV13 plus serotype 8. It is suitable for use on body fluids for the determination of the 
commonest serogroups and serotypes of S. pneumoniae prevalent in the UK.[192] This 
test therefore has considerable potential for the epidemiological assessment of 
pneumococcal infections including serotype distribution and replacement in children. A 
national surveillance of IPD has been extended to include pleural fluid from empyema 
thoracis and a national prospective reporting system is being established in order to 
monitor the incidence of pleural empyema. With the expected decrease in incidence, 
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new data on the aetiology of those presenting with pneumonia and pneumococcal 
contribution are important and nothing is yet known about this in the UK.  
 
The timing of the study towards the end of three years of PCV7 and during the first year 
of PCV13 gives a unique opportunity for future evaluation of the aetiology of 
pneumonia in the same setting. It also aimed to investigate the contribution of S. 
pneumoniae in the aetiology of CAP in hospitalised children and identifies the 
pneumococcal serotypes responsible within a population routinely offered PCV. 
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1.4 Radiological diagnosis of pneumonia 
Chest radiograph is frequently performed when managing pneumonia in children,[208] 
but usually does not affect the clinical outcome.[209] In epidemiological studies, the 
chest radiograph remains a major criterion in classification of pneumonia.[150, 151] 
Variability in the interpretation of chest radiographs for the diagnosis of pneumonia in 
children is a recognised problem.[38] This problem is well-known since radiology 
reporting was initiated in the middle of last century.[210, 211] It has been suggested that 
if all radiologists followed the standardised WHO radiological criteria for classifying 
pneumonia,[150] this would allow more accurate comparative data in epidemiological 
studies for assessment of the impact of pneumococcal vaccination.[151] Broadly four 
categories are defined: “End-point consolidation”, “Other (non-end-point) infiltrate”, 
“Pleural effusion” and “No pneumonia”. 
 
The WHO criteria of radiological pneumonia are summarised as following:[150, 151] 
1. “End-point consolidation”: a dense opacity that may be a fluffy consolidation of 
a portion or whole of a lobe or of the entire lung, often containing air 
bronchogram and sometimes associated with pleural effusion. 
2. “Other (non-end-point) infiltrate”: a linear and patchy densities (interstitial 
infiltrate) in a lacy pattern involving both lungs, featuring peribronchial 
thickening and multiple areas of atelectasis with lung inflation is being normal to 
increased. It also includes minor patchy infiltrates that are not of sufficient 
magnitude to constitute primary end-point consolidation, and small areas of 
atelectasis which in children can be difficult to distinguish from consolidation. 
3. “Pleural effusion”: this refers to the presence of fluid in the pleural space 
between the lung and chest wall. Mostly this will be seen at the costo-phrenic 
angle or as a layer of fluid adjacent to the lateral chest wall. This does not 
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include fluid seen in the horizontal or oblique fissures. Pleural effusion is 
considered as primary end-point if it is in the lateral pleural space (and not just 
in the minor or oblique fissure) and is spatially associated with a pulmonary 
parenchymal infiltrate (including other infiltrate), or if the effusion obliterates 
enough the hemithorax to obscure an opacity. 
4. “No pneumonia”: if there is no evidence of consolidation, infiltrate, or pleural 
effusion. 
 
The diagnosis of pneumonia in children based on a combination of clinical and 
radiological features is important for prompt management.[159] Yet, subtle 
radiographic changes can be difficult to recognise or interpret and failure to diagnose 
pneumonia may result in inappropriate management.[212, 213] The initial interpretation 
of chest radiographs is usually performed by clinicians with the radiologists’ reports 
following later, often after the patient has been discharged from hospital.[212] 
Interpretation by clinicians could be biased by inadequate training in radiology and lack 
of clinical information may limit the accuracy of reporting by the radiologists.[214] For 
research purposes blinded interpretation of the chest radiograph may improve detection 
of subtle changes and differentiating normal biological variants.[215] Making clinical 
information available may reduce inter-observer variability but does not result in 
marked improvement in the overall accuracy.[216] 
 
Usually inter-observer variability is related to the interpretation of patchy and perihilar 
changes, which need careful viewing and the availability of clinical information during 
interpretation.[217] It is well recognised that abnormal chest radiographs may be 
interpreted as normal.[217] A recently reported chest radiographs according to the 
WHO radiological classification of Pakistani children aged 2–59 months diagnosed with 
 24 
 
non-severe pneumonia showed normal films in 82% (1519/1848) and lobar 
consolidation in 26 children.[218] Variation in reporting of chest radiographs mostly 
occur in those aged under five years which represents particular challenge of making a 
radiological diagnosis of pneumonia in this age group.[213, 219] It is widely accepted 
in the literature that chest radiographs cannot reliably differentiate viral from bacterial 
aetiology of pneumonia.[1, 2] Therefore these variations on the interpretation of chest 
radiographs do not significantly affect the clinical outcomes and management decisions 
of pneumonia in children.[1, 2, 209, 220, 221]   
 
It is interesting that irrespective of the level of experience there continues to be 
significant variability in interpretation between reporters, particularly senior 
radiologists.[213, 222] A previous study showed that qualified radiologists had less 
inter-observer variability on reporting of chest radiographs compared to radiology 
trainees and physicians.[223] Despite the specialized training in paediatric radiology 
and advanced technology, human error remains a likely factor.[211] The level of 
variability between the senior radiologists could be a reflection of inconsistency in the 
application of the WHO criteria, as this has been shown to decrease inter-observer 
variability.[224] However, false negative reports between the two interpretations of 
chest radiographs is a well recognised problem [217] which may jeopardize the results 
of epidemiological studies by underestimating the true burden of pneumococcal 
pneumonia.[225] In previous pneumococcal vaccine efficacy studies the radiographic 
evidence of pneumonia was observed in up to 34% of the enrolled children.[226] It has 
been suggested that using the WHO criteria would make any differences in the results 
reflect geographical variations in disease epidemiology or vaccine effects rather than 
methodological factors.[151] Despite the application of this classification, the 
concordance rate between two trained reviewers was only 48% (250/521).[227] 
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Radiological findings were part of the entry criteria to the epidemiology and radiology 
studies in this research. Therefore using data from the aetiology study this analysis 
aimed to characterise inter-observer variability in the interpretation of chest radiographs 
for the diagnosis of pneumonia in children according to the WHO radiological 
classification.[150] 
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1.5 Hypotheses and aims 
1.5.1 Hypotheses 
The study hypotheses were as following:  
1. The introduction of the pneumococcal conjugate vaccination programme in 2006 
was associated with a reduction in the incidence of radiologically-confirmed 
pneumonia and rates of hospitalisation in children. 
2. The management practices of CAP in children have changed since the 
implementation of national management guidelines from the British Thoracic 
Society (BTS) in 2002 [160]. 
3. The application of more PCR-based assays and expanded microbiological 
screening would improve the detection rates of causative pathogens. 
4. The non-PCV7 serotypes are an important cause of pneumococcal infections in 
childhood CAP. 
5. Inter-observer variability in the interpretation of chest radiographs for the 
diagnosis of pneumonia in children is continuing despite the acceptance of the 
recommended WHO criteria [150, 151] for reporting radiological changes in 
childhood pneumonia. 
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1.5.2 Aims 
There were two parts of this research that involved children aged 0–16 years with 
clinical and radiological features suggestive of pneumonia. The aims were as following:    
1.5.2.1 Epidemiology survey 
1. To investigate the annual incidence of all-cause community-acquired pneumonia 
(CAP) in children seen in hospital in the North East of England. 
2. To evaluate the impact of PCV7 on the incidence of childhood CAP by 
comparing the established data with those from a similar survey undertaken in 
the same hospitals in 2001–2002 [59].  
3. To identify the risk factors for the development of severe disease in children 
presented to hospital with pneumonia based on demographic and social data. 
4. To compare the clinical features and management of childhood CAP following 
the publication of the national management guidelines from the BTS in 2002 
[160] with data from a similar survey at the same hospitals in 2001–2002 (pre-
guidelines) [157]. 
1.5.2.2 Aetiology study  
1. To investigate the aetiology of CAP in children seen in hospital before the 
introduction of the pneumococcal conjugate vaccine by analysing a previously 
collected prospective data in 2001–2002.  
2. To investigate the aetiology of CAP after the introduction of the pneumococcal 
conjugate vaccine. 
3. To determine the contribution of S. pneumoniae in the aetiology of CAP in 
hospitalised children and identify the pneumococcal serotypes responsible 
within a population routinely offered pneumococcal conjugate vaccine using 
culture and molecular identification methods. 
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4. To develop, validate and apply a molecular test using a sequential multiplex 
PCR assay to identify the pneumococcal capsular serotype-specific sequences. 
5. To identify the serotypes of S. pneumoniae causing pneumonia using sequential 
multiplex PCR assay on clinical biological samples. 
1.5.2.3 Radiology study 
1. Among children enrolled in the aetiology study (2009–2011), to characterise 
inter-observer variability in the interpretation of chest radiographs for the 
diagnosis of pneumonia in children according to the WHO radiological 
classification [150, 151]. 
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Chapter 2 Materials and Methods
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2.1 Epidemiology survey 
2.1.1 Study design and participants 
This was a prospective survey involving 11 hospital sites in the North East of England 
(excluding Cumbria). It was conducted from August 2008 to July 2009, covering the 
same months as the survey in 2001–2002. The hospital configuration changed slightly 
from the previous survey in 2001, with a reduction in the number of units treating 
children from 13 to 11. However, the geographical area and population served by these 
hospitals were the same as in 2001 as were the methods of enrolment criteria and case 
ascertainment.[59] The participating hospitals were: Queen Elizabeth Gateshead, James 
Cook Middlesbrough, North Tyneside, South Tyneside, Sunderland Royal, North Tees, 
North Durham, Darlington Memorial, Freeman, Newcastle General and Royal Victoria 
Infirmary. A family doctor/General Practitioner or medical staff at the accident and 
emergency departments saw children before referral for further assessment by the 
hospital-based paediatric team if secondary care was required. The survey included only 
children who attended the paediatric services but not the accident and emergency 
departments. 
 
Eligibility criteria were children aged 0–16 year, who presented with clinical and 
radiological features of pneumonia and were seen in hospital by a paediatrician. Data on 
chest radiographs were collated from local radiologists’ reports and findings were 
grouped according to a modified version of the WHO criteria.[150, 151] Radiological 
reports were grouped into five categories of lobar, patchy consolidation, perihilar 
infiltrates, other infiltrates/abnormalities and normal. The other infiltrates/abnormalities 
included reports of increased bronchovascular markings, peribronchial thickening, 
bronchial wall thickening, or peribronchial cuffing and were analysed as pneumonia. 
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The modification of including a further category of non-end-point pneumonia (other 
infiltrates/abnormalities) is in line with the extended definitions of pneumonia used by 
Enwere and colleagues [228] in their study of the epidemiology of pneumonia in The 
Gambian PCV9 trial. This was used because WHO did not include specific criteria for 
‘other infiltrates/abnormalities’. Exclusion criteria included being resident outside the 
North East of England, clinically-diagnosed bronchiolitis, hospitalization for any reason 
in the preceding three weeks, or a chest radiograph reported as normal.  
 
A favourable ethical opinion was obtained from the regional Newcastle and North 
Tyneside Research Ethics Committee (Appendix 1). Caldicott approvals were granted 
from all collaborating sites. 
2.1.2 Case ascertainment and data management 
Children were identified prospectively by local paediatric teams who completed a 
questionnaire containing data on demographics (including date of birth, sex, date of 
admission and discharge, parents age and occupation and postcode of residence), 
preadmission use of antibiotics, potential risk factors (including gestational age, 
immunodeficiency, chronic lung disease, cystic fibrosis, sickle cell disease, 
bronchiectasis, use of steroids, attendance of nursery school, and child and parental 
smoking), clinical examination findings, treatment given and management outcomes as 
well as any complications occurred. Also data were gathered of the results of any 
performed laboratory investigations as part of routine clinical care (Appendix 2). This 
questionnaire was approved by the Ethics Committee when the present survey was 
approved and is the same used one that was validated and approved by the Ethics 
Committee in 2001–2002 survey.[59] No data were collected neither on the number of 
referrals from primary care nor children seen in accident and emergency departments. 
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A recently pooled review data showed that parental and household smoking is a 
significant risk factor of lower respiratory tract infections and asthma in children.[73, 
74, 229] Self-reporting of parental smoking is subject to underestimation.[230-232] In 
the present survey collected information on parental smoking was based on self-
reporting. Hence this might introduce bias when to the analysis of smoking as a 
predictor of severe disease. In contrast the use of women recall of gestational age of 
their children from maternal interviews is valid for use in epidemiological studies.[233-
236]   
 
Enrolment data were cross-checked to assure complete ascertainment by reviewing 
ward admission diaries for children admitted with respiratory symptoms (eight sites), or 
by obtaining hospital coding data on pneumonia where admissions are carried out 
electronically (three sites). Case notes and electronic records were reviewed to confirm 
the diagnosis, and to collect any missing data. Pneumococcal immunisation history was 
obtained for each child from parents, and where available it was cross-checked with the 
child’s health records. If there was uncertainty about the immunisation history, general 
practice surgeries/primary care providers were contacted and practice records of 
vaccines given checked.  
 
The data sets were manually entered into a Microsoft Office Access Database. Data 
cleaning was carried out manually and electronically for systematic errors; extreme 
values or random samples were cross-checked against the hard copy of original 
questionnaire where it was felt necessary. Duplicates and those who did not fulfil the 
inclusion criteria were removed after the completion of validation process. The master 
data file and subfolders used for statistical analyses were encrypted to secure patients’ 
data protection and only the study team members have access to these data. 
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2.1.3 Classification of disease severity and social class 
Disease severity was determined using modified criteria from the British Thoracic 
Society (BTS) management guidelines for pneumonia.[160] The symptom of dyspnoea 
was excluded as the definition was deemed subjective, particularly in preschool-age 
children.[237] Any of the following led to the classification of “severe disease”: 
respiratory rate >70 or >50 for ≤1- or >1-year-olds respectively; oxygen saturation 
<93%; oxygen therapy; nasogastric feeds; intravenous fluid infusion; septicaemia; 
empyema; high dependency or intensive care admission. “Mild disease” included 
immediate discharge home or hospital stay <3 days and no oxygen; no nasogastric feeds 
and no intravenous fluid infusion. Children with none of the above were classified as 
“moderate disease”.  
 
Deprivation has multiple dimensions such as financial, health, education, services or 
crime.[238-240] Townsend score [238] which includes census-derived deprivation 
indices does not adequately correlate with health in rural areas of the UK.[241] 
Therefore the index of multiple deprivation (IMD) has been developed and used in the 
UK to identify small areas of deprivation,[242, 243] and is based on methodology 
developed at the University of Oxford Social Disadvantage Research Centre.[244] It 
was used in childhood health study in the North East of England and was found to be 
valid to identify inequalities in accessing primary dental care for children.[245] 
  
Parental occupation information was incomplete, therefore socioeconomic class and the 
measure of deprivation were derived for each child based on the IMD score for the 
parental postcode of residence (The English Index of Deprivation 2007, Office for 
National Statistics (ONS)).[242, 243] It is measured at the Lower Super Output Areas 
(LSOAs) and includes domains which are related to income deprivation, employment 
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deprivation, health deprivation and disability, education skills and training deprivation, 
barriers to housing and services, living environment deprivation, and crime.[242] It was 
used in this in the present survey to determine residential area-level deprivation of rural 
and urban areas.[242, 246] 
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2.1.4 Sample size and statistical analysis 
The sample size calculation was based on a previous local regional data before the 
introduction of PCV7.[59] These data suggested that approximately 750 children could 
be seen with clinical diagnosis and radiologically-confirmed pneumonia over a year 
period. Pooled review data concluded that the pneumococcal conjugate vaccines were 
associated with 27% to 32% reduction in the rates of radiological pneumonia.[145, 146] 
Therefore, it was estimated that a sample size of 530 children with pneumonia 
confirmed by chest radiograph would be sufficient to identify the true changes in 
disease incidence rates with 80% power. 
2.1.4.1 Incidence of pneumonia 
Annual incidence rates were established by age and sex using the population estimates 
for the North East Strategic Health Authority area from the UK Office of National 
Statistics for 2009, and compared with those from the 2001 survey.[59] There were 458 
500 children aged under 16 years, of which 146 200 were aged under five years.[247] 
Confidence intervals (CIs) of annual incidence rates were calculated assuming a Poisson 
distribution and using the EpiTools package in R statistical software version 2.14.0 (The 
R Foundation for Statistical Computing, Austria). Univariate and multivariate logistic 
regression was used to establish risk factors for severe compared to mild/moderate 
CAP. Fisher’s exact test with calculated odds ratios (ORs) and 95% CIs was used to 
compare differences in count data between 2001 and 2009 for disease severity.  
 
Although the geographical area and population served by the reduced number hospitals 
from 13 to 11 were the same as in 2001 as were the methods of enrolment criteria and 
case ascertainment,[59] calculation of annual incidence rates by county of residence of 
lobar finding in chest radiographs and compare them between hospitals to relate any 
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geographical differences to the potential variation in reporting of chest radiographs was 
deemed to be a source of bias to data. This is because the referral pathways from 
primary care to secondary care have changed overtime. Therefore comparisons of 
overall figures for both the annual disease incidence and lobar findings would be more 
accurate than the geographical sub-analysis of data. Hence geographical analysis either 
by county or hospital of recruitment was not performed to avoid inaccuracies of the 
conclusions. However, variability in the interpretation of chest radiographs for the 
diagnosis of pneumonia in children is presented and discussed at greater length in 
(Chapter 7) of the radiology study on the application of WHO radiological classification 
of end-point pneumonia. This can give an idea on the inter-observer variability of 
radiological reporting.    
2.1.4.2 Outline of the steps for the calculation of incidence of pneumonia 
The following steps were undertaken to establish the denominators for the calculation of 
annual disease incidence and hospitalisation rates between the two surveys as well as 
incidence of pneumonia in PCV7-vaccinated versus unvaccinated groups. A meeting 
with epidemiologists: Prof Stephen Rushton and Dr Russell Gorton and discussion with 
supervisors: Drs Julia Clark and Andrew Gennery were carried out about the calculation 
of rates and agreed the steps. It was also agreed that because of sample size limitation 
the calculation of vaccine efficacy would be subject to bias and inaccuracy. 
 
 2001–2002 survey [59] 
1. Of 711, 530 aged <5 years, 181 ≥5 years. 
2. But 750 is value the incidence was calculated on (include 39 where data 
incomplete but known to have pneumonia). 
3. Therefore predict the age distribution of those that are missing based on pre-
existing data. 
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4. Assuming that those missing are equally distributed between different age 
groups: 
a. Therefore 530/711 = 74.5% 
b. Therefore 30/39 presumed to be aged <5 years 
c. 9/39 presumed to be aged ≥5 years 
d. Therefore cases are: 190 aged ≥5 and 560 aged <5 years  
5. These numbers are the basis for the incidence rates quoted in the paper at the 
moment. 
6. However, there is an issue with the population estimates as if use the official 
ONS population estimates these no longer match the published 2001 data – 
likely a revision of numbers post 2001 census. This means there is an issue with 
using the official ONS published data. 
7. So calculated from published rate of 33.8/10000 for those aged <5 years and 
total cases of 560 (as above): 
a. Estimate of the <5 years old population is therefore: 
i. (560/33.8)*10000 = 165680.47 people aged <5 years 
b. Therefore children aged 5-16 years = Total population – <5 years 
population = 522158 – 165680.47 = 356478 
c. Therefore rate in 5-16 = (190/356478)*10000 
8. Now hospitalisations were 636 children according to the paper [59] (i.e. none of 
39 missing having been admitted). 
a. Therefore using hospitalisation rate of those aged <5 years and 
population estimate to calculate distribution of hospitalisations: 
b. Therefore hospitalisations of those aged <5 years = population * rate 
= 165680.47 *28.7 = 476 of 636 aged <5 years hospitalised 
c. Therefore children aged ≥5 years = 636 – 476 = 160 
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 2008–2009 survey  
1. Calculating vaccine efficacy given numbers with known vaccination status: 
a. Aged <5 years = 400 
b. Cases with known vaccine status = 392  
c. Vaccinated cases = 321 
d. Unvaccinated cases = 71 
e. Aged <5 years population = 146200 
2. Primary PCV7 coverage varied between 87–94.2% 
3. Catch up coverage of PCV7 in Scotland 86% 
4. Catch up coverage of PCV7 in North East 70.3% 
5. So calculate on best/worst case scenarios: 
a. Best scenario = 94.2%  
b. Worst scenario =70.3% 
6. Best scenario for VE: 
a. Vaccinated population = 146200 * 0.942 = 137720.4 
b. Unvaccinated population = 146200 – 137720.4 = 8479.6 
c. Therefore vaccine efficacy (VE) = 1 – ((321/137720.4)/(71/8479.6)) 
d. With CI calculated: 
i. VE = 0.7216291 (95% CI = 0.6422732 to 0.7857344) 
7. Worst scenario for VE: 
a. Vaccinated population = 146200 * 0.703 = 102778.6 
b. Unvaccinated population = 146200 – 102778.6 = 43421.4 
c. Therefore VE = 1 – ((321/102778.6)/(71/43421.4)) 
d. With CI calculated: 
i. VE = -0.9100635 (95% CI =  -0.4702005 to -1.454571) 
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8. Fisher’s exact test comparing counts of vaccinated versus unvaccinated cases 
and population: 
a. Note: still dependent on knowing the correct vaccinated/unvaccinated 
distribution in population. 
b. Cases of pneumonia: vaccinated = 321, unvaccinated = 71 
c. Non-cases (population): vaccinated = 127143, unvaccinated = 19057 
d. P-value = 0.004216 
2.1.4.3 Audit of the national management guidelines of pneumonia 
Descriptive statistical analysis was performed using Epi Info
TM
 7. Fisher’s exact test 
with ORs and 95% CIs was used to compare counts of individual cases as classified 
using categorical variables between groups and with those from the pre-guidelines 
survey.[157] A comparison of treatment approaches, clinical and radiological features 
for severe versus mild/moderate CAP was performed using logistic regression. Logistic 
regression analyses were undertaken in the Predictive Analytics SoftWare program 
(PASW Statistics 17).  
 
Cox-proportional hazards models [248] were used to investigate the impact of different 
covariates including disease severity (categorical), hospital site (categorical), use of 
antibiotics and their route of admission (categorical) on the length of stay (continuous). 
The discharge from hospital was assumed an event and that these parameters influenced 
this event. It was hypothesised that the severity and absence of antibiotic treatment 
would decrease the risk of early discharge from hospital. Models were fitted in the 
statistical software R-2.14.0 using the survival package of Therneau and Grambsch 
(2001).[249] Length of stay is a variable constrained by the time of zero, with many 
children diagnosed to have pneumonia being discharged early from hospital with few 
children staying longer. Such data are effectively “life time” of stay in hospital which 
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means that these covariates are most appropriately analysed using a survival analysis 
approach. Analyses were undertaken with leaving date from hospital as the response 
and disease severity, hospital site and use of antibiotics and their route of admission as 
covariates of risk of factors for prolonged hospital stay whilst adjusting for age. For 
each covariate, likelihood ratio (LHR) test p-value was calculated to show the overall 
association between a covariate and length of stay. This is different to the Wald test p-
values that just show whether each level of a covariate is significantly different to the 
reference level or not. 
 
The baseline hazard function in the Cox proportional hazard model is modified 
multiplicatively by the above mentioned covariates. This makes the interest is in the 
cumulative hazards which will be a proportional factors rather than the baseline hazard. 
Then conditional on the event of discharge from hospital, the probability does not 
depend on the baseline hazard of each covariate. The hazard ratio yields an estimate of 
the ratio between the baseline excess hazards of longer hospital stay attributable to 
children admitted with pneumonia and the population hazard for each child.[250] The 
association between the covariates and length of stay and discharge from hospital as 
outcomes was investigated using event analysis while adjusting for child’s age.[248] 
Initially fitted full models with all variables and identified the best model by a stepwise 
removal of non-significant variables. For validity of significant models’ modelling, the 
assumptions of proportionality of hazard were assessed using the Schoenfeld residuals 
according to the methodology of Therneau and Grambsch.[249] Then the best models 
were used for each covariate to predict the time of discharge from hospital. 
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2.2 Aetiology study 
2.2.1 Study design and participants 
Two prospective studies were undertaken from August 2001 to July 2002 and October 
2009 to March 2011 of children aged 0–16 years with clinical and radiological features 
suggestive of pneumonia. They were from the North East England (excluding Cumbria) 
who presented or transferred to the paediatric services at the Great North Children’s 
Hospital (formerly Newcastle General and Royal Victoria Infirmary), the regional 
cardiothoracic centre at Freeman Hospital Newcastle where empyema is managed or the 
James Cook University Hospital in Middlesbrough. The cohort of 2001–2002 study was 
a proportion of children with pneumonia seen at these recruitment sites as part of a 
previously published epidemiological survey.[59, 157] They were consented and 
enrolled in the aetiological study with an extended panel of investigations.  
 
Recruitment methods and enrolment criteria were consistent across the two studies and 
included children with any history, signs or symptoms suggestive of lower respiratory 
tract infection and chest radiographic findings consistent with infection as determined 
by the local paediatrician and subsequently approached by a member from the research 
team. No recruitment was carried out in accident and emergency departments. 
Exclusion criteria included resident outside of North East England; clinical diagnosis of 
bronchiolitis; hospitalisation in the preceding three weeks or normal chest radiograph 
after formal reporting by a radiologist. All chest radiographs were reviewed by a second 
consultant radiologists (Drs R Lee and M Muller in the pre- and post-vaccine studies 
respectively) at the regional centre in Newcastle who were blinded to both clinical data 
and the first reports. Chest radiographic findings were categorised into lobar, patchy or 
perihilar according to the WHO criteria.[150, 151] Research teams of doctors and 
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nurses led and ascertained the standardised diagnosis of pneumonia and the recruitment 
procedures. Pneumococcal conjugate immunisation history including the vaccine 
valency was obtained from parents and cross-checked with the child’s parent held health 
records. General practice surgeries were contacted to clarify doses given if there was 
uncertainty. This immunisation history was not collected in the pre-vaccine study. 
 
Ethical approvals were granted by the Newcastle and North Tyneside Research Ethics 
Committee for both studies and Research Approval Board at South Tees Hospitals NHS 
Trust, Middlesbrough (Appendix 1). Caldicott approvals were also obtained. 
 
I led the recruitment procedures of 2009 study at the sites of Newcastle upon Tyne 
Hospitals NHS Trust, supported by Kerry Pollard (research nurse). At the JCUH, the 
recruitment was facilitated by Dr Fiona Hampton (consultant paediatrician) and Pauline 
Singleton (research nurse). I visited James Cook site to validate data on enrolled 
children. Written information on the pneumonia study consisted of a four page parent 
information sheet and a two page age appropriate information document for the child of 
either aged under or above 10 years. Written informed consent was obtained from 
child’s parents as well as assent from older children using a generic consent forms 
(Appendix 3). 
 
Data were collected on standard proforma for epidemiological, laboratory and clinical 
characteristics (Appendix 2), together with samples of nasopharyngeal secretions, urine 
and blood. If blood tests were performed as part of the child's routine care then a little 
more blood was taken at the time for the purposes of the study. If the children did not 
require blood tests as part of their routine care then blood sample was collected for the 
purpose of the study if convenient for both child and parents.  
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2.2.2 Laboratory procedures 
Samples included blood, urine and respiratory secretions. Approximately four weeks 
later blood was collected for convalescent serology. Parents often declined returning for 
these convalescent samples (all in the post-vaccine study), contributing to the variability 
of investigations performed. Blood samples were collected for serum, blood culture 
(BacT/ALERT
®
, bioMérieux, France) and pneumococcal PCR testing. Nasopharyngeal 
secretions included aspirates (NPA) from infants as appropriate for age, and/or two 
swabs (NPS) from older children. The NPA sample was placed in 0.9% sodium chloride 
transport solution or swabs (Medical Wire & Equipment Co Ltd, UK). 
Tracheobronchial secretions (collected via endotracheal tube or bronchoalveolar 
lavage), non-induced sputum and pleural fluids were tested when obtained. The nature 
of collected samples were standardised across all ages and in both studies.   
 
Where tests were not part of routine clinical care, samples were stored at –20°C for 
subsequent analysis. Investigations were performed in the Microbiology Laboratory, 
Newcastle upon Tyne Hospitals NHS Trust and the Health Protection Agency (HPA) 
Public Health Laboratory, Newcastle. Apart from locally performed routine diagnostic 
tests, samples from Middlesbrough were transported to Newcastle via daily transport 
services. Pneumococcal isolates from blood, urine (positive antigen testing) and 
respiratory secretions including pleural fluids were serotyped by multiplexed 
immunoassay using xMAP beads for detection of serotype-specific S. pneumoniae 
antigens at the national HPA Respiratory and Systemic Infection Laboratory in 
London.[207] 
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2.2.2.1 Viral laboratory diagnostic tests 
In the pre-vaccine study, immunofluorescence antibody testing (IFAT) was applied to 
respiratory secretions using Chemicon SimuFluor FITC for respiratory syncytial virus 
(RSV), influenza A and B, parainfluenza 1-3, and adenovirus and human 
metapneumovirus (hMPV) was tested for using IFAT utilising an in-house pool of anti-
hMPV monoclonal antibodies.[251] Viral screening was performed in the post-vaccine 
study using an in-house multiplex real-time PCR assay. The target panel was expanded 
to include pandemic influenza A subtype H1N1, parainfluenza virus 4, rhinovirus, 
coronavirus (229E, OC43 and NL63), and bocavirus plus the viruses previously tested 
for by IFAT. Viral serological tests included respiratory syncytial virus (RSV), 
influenza A and B virus, and adenovirus. 
2.2.2.2 Bacterial laboratory diagnostic tests 
An aliquot of NPA or bacterial NPS was inoculated onto plates of Columbia agar 
(Oxoid) supplemented with 5% horse blood (CBA). Samples were also inoculated into 
Oxoid brain-heart infusion enrichment broth with 10% serum (BO0129E; Oxoid, UK) 
and were incubated overnight at 37°C. Enrichment cultures were sub-cultured (10 µL) 
into CBA plates which were incubated at 37°C in atmospheric air supplemented with 
5% carbon dioxide for 48 hr. Isolates of S. pneumoniae and group A Streptococcus 
(GAS) were identified by standard methods including latex agglutination and API 32 
STREP (bioMérieux, France). These were stored in STGG medium (skim milk-
tryptone-glucose-glycerol), prepared in-house as previously described.[252] In the post-
vaccine study, bacterial screening of respiratory secretions was performed using an in-
house real-time PCR assays which targeted S. pneumoniae, Haemophilus influenzae, 
Bordetella pertussis, Mycoplasma pneumoniae, and Chlamydophila  pneumoniae.[253-
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256] All of the assays used have been validated for the detection of the target organisms 
(Dr Andrew Sails, personal communication). 
  
Total nucleic acid was extracted from blood samples from both studies and tested using 
a S. pneumoniae specific PCR assay targeting the pneumolysin gene.[255]  Samples 
post-vaccine were also tested in a 16S rRNA PCR assay (Molzym GmbH and Co., 
Bremen, Germany). An acute complement fixation test (CF) antibody screen for 
‘atypical’ bacteria and respiratory viruses was also performed which included 
Mycoplasma IgM antibody, M. pneumoniae, C. pneumoniae and C. psittaci, as well as, 
Coxiella burnetii, and Legionella pneumophila serogroup 1-6 in the post-vaccine study. 
Antistreptolysin O titre (ASOT) was assayed in both studies by Rheumajet ASO kit 
(Launch Diagnostics, UK). In the pre-vaccine study, urine samples were tested for 
pneumococcal antigen with an in-house counter-current immunoelectrophoresis (CIE) 
assay and in the post-vaccine study this was replaced by Binax NOW (Inverness 
Medical Innovations Ltd, Galway, Ireland). 
 
Isolation of pathogenic bacteria from sputum samples was considered as possible 
infection due to the risk of contamination from nasopharyngeal secretions. Together 
with blood and pleural fluids, tracheobronchial secretions were considered as normally 
sterile sites, so any recovered bacteria from these sources suggested a definite infection 
as per diagnostic criteria outlined in Table 2-1. 
2.2.2.3 Pneumococcal PCR assays and serotyping 
Blood samples were subjected to molecular diagnostic investigations including 16S 
rRNA PCR (Molzym GmbH and Co., Bremen, Germany) and a S. pneumoniae specific 
PCR targeting the pneumolysin gene using an in-house assay.[255] Clinical 
pneumococcal isolates from respiratory secretions, pleural fluids and blood, plus 
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pneumococcal antigen positive urine samples were serotyped by a multiplexed 
immunoassay using xMAP beads for detection of serotype-specific S. pneumoniae 
antigens at the national HPA Respiratory and Systemic Infection Laboratory in 
London.[207] The pneumococcal serotyping on pleural fluids was part of the enhanced 
surveillance of pneumococcal empyema in UK children (UK-ESPE study). 
 
For the 16S rRNA PCR assay, DNA was extracted from 1 mL aliquots of blood 
(following storage at –800C) using a MolYsis Complete 5 kit (Molzym GmbH and Co., 
Bremen, Germany) according to the manufacturer’s instructions. The kit utilises a novel 
technology which facilitates the selective lysis of blood cells followed by the 
quantitative degradation the released DNA by a proprietary DNase (MolDNase). The 
bacteria are then enriched from the lysate by centrifugation, and DNA is extracted by 
column purification. The DNA extracts were used as template in a PCR assay targeting 
a conserved region of the 16S rDNA gene.  Following PCR amplification PCR products 
were analysed by gel electrophoresis. 
 
The pneumolysin PCR used in this study was established by Corless and colleagues in 
the UK.[255] It was developed on the ABI 7700 Sequence Detection System (TaqMan) 
for the detection of S. pneumoniae from clinical samples of cerebrospinal fluid, plasma, 
serum, and whole blood. Pneumolysin (ply) gene target specific for S. pneumoniae was 
selected. Sensitivity was evaluated using these clinical samples which were collected 
from culture-confirmed cases of pneumococcal infections. It gave an overall 91.8% 
sensitivity and 100% for the 36 samples tested. The ply primers amplified 
pneumococcal serotypes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10A, 11A, 12, 14, 15B, 17F, 18C, 19, 
20, 22, 23, 24, 31, and 33.[255] The in house pneumolysin PCR used in the present 
study has been validated and used previously for the detection and identification of S. 
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pneumoniae for many years in the Microbiology Laboratory, Newcastle Hospitals NHS 
Trust and the Newcastle HPA Laboratory (Dr Andrew Sails, personal communication). 
 
The multiplexed immunoassay using xMAP beads for detection of serotype-specific S. 
pneumoniae antigens was developed at the HPA in London.[207] This assay can 
identify all of the serotypes included in PCV13 plus serotype 8. It is suitable for use on 
body fluids for the determination of the commonest serogroups and serotypes of S. 
pneumoniae prevalent in the UK.[192] It has good sensitivity (79.3%, 46/58) and 
specificity (99.3%, 145/146) on correctly identifying the pneumococcal serotypes when 
testing urine samples from patients with culture-confirmed pneumococcal or non-
pneumococcal disease.[207] This test therefore has considerable potential for the 
epidemiological assessment of pneumococcal infections including serotype distribution 
and replacement in children. A national active surveillance of IPD has been extended to 
include pleural fluid from empyema thoracis and a national prospective reporting 
system is being established in order to monitor the incidence rates of pleural empyema 
(UK-ESPE study). 
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2.2.3 Development of pneumococcal serotype-specific PCR 
A sequential multiplex pneumococcal serotype-specific PCR was developed at the HPA 
Public Health Laboratory Newcastle. Its technical development was adopted from the 
previously described study by Pai and colleagues [200] at the CDC in the USA. It 
targeted the prevalent 29 primer pairs of pneumococcal serotypes which were grouped 
into seven multiplex reactions. These serotypes included 1, 3, 4, 5, 6A/B, 7F, 7C, 8, 9V, 
10A, 11A, 12F, 14, 15A, 15B/C, 16F, 17F, 18, 19A, 19F, 20, 22F, 23F, 31, 33, 34, 35B, 
35F, and 38. 
   
For the purpose of this study, I led the process of development and application of this 
test under the supervision of Dr Andrew Sails. I performed the aliquoting of primers, 
prepared the master mix solution and extracted the DNA from the batched 
pneumococcal isolates from blood and nasopharyngeal secretions. All primers were 
synthesised at the Eurogentec. The control pneumococcal serotypes were provided by 
the Microbiology Laboratory at the Newcastle upon Tyne Hospitals NHS Trust and the 
Respiratory and Systemic Infection Laboratory, HPA in London. I attempted using this 
test to serotype the stored pneumococcal PCR-positive samples from blood obtained 
from previous aetiological study in the same setting in 2001–2002. But unfortunately 
this was unsuccessful because the long storage period of the samples resulted in DNA 
degradation, causing multiple non-specific PCR amplification. 
 
This test was applied to the culture-negative, pneumolysin PCR-positive blood or 
respiratory secretion samples. The selected samples were those with a cycle threshold 
(Ct) of ≤30. This cut off was decided following testing couple of representative samples 
of different Ct levels of positive pneumolysin PCR assays to detect a good DNA signal 
for the capsular polysaccharide antigens (cps). 
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2.2.4 Case ascertainment and data management 
Admitted children with pneumonia were identified prospectively by me and research 
nurses. Questionnaire containing data on demographics (including date of birth, sex, 
date of admission and discharge, parents age and occupation and postcode of residence), 
preadmission use of antibiotics, potential risk factors (including gestational age, 
immunodeficiency, chronic lung disease, cystic fibrosis, sickle cell disease, 
bronchiectasis, use of steroids, attendance of nursery school, and child and parental 
smoking), clinical examination findings, treatment given and management outcomes as 
well as any complications occurred (Appendix 2). This questionnaire was approved by 
the Ethics Committee when the present survey was approved and is the same used one 
that was validated and approved by the Ethics Committee in 2001–2002 survey.[59] 
With the approval from Ethics Committee, few questions were added on the use of 
Ibuprofen (anti-inflammatory drug). This was to investigate a separate secondary 
outcome of its potential association with the development of severe pneumonia.[95, 
257] No data were collected neither on the number of referrals from primary care to 
paediatric assessment units nor children seen in accident and emergency departments.  
 
The data sets were manually entered into a Microsoft Office Access Database. Data 
cleaning was carried out manually and electronically for systematic errors; extreme 
values or random samples were cross-checked against the hard copy of original 
questionnaire where it was felt necessary. Duplicates and those who did not fulfil the 
inclusion criteria were removed after the completion of validation process. The master 
data file and subfolders used for statistical analyses were encrypted to secure patients’ 
data protection and only the study team members have access to these data. Data were 
analysed using Epi Info
TM
 7.
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2.2.5 Statistical analysis 
2.2.5.1 Causes of pneumonia 
Summary of the isolated pathogens was presented as frequencies and categorised as 
viral, bacterial or mixed viral-bacterial infections. Detection rates of pathogens are 
expressed as proportions of those tested, and results were compared in relation to age 
group. The age group classification was under/above five years as by the start of post-
vaccine study, children in the under five age group should have been vaccinated with 
PCV. This would allow the investigation of the relative contribution of pneumococcal 
infection in causing pneumonia, as well as the role of other pathogens. Depending on 
the nature of samples and type of test applied, positive results were classified as definite 
or possible according to defined diagnostic criteria (Table 2-1), and only the definite 
results are presented and discussed. A Venn diagram was used to show different 
positive applied diagnostic approaches for pneumococcal and group A streptococcal 
infections. 
 
Recovery of bacterial pathogens from NPAs, NPSs or sputum was not considered 
evidence of definite infection due to the risk of physiological colonisation, but bacteria 
from tracheobronchial secretions was.[1] Where there was a common methodology for 
diagnosis between studies, identification rates were compared using Fisher’s exact test 
with ORs and 95% CIs. 
2.2.5.2 Diagnosis and serotyping of pneumococcal infections 
Detection rates of pathogens are expressed as proportions of those tested. According to 
the nature of samples and type of test applied, positive results were classified as definite 
or possible and only the definite results are presented and discussed. Isolation of 
pneumococci from NPAs, NPSs or sputum was not considered evidence of definite 
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infection whereas isolation from tracheobronchial secretions was.[1] Together with 
blood and pleural fluids, tracheobronchial secretions were considered as normally sterile 
sites, so any recovered S. pneumoniae from these sources suggested a definite infection 
as per the diagnostic criteria outlined in Table 2-1. 
 
Fisher’s exact test was used to compare infection status between different detection 
methods and ORs and 95% CIs calculated where possible. Logistic regression was used 
to investigate the extent to which selected clinical and laboratory variables were 
predictors of positive status by each diagnostic test with a view to providing clinical 
guidelines for use of different tests during assessment at presentation. The receiver 
operating characteristic (ROC) curve was used to determine the specificity and 
sensitivity of urinary pneumococcal antigen test to identify definite pneumococcal 
infection. 
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Table 2-1 Laboratory investigations and diagnostic criteria 
  
Tests
*
 Diagnostic criteria 
Sample Pathogen/antigen 2001–2002 study 2009–2011 study Definite Possible 
Serum Respiratory viruses Complement fixation Complement fixation Acute titre ≥1/128 or  
4-fold rise between paired sera 
NA
†
  
  Atypical bacteria 
 Mycoplasma  IgM antibody IgM antibody Positive NA 
 Group A Streptococcus ASOT (IU/mL) ASOT (IU/mL) Acute 2-fold rise or  
4-fold rise between paired sera 
NA 
Blood S. pneumoniae Real-time PCR Real-time PCR Positive NA  
 16S rRNA gene Not tested PCR Positive NA 
 Bacteria Culture Culture Growth NA 
Nasopharyngeal secretions/sputum Respiratory viruses IFAT Real-time PCR Positive NA  
 Bacteria Culture Culture/real-time PCR NA Growth/Positive 
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Tests
*
 Diagnostic criteria 
Sample Pathogen/antigen 2001–2002 study 2009–2011 study Definite Possible 
Tracheobronchial secretions Respiratory viruses IFAT Real-time PCR Positive NA
†
  
(collected via bronchoalveolar lavage 
and/or endotracheal) 
Bacteria Culture Culture/real-time PCR Growth/Positive NA 
Pleural fluids Bacteria Culture Culture Growth NA  
 Pneumococcal antigen ELISA ELISA Positive NA 
 S. pneumoniae Not tested Real-time PCR Positive NA 
Urine S. pneumoniae CIE Binax NOW NA Positive 
*ASOT, antistreptolysin O titre; IFAT, immunofluorescence antibody testing; ELISA, enzyme-linked immunosorbent assay; CIE, counter-current immunoelectrophoresis. 
†
NA, not applicable. 
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2.3 Radiology study 
2.3.1 Study design and participants 
A prospective study to investigate the aetiology of pneumonia in children was 
undertaken from October 2009 to March 2011 in two teaching hospitals in North of 
England as described in section 2.2. Caldicott approval was granted and the study was 
ethically approved by the Newcastle and North Tyneside Research Ethics Committee 
(No: 08/H0906/105), and the Research Approval Board at South Tees Hospitals NHS 
Trust (No: 2008075) (Appendix 1).  
 
Children aged 0–16 years who presented to paediatric services with signs and symptoms 
suggestive of lower respiratory tract infection including any of fever, tachypnoea, 
dyspnoea, cough, respiratory distress and auscultatory chest crackles, with chest 
radiographic findings consistent with pneumonia as determined initially by the 
admitting paediatrician were enrolled. Paediatricians were not asked to give specific 
radiological interpretations which were provided by radiologists. As this study was on 
the CAP aetiology, exclusions included being resident outside of North East England, 
clinical bronchiolitis, or hospitalization in the preceding three weeks. Children with 
recent hospitalisation were excluded in order to eliminate the potential risk of having 
hospital rather than community-acquired pneumonia. Children with underlying chronic 
chest diseases (such as cystic fibrosis) were also excluded to avoid any ambiguity in the 
interpretation of acute and chronic changes on chest radiographs. Research teams of 
doctors and nurses led and ascertained the standardised diagnosis of pneumonia and the 
recruitment process across the two sites. All enrolled children irrespective of the chest 
radiographic findings received treatment for pneumonia according to the management 
guidelines from the BTS.[1] 
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2.3.2 Radiology 
All chest radiographs were anteroposterior views and first reported by radiologists 
locally as per routine clinical care and viewed electronically via the Picture Archiving 
and Communications System (PACS). There were uniform and regular quality 
assessments performed on the system performance including display characteristics. All 
reporters used similar workstations of radiological standards when reporting the chest 
radiographs. Using the full text written first reports, each radiograph was categorised 
into lobar (end-point consolidation), patchy, perihilar (non-end-point 
consolidation/infiltrate) or normal (no pneumonia) according to the WHO criteria.[150, 
151] Effusion with fluid in the pleural space between the lung and chest wall was 
considered as primary end-point and classified simply as either present or absent.[151] 
This does not include fluid in the horizontal or oblique fissures. First reports were 
generated with the benefit of clinical information, a standard institutional requirement 
for routine reporting. All radiographs were reviewed by a second consultant 
cardiothoracic radiologist (Dr Michelle Muller) at the regional centre (designated as the 
“gold standard”) who was blinded to both the first report and specific clinical data. 
However, this radiologist knew the radiographs were from a child enrolled in the CAP 
study, thus clinically pneumonia had been suspected. Radiologists involved in 
performing the first and second reporting received the same training in radiology 
including the classification of radiological pneumonia. Those involved in first reporting 
included five radiology trainees, three consultants general, two paediatric and two 
cardiothoracic radiologists.   
 
A workshop including me, Dr Michelle Muller, Dr David Spencer (consultant 
respiratory paediatrician) and Dr Julia Clark (chief investigator and consultant in 
paediatric infections disease) was carried out before the application of WHO criteria 
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[150] on the first reports and performing the second reading in order to discuss and 
refine the potential definitions which could be a source of disagreement such as 
interstitial infiltrates of patchy or perihilar changes. The study team agreed that if more 
than one radiographic change were reported, then in line with WHO recommendations 
the most significant one is reported.[150] The WHO criteria were prioritised according 
to the clinical significance, as follows: lobar (end-point consolidation) in favour of other 
changes (non-end-point infiltrates) if both were present.[150] When more than one 
radiographic change was reported then the radiograph was classified overall according 
to the most significant category. I carried out the grouping of the first reports and there 
was no ambiguity on the wording of first reports that might cause confusion on 
categorization. Inter-observer variability in the interpretation of chest radiographs was 
measured by the comparison of first reports with their second reading. The intra-
observer variation was not calculated because all radiologists read the radiographs only 
once. 
2.3.3 Statistical analysis 
Data analysis was performed using the PASW Statistics 19 program. The significance 
of inter-observer variability was assessed using Fisher's exact test because there were 
small values <5 in the tables. Cohen's kappa index (k) was calculated to measure the 
agreement between the first and second readers above that which would be expected by 
chance.
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Chapter 3 Incidence of Childhood Pneumonia
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3.1 Results 
A total of 582 children were initially identified; 40 were excluded (34 had a normal 
chest radiograph, six lived outside of the North East), leaving 542 eligible for inclusion 
(58% males). There were no deaths. Overall, 98% received antibiotics and 84% were 
admitted to hospital. Lobar consolidation was reported in 30%, and pleural effusion was 
present on 9.6% of the chest radiographs. Four hundred (74%) children aged under five 
years old were included. Of these, 320 were vaccinated with PCV7, 33 were eligible for 
this vaccine but had not received it, for nine their vaccination status was unknown and 
38 were ineligible for the vaccine on age grounds. One child who was ineligible on age 
grounds had received the vaccine. Hence, the PCV7 uptake was 90.7% amongst the 
eligible children in the survey. 
 
The annual incidence of pneumonia was 11.8/10 000 children aged ≤16 years (95% CI 
10.9–12.9), with 27.4/10 000 (95% CI 24.8–30.2) in the under five age group. This 
compared to 14.4/10 000 (95% CI 13.4–15.4) and 33.8/10 000 (95% CI 31.1–36.7), 
respectively in 2001.[59] The annual hospitalisation rate was 9.9/10 000 (95% CI 9.0–
10.9) for all, and 22.4/10 000 (95% CI 20.1–25.0) for the under fives. This was lower 
than the 2001 annual rates; 12.2/10 000 (95% CI 11.3–13.2) and 28.7 (95% CI 26.2–
31.4), respectively. By calculation of the incidence rate ratio, the overall reduction in 
annual incidence between 2001 and 2009 was 17.7% (95% CI 8–26) and the reduction 
in annual hospitalisation rate 18.5% (95% CI 8–28). The reduction in annual incidence 
of pneumonia in the under fives was 19% (95% CI 8–29%). Table 3-1 compares data 
between the 2001 and 2009 surveys.   
 
There was a significantly lower annual incidence of pneumonia among children aged 
under five vaccinated with PCV7 (25.2/10 000, 95% CI 22.6–28.2) compared with those 
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that were unvaccinated (37.4/10 000, 95% CI 29.2–47.1) (OR 4.5, 95% CI 3.5–5.9). 
However, there was no significant difference in the annual incidence of severe disease 
between the vaccinated children (13.0/10 000, 95% CI 11.1–15.1) and those 
unvaccinated in the under five age group (22.6/10 000, 95% CI 16.4–30.5) (OR 0.7, 
95% CI 0.4–1.2). Amongst those aged under two years, there was a significant 
reduction by 33.1% (95% CI 20–45) in the annual incidence of pneumonia from 49.9/10 
000 (95% CI 44.1–56.4) in 2001 to 33.5/10 000 (95% CI 28.9–38.4) in 2009, whereas 
the reduction in annual hospitalisation rate was 38.1% (95% CI 24–50) between 2001 
and 2009 (Table 3-1). Reduction in both the annual incidence of pneumonia and 
hospitalisation rate between 2001 and 2009 was also observed among the 2.0–4.9 years 
age group by 23.1% (95% CI 7–36) and 29.8% (95% CI 14–43) respectively. In the 
over five age group, there was no difference in the annual incidence of pneumonia 
between 2001 and 2009 (incidence rate ratio 0.85, 95% CI 0.7–1.2), nor the annual 
hospitalisation rate between both studies (incidence rate ratio 0.9, 95% CI 0.7–1.2). 
 
In common with the 2001 analysis [59], the differences in annual rates of pneumonia 
between girls and boys, and between different socioeconomic groups were not 
significant. Most cases (n=363, 67%) occurred during the winter and spring seasons. 
Table 3-2 summarises the annual incidence rates of CAP by age group for disease 
severity and chest radiographic findings. Overall, males had higher rates of CAP for 
different categories of disease severity. In both males and females the annual rates in 
children under five were six-times higher than those in the over fives. Patchy changes 
were the most common chest radiographic finding particularly in the under five age 
group. Lobar pneumonia was seen in a quarter of children aged under five years old, 
compared to approximately 15% in 2001. There was an overall significant increase in 
the annual incidence of lobar pneumonia from 2.8/10 000 (95% CI 2.3–3.3) in 2001 to 
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3.5/10 000 (95% CI 3.0–4.1) in 2009 (OR 1.3, 95% CI 1.01–1.6). No significant risk 
factors for severe pneumonia were identified with univariate or multivariate logistic 
regression. These included age, gender, socioeconomic status, prematurity, parental 
smoking and asthma (Table 3-3). Although parental smoking was not a significant risk 
factor for severe disease, where parents were smokers, 58% (84/146) of their children 
had severe disease. This is compared to 50% (123/247) of children with severe disease 
of non-smoking parents (OR 1.3, 95% CI 0.8–1.9, p=0.253). 
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Table 3-1 Comparison of annual incidence of pneumonia and hospitalisation 
between 2001 and 2008 data per 10 000 children 
 2001–2002 survey 2008–2009 survey Reduction 
Variables IR (95% CI)
*
 IR (95% CI) % (95% CI) 
Overall     
     Pneumonia 14.4 (13.4–15.4) 11.8 (10.9–12.9) 17.7 (8 to 26) 
     Hospitalisation 12.2 (11.3–13.2) 9.9 (9.0–10.9) 18.5 (8 to 28) 
Under two years (0–1.9)    
     Pneumonia 49.9 (44.1–56.4) 33.5 (28.9–38.4) 33.1 (20 to 45) 
     Hospitalisation 45.6 (40.1–51.8) 28.2 (24.1–32.8) 38.1 (24 to 50) 
2.0–4.9 years    
     Pneumonia 30.7 (27.1–34.6) 23.6 (20.4–27.1) 23.1 (7 to 36) 
     Hospitalisation 27.5 (24.1–31.3) 19.3 (16.5–22.5) 29.8 (14 to 43) 
Under five years    
     Pneumonia 33.8 (31.1–36.7) 27.4 (24.8–30.2) 19.1 (8 to 29) 
     Hospitalisation 28.7 (26.2–31.4) 22.4 (20.1–25.0) 21.9 (10 to 32) 
Over five years    
     Pneumonia 5.3 (4.6–6.1) 4.5 (3.8–5.4) 14.7 (-7 to 32)† 
     Hospitalisation 4.5 (3.8–5.2) 4.1 (3.4–4.8) 9.4 (-15 to 29)† 
*IR, incidence rate; CI, confidence interval. 
†Negative numbers denote an estimate of an increase in incidence. 
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Table 3-2 Annual incidence of pneumonia per 10 000 children (2008–2009) 
 Under fives (n=400) Over fives (n=142) Overall (n=542) 
Variables n (%) IR (95% CI)
*
 n (%) IR (95% CI) n (%) IR (95% CI) 
Male 227 (56.8) 15.5 (13.6–17.7) 86 (60.6) 2.8 (2.2–3.4) 313 (57.7) 6.8 (6.1–7.6) 
Female 173 (43.2) 11.8 (10.1–13.7) 56 (39.4) 1.8 (1.4–2.3) 229 (42.3) 5.0 (4.4–5.7) 
Disease severity       
     Mild 147 (36.8) 10.1 (8.5–11.8) 56 (39.4) 1.8 (1.4–2.3) 203 (37.5) 4.4 (3.9–5.1) 
     Moderate 40 (10.0) 2.7 (1.9–3.7) 16 (11.3) 0.5 (0.3–0.8) 56 (10.3) 1.2 (0.9–1.6) 
     Severe 213 (53.2) 14.6 (12.7–16.7) 70 (49.3) 2.2 (1.8–2.8) 283 (52.2) 6.2 (5.5–6.9) 
Chest radiographic findings       
     Patchy 227 (56.8) 15.5 (13.6–17.7) 69 (48.6) 2.2 (1.7–2.8) 296 (54.6) 6.5 (5.7–7.2) 
     Lobar 99 (24.8) 6.8 (5.5–8.2) 63 (44.4) 2.0 (1.6–2.6) 162 (29.9) 3.5 (3.0–4.1) 
     Perihilar 61 (15.2) 4.2 (3.2–5.4) 6 (4.2) 0.2 (0.1–0.4) 67 (12.4) 1.5 (1.1–1.9) 
     Other infiltrates 13 (3.2) 0.9 (0.5–1.5) 4 (2.8) 0.1 (0.03–0.3) 17 (3.1) 0.4 (0.2–0.6) 
Social class (IMD score)
†
       
     1st quantile (2.97–14.46) 101 (25.2) 6.9 (5.6–8.4) 29 (20.4) 0.9 (0.6–1.3) 130 (24.0) 2.8 (2.4–3.4) 
     2nd quantile (14.47–25.33)  92 (23.0) 6.3 (5.1–7.7) 36 (25.3) 1.2 (0.8–1.6) 128 (23.6) 2.8 (2.3–3.3) 
     3rd quantile (25.34–42.44) 102 (25.5) 6.9 (5.7–8.5) 43 (30.3) 1.4 (0.9–1.9) 145 (26.8) 3.2 (2.7–3.7) 
     4th quantile (42.45–78.53) 105 (26.3) 7.2 (5.9–8.7) 34 (23.9) 1.1 (0.8–1.5) 139 (25.6) 3.0 (2.6–3.6) 
*IR, incidence rate; CI, confidence interval; †IMD, index of multiple deprivation. 
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Table 3-3 Univariate risk factors of severe versus mild/moderate pneumonia 
  Disease severity, n (%)    
Characteristics n (%) Severe M/M
*
 OR
†
 95% CI P 
Age group (years)       
     Under fives 400 (73.8) 204 (51.0) 196 (49.0) 1.7 0.8–1.6 0.418 
     Over fives 142 (26.2) 79 (55.6) 63 (44.4) 1.0 –  
Sex       
     Female 229 (42.3) 115 (50.2) 114 (49.8) 1.0 –  
     Male 313 (57.7) 168 (53.7) 145 (46.3) 1.2 0.8–1.6 0.427 
Social class (IMD score)       
     1st quantile (2.97–14.46) 130 (24.0) 67 (51.5) 63 (48.5) 1.0 –  
     2nd quantile (14.47–25.33)  128 (23.6) 70 (54.7) 58 (45.3) 1.1 0.7–1.9 0.612 
     3rd quantile (25.34–42.44) 145 (26.8) 72 (49.7) 73 (50.3) 0.9 0.6–1.5 0.755 
     4th quantile (42.45–78.53) 139 (25.6) 74 (53.2) 65 (46.8) 1.1 0.7–1.7 0.780 
Gestation (weeks)       
     24–28  7 (1.3) 3 (42.9) 4 (57.1) 5.8 0.7–48.4 0.105 
     29–32 13 (2.4) 7 (53.8) 6 (46.2) 1.5 0.5–4.8 0.452 
     33–36  25 (4.6) 13 (52.0) 12 (48.0) 1.7 0.7–3.9 0.206 
     ≥37 497 (91.7) 260 (52.3) 237 (47.7) 1.0 –  
Parental smoking       
     No 247 (62.8) 123 (49.8) 124 (50.2) 1.0 –  
     Yes 146 (37.2) 84 (57.5) 62 (42.5) 1.3 0.8–1.9 0.253 
Asthma       
     No 501 (92.4) 261 (52.0) 240 (48.0) 1.0 –  
     Yes 41 (7.6) 22 (53.7) 19 (46.3) 1.6 0.9–3.2 0.139 
*M/M, mild/moderate. 
†OR, odds ratio. 
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3.2 Discussion 
This is the first prospective survey in the UK to evaluate the effect of PCV7 on the 
incidence of childhood CAP. It reports an 18% reduction in both the annual incidence of 
CAP presenting to hospital and annual hospitalisation rate between 2001 and 2009. 
There was a lower incidence of pneumonia among PCV7-vaccinated children under five 
years old than those unvaccinated. Rates of pneumonia and likelihood of hospital 
admission were highest among the under fives, consistent with previous studies.[33, 59] 
As in 2001, there were trends towards higher annual rates of pneumonia among male 
children living in deprived socioeconomic areas.[59, 258-260]  
  
There were no significant risk factors for severe pneumonia in this survey, although 
extreme prematurity was a risk factor for severe disease in 2001.[59] This may reflect 
changes in neonatal care in the intervening period or could be related to small sample 
size. However, in a recent study our region had the highest rate of bronchopulmonary 
dysplasia rate in Europe, suggesting that the relationship may be complex.[261] It was 
surprising that parental smoking was not a risk factor for severe pneumonia, given that 
there was a relative excess of smoking in the studied cohort (37%) compared to the 
national average rate of 21% for adults.[1] Although parental smoking was not a 
significant risk factor for severe disease, where parents were smokers, 58% of their 
children had severe disease. A recently pooled review data showed that passive family 
smoking is a risk factor of respiratory diseases in children.[73, 74, 229] Self-reporting 
of parental smoking is usually underestimated.[230-232] It has been suggested to 
measure cotinine levels in blood and urine of children to overcome under reporting of 
passive smoking.[230, 232] Therefore the lack of smoking as predictor of severe disease 
in the present survey is potentially influenced by recall bias. Similarly there is 
variability on defining asthma in children which makes parents inaccurately report 
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it.[262, 263] A recent study in the North East of England showed that IPD is not 
associated with low socioeconomic status in children.[264] This supports the finding 
from the present survey of lack of deprivation as a risk factor for severe disease. 
3.2.1 Comparison to other studies 
The reduction in both annual incidence of pneumonia and hospitalisation rate in this 
survey is comparable with a previous study in England,[115] which reported a 19% 
decrease between 2006 and 2008 in childhood pneumonia using hospital episodes 
statistics (HES) data. The reduction in the annual rate of hospitalisation was more than 
that reported in Canada of 13% in the under five following the routine introduction of 
PCV7.[79] The annual disease incidence is also close to the estimates of other studies of 
PCV11 in the Philippines [147] and PCV7 in the USA [144] who reported decreases in 
all-cause pneumonia by approximately 22%. It is however, lower than the 25% 
reduction against radiological pneumonia reported in randomized controlled trial of 
PCV9 in South Africa [142] and 30% in the USA [148]. This may be a reflection of the 
differences in pneumococcal disease between populations or in adherence and vaccine 
usage in our population compared to the trial settings. As this survey used a standard 
and comparable radiological definition of pneumonia it should not reflect differences in 
disease ascertainment between the studies.  
 
Interestingly, the major reduction in pneumonia admissions (38%) was observed in 
those aged under two years. This is similar to the finding from the USA of 
approximately 40%,[153] but higher than that observed (15%) during the PCV9 trial in 
The Gambia.[143] This variation with The Gambian trial could be related to the fact 
that many cases of pneumonia were missed as only 14% of all children were recruited at 
the sites where research teams were permanently onsite with the rest living in areas 
served by irregular mother-child-health clinics.[143] The marked reduction in the 
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annual disease incidence in the under two age group of 33%, is also comparable to the 
reported incidence reduction of up to 37% from the pneumococcal conjugate 
vaccination trials and pooled review data.[143, 145, 146] There was observed a greater 
decrease (30%) in the annual admission rate among those aged 2–4 years compared to 
the 17% found by Grijalva and colleagues.[153] 
  
This survey has demonstrated a reduction in all-cause pneumonia. Previous estimates 
have suggested around 10% of childhood pneumonia is attributable to S. pneumoniae in 
the UK.[28, 29] Given the decline in pneumonia and assuming the absence of other 
changes in disease or admission procedures, it seems likely that 10% is a significant 
underestimation of the true burden of pneumococcal related childhood pneumonia in the 
UK.[1, 265] It is only recently that any studies have been able to describe the relative 
contributions of different pneumococcal serotypes in paediatric pneumonia,[18] and 
these have not yet been established in UK children. At the moment the pneumococcal 
serotype distribution in childhood pneumonia in the UK has only been inferred from 
surveillance of invasive pneumococcal disease by the Health Protection Agency and 
studies from other countries. Thus the potential reduction in pneumococcal childhood 
pneumonia in the UK provided by PCV7 is not known with certainty. This survey is a 
significant step towards reducing that uncertainty. Future studies are needed to carefully 
evaluate the epidemiological and health economic impacts of the new generation of 
conjugate vaccines. 
3.2.2 Strengths and limitations 
The strengths of this survey include the use of a multi-centre large scale approach, well-
validated disease definition and previously studied population allowing accurate 
historical comparisons. Its significant limitation is that while the introduction of PCV7 
is the major change between the two surveys, the ecological nature of the survey means 
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that the decrease in disease incidence cannot be causally attributed to PCV7 alone.[50, 
266] Further potentially relevant factors include natural variations in disease incidence, 
other public health interventions such as anti-smoking campaigns,[267, 268] variation in 
national and local health policies, changes in admission criteria, referral pathways and 
threshold for radiological investigation, and the implementation of national guidelines 
for the management of CAP in children by the BTS in 2002.[160] The later factor might 
have resulted in more children being managed in primary care including accident and 
emergency departments. While cannot rule out these factors using the methodology in 
this survey, I feel it is unlikely that any of these factors would have reduced the 
incidence of pneumonia to the degree observed. Furthermore, it would be speculated 
that these factors would alter the overall incidence rate regardless of age group. The fact 
that no significant difference was found in the annual incidence of pneumonia in the 
over five age group, by definition non-vaccine recipients, therefore increases the 
likelihood that the observed changes were attributable to PCV7. 
 
It could be speculated that changes in the incidence of viral disease or vaccination may 
have contributed to the observed differences in the annual rates of pneumonia, though 
this is unlikely given that the neither age group (and specifically the under two age 
group) are routinely vaccinated against respiratory viral disease. No specific data were 
collected on influenza vaccination status but it is most likely that the overwhelming 
majority of enrolled children were unvaccinated. It has also been hypothesised that a 
considerable proportion of viral pneumonia may in fact have co-infection with bacterial 
pathogens including S. pneumoniae as shown by Michelow and colleagues [11] which 
could potentially ameliorate the effect of variations in the incidence of seasonal 
influenza or other viral infections. 
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The inclusion of a further group of the other infiltrates/abnormalities chest radiographic 
feature to the WHO definition of radiological pneumonia could have overestimated the 
incidence of pneumonia within our population. However, the number of such 
individuals was low and represented only 3% of all cases of pneumonia within the 
studied cohort. It would be therefore suggested that this should not have significantly 
influenced these findings, given the magnitude of the changes reported in this survey. In 
contrast to the observed substantial reduction in the annual incidence of lobar 
pneumonia following the conjugate vaccination programme in Canada,[79] this survey 
reported increased lobar findings. This could be attributed to either the relative 
implication of non-PCV7 pneumococcal serotypes in the aetiology of pneumonia in 
children or due to the recognized variation in the interpretation of paediatric chest 
radiographs,[38] which in this survey were reported by local radiologists that differed 
between sites and from the original survey. Although the diagnosis of end-point 
pneumonia was dependent on reading non-standardised chest radiograph reports by 
local radiologists, the application of standardised criteria provided by the WHO on 
defining the radiological end-point pneumonia would allow more accurate comparative 
data in epidemiological studies for assessment of the impact of pneumococcal 
vaccination.[150, 151]  
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3.3 Conclusions 
The findings suggest that PCV7 was effective in reducing by 18% both the annual 
incidence of childhood pneumonia seen in hospital and annual rates of hospitalisation in 
one population within the UK. In particular, these reductions were more marked, by 
nearly a third, in the under two age group. Cotinine levels in blood and urine of children 
should be measured in epidemiological studies of pneumonia to minimise inaccuracies 
of self-reporting passive household smoking. In addition, care should be taken to clearly 
define asthma when reporting it as a predictor of severe pneumonia in children.   
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Chapter 4 Management of Pneumonia in Children
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4.1 Results 
A total of 582 children with suspected pneumonia were identified initially; 40 were 
excluded (34 had a normal chest radiograph, 6 lived outside of the North East), leaving 
542 eligible for inclusion (58% males; 74% under five years). Similar to the pre-
guidelines survey (89%), 84% children were admitted. Of those who were discharged 
home after initial assessment, none returned to hospital within three weeks with clinical 
features suggestive of lower respiratory tract infection.  
 
Four hundred children were under five, of these 320 were vaccinated with PCV7, 33 
were eligible for this vaccine but had not received it, vaccination status was unknown in 
nine and 38 were ineligible for the vaccine on age grounds. One child who was 
ineligible on age grounds had received the vaccine. Hence, the PCV7 uptake was 90.7% 
amongst the eligible children in the survey, comparable to the national immunisation 
records for England.[269] 
4.1.1 Presentation 
Table 4-1 summarises the clinical features at presentation across both surveys. 
Comparing post- with pre-guidelines surveys; fewer children presented with severe 
disease (52% versus 59%) [OR 0.8, 95% CI 0.61–0.96, p=0.023], although there were 
no differences in the rates of hypoxia (p=0.204). There was no difference in disease 
severity between those aged under and over two years in both the post-guidelines 
(p=0.860) and pre-guidelines (p=0.615).  
 
Lobar changes were reported more often in the pre-guidelines survey (p=0.0001), whilst 
patchy findings (p=0.019) and perihilar infiltrates (p=0.006) were less common. The 
rate of empyema complicating pneumonia increased between the survey periods to 5.4% 
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compared to 3%. The rates of pleural effusion were similar between the two surveys; 
9.6% and 9% post- and pre-guidelines respectively [OR 1.1, 95% CI 0.72–1.55, 
p=0.845]. Among those with pleural effusion, reported lobar changes were present in 
77% post-guidelines compared to 42% pre-guidelines [OR 0.2, 95% CI 0.09–0.48, 
p=0.0002]. Empyema was associated with lobar changes in 96.6% and 62.5% post- and 
pre-guidelines respectively [OR 0.06, 95% CI 0.007–0.52, p=0.003]. 
 
Logistic regression analysis of the post-guidelines data suggested that children over two 
not given preadmission antibiotics were more likely to develop severe disease [OR 2.01, 
95% CI 1.17–3.45, p=0.010]. Hospitalisation was associated with disease severity [OR 
6.9, 95% CI 3.83–12.37, p<0.001], but not with pyrexia (triage temperature >38oC) 
(p=0.487) or chest radiographic changes (p=0.368). Disease severity was not associated 
with radiological findings (p=0.498).
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Table 4-1 Clinical features at presentation 
 All (0–16 y), n (%) Infants (≤1 y) 0–4 y 5–16 y 
Characteristics n=711 [2001–2002] n=542 [2008–2009] n=86 (16%) n=400 (74%) n=142 (26%) 
Triage temperature >38
o
C 435 (61.0) 266 (49.1) 29 (34.5) 205 (52.2) 61 (44.2) 
Oxygen saturation <93% 213 (30.0) 145 (26.7) 21 (25.0) 106 (27.1) 39 (28.3) 
Disease severity      
     Mild  155 (22.0) 203 (37.5) 27 (31.4) 147 (36.7) 56 (39.4) 
     Moderate  138 (19.0) 56 (10.3) 9 (10.5) 40 (10.0) 16 (11.3) 
     Severe  418 (59.0) 283 (52.2) 50 (58.1) 213 (53.3) 70 (49.3) 
Chest radiographic findings      
     Lobar 141 (20.0) 162 (29.9) 22 (25.6) 99 (24.8) 63 (44.4) 
     Patchy 435 (61.0) 296 (54.6) 55 (64.0) 227 (56.8) 69 (48.6) 
     Perihilar 127 (18.0) 67 (12.4) 7 (8.1) 61 (15.3) 6 (4.2) 
     Other infiltrates  – 17 (3.1) 2 (2.3) 13 (3.3) 4 (2.8) 
Pleural effusion (including empyema) 65 (9.0) 52 (9.6) 1 (1.2) 21 (5.3) 31 (21.8) 
Empyema 24 (3.0) 29 (5.4) 1 (1.2) 12 (3.0) 17 (12.0) 
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4.1.2 Investigations 
There was an association between the collection of blood samples for investigation(s) 
and use of intravenous (IV) antibiotics pre-guidelines [OR 37.7, 95% CI 21.43–66.16, 
p<0.001], but not in the post-guideline period [OR 0.97, 95% CI 0.68–1.37, p=0.858]. 
There was a significant reduction in the number of all investigations performed 
(p<0.001) except C-reactive protein (CRP) (p=0.448) between the pre- and post-
guidelines surveys. Full blood count (FBC) decreased from 76% to 61%; blood culture 
from 70% to 53%; testing respiratory secretions for viruses (24% to 12%) and bacteria 
(18% to 8%); and CRP from 62% to 59%. The yield of blood culture was the same in 
both surveys (4% and 4.9%) and not related to age (p=0.451). Post-guidelines, viral 
PCR assay (immunofluorescence test was instead used in pre-guidelines) was performed 
on respiratory secretions from 66 children with 26 (39%) positive. Obtaining a viral 
respiratory screen was age-dependent and more frequently performed in those aged 
under two (22%) than over two years, but less often when compared with pre-guidelines 
(34%) [OR 0.5, 95% CI 0.33–0.75, p=0.001]. 
 
CRP was obtained in 322 (59%). Of which 27% were >100 mg/L; 9% of infants, 58% 
of under five years old and 42% in the above five. Pleural effusion was associated with 
higher CRP greater than 100 mg/L (p<0.001). Lobar and patchy changes were 
associated with a CRP more than 150 mg/L (p<0.05). Mean values of CRP, total white 
cell count (WCC) and neutrophils were higher with lobar changes (p<0.001). There was 
no significant difference in the CRP and WCC values with disease severity. 
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4.1.3 Management 
Table 4-2 summarises the clinical management. Preadmission prescription of antibiotics 
in the community was less frequent post-guidelines (22%) than pre-guidelines (30%) 
[OR 0.65, 95% CI 0.50–0.85, p=0.001]. The use of IV fluids and nasogastric feeds were 
related to severe disease in both surveys (p<0.001) and hence both were given less 
frequently post-guidelines. IV fluids were given in 13.7% versus 21% [OR 0.6, 95% CI 
0.45–0.83, p=0.002] post- compared with pre-guidelines, and nasogastric feeds 4.1% 
versus 9% [OR 0.5, 95% CI 0.27–0.75, p=0.002] respectively. 
 
Between the pre- and post-guidelines surveys, overall IV antibiotics as a proportion of 
the total prescribed antibiotics decreased from 47% (501/1065) to 36% (318/891) [OR 
1.6, 95% CI 1.33–1.93, p<0.001], and oral antibiotics alone increased from 16% to 50% 
[OR 4.4, 95% CI 3.37–5.71, p<0.001]. There was also a reduction in the use of IV route 
only from 8% to 5% [OR 1.8, 95% CI 1.08–2.86, p=0.025] and the use of both oral and 
IV routes (p<0.001) between the pre- and post-guidelines surveys respectively. Despite 
the overall reduction in IV antibiotic use post guidelines there was a wide variation in 
IV use between hospitals, from as little as 30% of admissions to as many as 70% 
(Figure 4-1). Post-guidelines, Amoxicillin prescription both orally and intravenously 
increased (p<0.001) with a decrease in IV cephalosporins (Cefuroxime and Cefotaxime) 
[OR 4.7, 95% CI 3.47–6.49, p<0.001] and total oral macrolides (Erythromycin, 
Azithromycin and Clarithromycin) [OR 2.4, 95% CI 1.79–3.14, p<0.001]. However, the 
individual use of Azithromycin or Clarithromycin remained the same, whilst use of 
Erythromycin decreased (p<0.001). Comparison of individual antibiotics prescribed in 
both surveys is shown in Table 4-3. 
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Pre-guidelines, initial IV antibiotics were significantly associated with severe disease 
(p=0.003); lobar changes (p=0.002); pleural effusion (p=0.00003); or pyrexia of >38
o
C 
(p=0.014); but not with low oxygen saturation of <93% (p=0.826). These associations 
were replicated in post-guidelines with the initial use of IV antibiotics being 
significantly associated with severe disease [OR 1.91, 95% CI 1.35–2.70, p=0.0003], 
lobar changes [OR 0.6, 95% CI 0.43–0.91, p=0.018], or pleural effusion [OR 1.9, 95% 
CI 1.03–3.37, p=0.041], but not with low oxygen saturation of <93% (p=0.324) or 
pyrexia of >38
o
C (p=0.161). Comparing post- with pre-guidelines; IV antibiotics were 
more likely to be given to those with lobar chest radiographic findings (35% versus 
25%) [OR 0.6, 95% CI 0.45–0.85, p=0.004], but less likely to be given to children 
presenting with low oxygen saturations (25% versus 34%) [OR 0.6, 95% CI 0.45–0.89, 
p=0.009]. There were no differences in the surveys between rates of IV antibiotic 
administration and disease severity (p=0.08), pleural effusion (p=0.908) or pyrexia 
(p=0.646). Table 4-4 summarises antibiotic treatment by disease severity and 
radiological findings in the post-guidelines survey. 
 
Mean (± standard deviation (SD)) hospital stay decreased from the pre- to post-
guidelines surveys (4.7 ± SD 7.16 versus 3.2 ± SD 3.02 days, p<0.001). Those with 
severe disease, lobar changes or pleural effusion had a longer hospitalisation (p<0.001). 
All children irrespective of their age group who received any IV antibiotics (alone or in 
combination with oral) had a longer average hospitalisation than those who had only 
oral (4.1 ± SD 3.4 versus 2.0 ± SD 1.9 days, p<0.001). Figure 4-2 shows the probability 
of discharge from hospital in relation to the duration of admission. Approximately 75% 
of children were likely to be discharged within two days of hospital admission, whilst 
hospital stay for up to five days was required for nearly 20% of children. Approximately 
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5% of children stayed for nearly three weeks because of complications and presence of 
pre-morbid medical illnesses.  
 
In the survival analyses (Table 4-5), use of IV antibiotics alone or in combination with 
oral was a risk factor for an extended hospital stay by 66% and 58% respectively 
(p<0.05). Unsurprisingly, moderate and severe disease were associated with risk of 
longer hospitalisation in 83% and 79% respectively (p<0.001). Children admitted to site 
‘G’ had a 70% chance of being discharged sooner (p=0.024) in relation to the reference 
site ‘F’. Likelihood ratio (LHR) test showed that the overall association of these risk 
factors with longer hospital stay was only significant for disease severity (LHR=148, 
p=0.001).  
 
 
 78 
 
Table 4-2 Clinical management outcomes 
 All (0–16 y), n (%) Infants (≤1 y) 0–4 y 5–16 y 
Characteristics n=711 [2001–2002] n=542 [2008–2009] n=86 (16%) n=400 (74%) n=142 (26%) 
Pre-admission antibiotics 214 (30.0) 119 (22.0) 21 (24.4) 90 (22.5) 29 (20.4) 
     Days given, median (IQR)* [range] – 4 (2–7) [1–14] 4 (3–7) [2–14] 4 (2–7) [1–14] 4 (2–7) [1–14] 
Oxygen therapy 276 (39.0) 197 (36.3) 46 (53.5) 148 (37.0) 49 (34.5) 
     Days given, median (IQR) [range] 2 (1–4) [1–57] 2 (1–3) [1–14] 2 (1–4) [1–11] 2 (1–3) [1–11] 2 (1–4) [1–14] 
Nasogastric feeds 61 (9.0) 22 (4.1) 17 (19.8) 18 (4.5) 4 (2.8) 
     Days given, median (IQR) [range] 4 (2–10) [1–28] 3 (2–5) [1–9] 3 (1.5–4.5) [1–6] 3 (1.5–4.5) [1–6] 7 (5–9) [5–9] 
Intravenous (IV) fluid infusion 147 (21.0) 74 (13.7) 21 (24.4) 52 (13.0) 22 (15.5) 
     Days given, median (IQR) [range] 2 (1–3) [1–21] 1 (1–2) [1–10] 1 (1–3.7) [1–6] 1 (1–2) [1–8] 2 (1–2.5) [1–10] 
Antibiotics treatment 682 (96.0) 531 (98.0) 83 (96.5) 391 (97.8) 140 (98.6) 
     Oral route [days], median (IQR) [range] 6 (5–7) [1–90] 7 (5–7) [1–56] 7 (5–7) [1–28] 7 (5–7) [1–42] 7 (5–9.5) [2–56] 
     IV route [days], median (IQR) [range] 2 (2–4) [1–22] 2 (2–4) [1–20] 4 (2–6) [1–18] 2 (2–4) [1–18] 3 (2–6) [1–20] 
Hospitalisation by disease severity      
     Mild disease 102 (66.0) 131 (64.5) 18 (66.7) 89 (60.5) 42 (75.0) 
     Moderate disease 138 (100) 56 (100) 9 (100) 40 (100) 16 (100) 
     Severe disease 403 (94.0) 268 (94.7) 50 (100) 199 (93.4) 69 (98.6) 
Days in hospital, median (IQR) [range] 3 (2–5) [1–122] 2.5 (1–4) [1–23] – – – 
     Mild/moderate disease 3 (2.5–4.5) [1–14] 2.5 (1–2.5) [1–13] 2 (1.5–3) [1–6] 2 (1–2) [1–13] 2 (1.5–3) [1–5] 
     Severe disease 3 (2–6.5) [1–122] 3.5 (2.5–5.5) [1–23] 2 (1–5.5) [1–11] 3.5 (2.5–5.5) [1–23] 3.5 (2.5–5.5) [1–20] 
*IQR, interquartile range.
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Table 4-3 Comparison of prescribed antibiotics (2001 and 2008) 
  2001 survey 2008 survey   
Route Antibiotics n (%) n (%) OR (95% CI) P 
Oral   [N=564] [N=573]   
 Amoxicillin 134 (25) 253 (44) 0.4 (0.30–0.51) <0.001 
 Erythromycin 114 (20) 29 (5) 4.7 (3.07–7.55 <0.001 
 Co-amoxiclav 103 (19) 124 (22) 0.8 (0.59–1.09) 0.159 
 Azithromycin 80 (14) 66 (12) 1.3 (0.89–1.83) 0.185 
 Cephalexin 73 (13) 14 (2) 5.9 (3.27–11.53) <0.001 
 Clarithromycin 6 (1) 13 (2) 0.5 (0.14–1.32) 0.164 
Intravenous (IV)  [N=501] [N=318]   
 Cefuroxime 304 (61) 92 (29) 3.8 (2.77–5.19) <0.001 
 Benzylpenicillin 57 (11) 6 (2) 6.7 (2.83–19.15) <0.001 
 Amoxicillin 56 (11) 120 (38) 0.2 (0.14–0.30) <0.001 
 Cefotaxime 50 (10) 15 (5) 2.2 (1.21–4.37) 0.008 
 Co-amoxiclav 28 (6) 32 (10) 0.5 (0.30–0.93) 0.019 
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Table 4-4 Antibiotic treatment by disease severity and radiological findings 
 Disease severity Chest radiographic findings 
 Mild Moderate Severe Patchy Lobar Perihilar Other infiltrates 
Antibiotics (n=203) (n=56) (n=283) (n=296) (n=162) (n=67) (n=17) 
Oral only, n (%) 135 (66.5) 14 (25.0) 118 (41.7) 164 (55.4) 54 (33.3) 39 (58.2) 10 (58.8) 
     Days given, median [IQR] 6 [5–7] 6 [5–7] 7[(5–9] 7 [5–7] 7 [5–8] 7 [6–8] 5 [5–7] 
IV only, n (%) 4 (2.0) 4 (7.1) 18 (6.4) 12 (4.1) 8 (4.9) 6 (9.0) 0 (0) 
     Days given, median [IQR] 2 [1–2] 3 [2–3] 3 [2–6] 2 [2–4] 3 [2–6] 2 [1.5–3] 2 [1–2] 
Total oral and IV, n (%) 61 (30.0) 36 (64.3) 141 (49.8) 116 (39.2) 97 (59.9) 19 (28.4) 6 (35.3) 
     Days given, median [IQR] 7 [6–7] 7 [7–10] 7 [6–10] 7 [6–9] 7 [7–10] 7 [7–9] 7 [6–8] 
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Table 4-5 Cox-proportional hazard model with admission duration 
Variable Coefficient Exp coefficient SE Wald test LHR
§
 P 
Hospitals
*
  
(as coded in Figure 4-1) 
    12.1 0.206 
     A 0.23 1.26 0.22 1.049 – 0.294 
     B 0.16 1.18 0.23 0.709 – 0.478 
     C 0.41 1.51 0.24 1.751 – 0.080 
     D 0.17 1.19 0.21 0.821 – 0.412 
     E -0.03 0.96 0.22 -0.158 – 0.875 
     G 0.52 1.69 0.23 2.260 – 0.024 
     H 0.54 1.71 0.28 1.944 – 0.052 
     I 0.21 1.24 0.26 0.828 – 0.408 
     J 0.17 1.19 0.24 0.702 – 0.483 
Disease severity
†
     148 0.001 
     Moderate -1.75 0.17 0.20 -8.725 – <0.001 
     Severe -1.58 0.21 0.14 -10.912 – <0.001 
Antibiotic treatment
‡
     74.1 1.0 
     Oral only -0.02 0.97 0.42 -0.058 – 0.954 
     IV only -1.07 0.34 0.47 -2.275 – 0.023 
     Both IV and oral -0.86 0.42 0.42 -2.04 – 0.041 
Reference categories: *hospitals, site F; †disease severity, mild; ‡antibiotics, not given. 
§LHR, likelihood ratio. 
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Figure 4-1 Proportions of children who had severe disease and of those who received intravenous (IV) antibiotics in each hospital 
 
 
 
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
100 
A B C D E F G H I J All 
P
ro
p
o
rt
io
n
 o
f 
ca
se
s 
(%
) 
Hospital 
Severe disease IV antibiotics (either alone or in combination with oral route) 
 83 
 
Figure 4-2 Probability of discharge from hospital in relation to duration of 
admission with associated 95% confidence intervals  
 
Solid line, probability of discharge from hospital; broken lines, 95% CIs. 
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4.2 Discussion 
This survey completes the audit cycle started with a pre-guidelines survey in 2001–2002 
of presentation and management of children seen in hospital with pneumonia,[157] 
comparing selected standards.[160] Clinical management of children with pneumonia 
has changed significantly between 2002 and 2008. This included a reduction in the 
number of investigations performed, and a change in the type and administration of 
antibiotics to a decrease in IV and a concomitant increase in oral antibiotics.  
 
Factors potentially influencing the change of clinical practice include the introduction of 
the 7-valent pneumococcal conjugate vaccination programme, the publication of the 
BTS management guidelines and an expanding literature on oral/IV antibiotic use.[161, 
162, 270] Although this survey does not provide information on the management of 
paediatric CAP at the primary care/community level, it gives invaluable findings on the 
attitude of clinicians on managing this infection at hospitals where the local 
management policies may be driven by the published BTS guidelines.[160]  
 
Drivers of change are complex. Some are likely to be literature driven; others probably 
reflect the complex relationships around perceived benefits and risks of IV cannulation, 
venepuncture and differing usefulness of investigations. It is interesting that fewer blood 
tests in terms of FBC and blood cultures were taken, but just as many CRP samples 
were ordered. This may reflect the fact that some children did not have IV access, as 
there was no association between blood sample collection and IV antibiotic use in the 
post-guidelines. This association however was significant pre-guidelines. The BTS 
guidelines including the recently updated version [1] made no specific 
recommendations around FBC, but blood cultures were (and are) specifically 
encouraged, whilst CRP is not.[160] In this survey, the correlation between high CRP of 
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>100 mg/L with pleural effusion demonstrates the usefulness of CRP in differentiating 
between uncomplicated and complicated pneumonia. Hence, it could be argued that 
CRP should be included in the further guidelines.  
 
The reduction in collection of blood cultures perhaps reflects the feeling that bacterial 
pneumonia is less likely given the introduction of pneumococcal conjugate vaccine. 
However, the proportion of positive blood cultures has remained the same, suggesting 
that blood cultures, even with a low yield, are useful in terms of diagnosis. It is 
disappointing that the apparent perception of usefulness appears to favour obtaining 
CRP than blood culture, when blood culture is usually the only routine investigation 
that can potentially provide a rapid microbiological diagnosis. Although clinicians were 
not asked directly, the shift towards less testing of respiratory secretions for either 
viruses or bacteria could reflect the feeling that the results would not affect the decision 
on antibiotic use following detection of bacterial nasopharyngeal carriage. 
 
More positive changes are seen with antibiotic usage. These included a significant 
reduction in the use of antibiotics prior to admission. This is in line with the observed 
substantial decline since 1990s in the prescription of antibiotics in primary care for 
lower respiratory tract infection in children.[271] This fall in antibiotic prescriptions 
predate the published BTS management guidelines of pneumonia in 2002.[160] They 
reflect a continued fall in the use of antibiotics despite a marginal increase in antibiotic 
prescription during the period between 2003 and 2006, primarily for non-specific upper 
respiratory tract infections, for which national guidance aimed at primary care was 
introduced in 2008.[271, 272] Intravenous antibiotics were used far less frequently than 
oral, with a substantial increase in the use of Amoxicillin overall and orally, at the 
expense of IV Cefuroxime and oral cephalosporins, which decreased from one fifth to 
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2%. In contrast, oral macrolides remain frequently prescribed particularly to those aged 
under five, similar to previous data,[157] although not recommended as first line 
treatment.[160] Evidence for the safety and efficacy of oral antibiotics even in severe 
pneumonia in children accumulated over the 6 years between surveys, including a 
Cochrane review in 2006 [161] and the PIVOT trial in 2007 [162]. Recent review of 
data sets from four studies of the management outcomes of severe pneumonia in 
children aged under three years in the community was associated with few 
complications, supporting the management of such cases with oral antibiotics in primary 
care settings.[163]   
 
The selection of initial antibiotic route was influenced by disease severity and lobar 
changes, possibly reflecting that these criteria were considered markers of bacterial 
infection. The fact that lobar changes were associated with high mean value of 
inflammatory markers may support this. However, the use of IV antibiotics in relation 
to severe disease varied by site. This illustrates a variation in departmental practice, 
despite accumulating evidence of the benefits and safety of oral antibiotics in severe 
pneumonia.[162, 270, 273] Other factors that could have influenced the decision to give 
IV antibiotics, such as the level of training of admitting medical staff or the knowledge 
of the published guidelines, could not be ascertained with the data collected. In line with 
these findings, Gerber and colleagues conducted a major retrospective study on the 
variability of antibiotic use across 40 children’s hospitals in the USA.[274] They found 
substantial variations in the prescription of antibiotics between sites, including both the 
proportion of children exposed to antibiotics (38%–72%) and the duration of treatment 
(368–601 antibiotic-days per 1000 patient-days). Also more recently considerable 
variability of antibiotic selections for management of CAP in children was observed 
among paediatric infectious disease consultants.[275] The variability in antibiotics use 
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highlights the need to implement and monitor effective antibiotic stewardship policies 
across and within hospitals to reduce the over or underuse of them, thus reducing the 
risks of development of antibiotic-resistant bacteria and treatment failures.[276]  
 
Both severe disease and use of IV antibiotics alone or in combination with oral were 
found to be risk factors for longer hospital stay. However, adjusted analysis of Cox 
regression models showed that the severe disease was the main over-riding reason for 
extended hospital stay. Recent studies and pooled review data have shown that viruses 
play remain important causative pathogens of CAP in children.[1, 2, 37, 277, 278] 
These findings can give plausible explanation that a significant proportion of children 
with pneumonia in the present survey may have had viral rather than bacterial 
infections. Accordingly, the lack of association of the use of IV antibiotics as a risk 
factor for an extended hospital stay in the likelihood ratio analysis, whereas disease 
severity was, points to the fact that antibiotic treatment did not alter the course of viral 
pathogens which can cause severe pneumonia in children.[21, 279, 280]  
4.2.1 Strengths and limitations 
This survey provides invaluable evaluation of the presentation and management of 
childhood CAP seen in hospital over a year period with particular focus on the 
investigations performed and use of antibiotics. Lack of data collection and interviewing 
of admitting clinicians about their decisions for performing investigations and selection 
of the type and administration route of antibiotics limited the interpretations of potential 
factors surrounding the observed changes on these areas. 
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4.3 Conclusions 
It is important for treating doctors to appreciate that intravenous antibiotics appear to be 
associated with increased hospital stay and to consider carefully the type and route of 
antibiotic to prescribe when admitting children with pneumonia to hospital. The large 
variation in intravenous antibiotic use and hospital stay between hospitals is highlighted 
and should be explored further. This is not explained fully by disease severity in our 
survey. In addition, a cost analysis focusing on the impact of reduced hospitalisation, 
intravenous antibiotic use and preadmission antibiotics would provide useful economic 
information. 
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Chapter 5 Aetiology of Childhood Pneumonia
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5.1 Results 
A total of 401 children were enrolled, 241 and 160 in the pre- and post-vaccine studies 
respectively. All had at least one microbiological investigation performed. There were 
similar demographic characteristics between the pre- and post-vaccine studies; 
including median age (2.5 versus 2.6 years), proportions of males (57% versus 56%) 
and aged under five years (75.5% versus 69%). The proportion of children who were 
referred directly in the pre-vaccine study from primary care was 86%, whereas 14% of 
children were referred in from secondary care district general hospital in the North East 
of England. This is compared to 78% and 22% respectively in the post-vaccine study 
(OR 1.8, 95% CI 1.04–2.98, p=0.041). Lobar consolidation was more often present 
post-vaccine in 61% compared to 23% of pre-vaccine (OR 0.2, 95% CI 0.13–0.30, 
p<0.001). More children developed empyema post-vaccine (25%, n=40) than pre-
vaccine (7%, n=17).  
 
A presumptive causative pathogen was established in 89% of all children post-vaccine, 
compared to 55% pre-vaccine (OR 0.2, 95% CI 0.09–0.27, p<0.001) when the results of 
all tests were combined. This significant difference in detection rates was similar for 
definite infective causes; being 61% in post-vaccine and 48.5% pre-vaccine (OR 0.6, 
95% CI 0.41–0.92, p=0.019). Figure 5-1 summarises the aetiological and radiological 
classifications and Table 5-1 lists the results of the diagnostic tests performed. The 
differences in the numbers of tested samples such as serology were related to the 
availability of sufficient serum to perform as many as possible tests. Parents often 
declined returning for these convalescent samples (all in the post-vaccine study), 
contributing to the variability of investigations performed. Bronchoscopy fluids were 
available from 14 and 4 children in the pre- and post-vaccine studies respectively. 
 
 91 
 
Forty-one children were not eligible for the pneumococcal conjugate vaccination due to 
age criteria whilst its uptake was 94% (112/119) among eligible children (89 had PCV7, 
10 PCV13 and 13 received combined doses of each with age-appropriate schedule). Of 
those vaccinated with PCV7 either routinely or according to the catch up programmes, 
83 of them received age-appropriate doses (57 had full schedule) whereas six children 
had partial schedule with one dose less for their age. Among those who had PCV13, one 
received full schedule, one child had one dose less for age, and eight had not completed 
but had appropriate doses for their age. 
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Figure 5-1 Summary of the aetiological and radiological classifications 
401 children with pneumonia 
(≥1 microbiological test performed) 
241 enrolled in 2000-01 study 
possible bacterial 
16 (6.5%) 
 definite infections 
117 (48.5%) 
viral, 47 (19.5%) 
- 44 single 
- 3 multiple (≥2) 
7 lobar 
27 patchy 
13 perihilar 
bacterial, 57 (24%) 
- 47 single 
- 10 multiple (≥2) 
22 lobar 
32 patchy 
3 perihilar 
mixed, 13 (5%) 
0 lobar 
9 patchy 
4 perihilar 
unknown cause 
108 (45%) 
160 enrolled in 2009-11 study 
 possible bacterial 
45 (28%) 
 definite infections 
97 (61%) 
 viral, 49 (31%) 
- 38 single 
- 11 multiple (≥2) 
17 lobar 
12 patchy 
20 perihilar 
bacterial, 28 (17.5%) 
- 24 single 
- 4 multiple (≥2) 
20 lobar 
3 patchy 
5 perihilar 
mixed, 20 (12.5%) 
17 lobar 
3 patchy 
0 perihilar 
unknown cause 
18 (11%)  
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Table 5-1 Results of the diagnostic tests performed 
 2001–2002 study (n=241) 2009–2011 study (n=160) 
Tests Tests, n Positive, n (%) Tests, n Positive, n (%) 
Blood and serology 238 75 (31.5) 138 32 (23.2) 
Blood, overall 236 36 (15.3) 136 13 (9.6) 
     Bacterial culture 185 6 (3.2) 126 7 (5.6) 
     S. pneumoniae PCR 228 30 (13.2) 86 7 (8.1) 
     16S rRNA PCR 0 0 89 1 (1.1) 
Serology, overall 181 49 (27.0) 105 22 (21.0) 
     Acute serology     
          Mycoplasma IgM antibody 34 11 (32.4) 77 8 (10.4) 
          ASOT 158 12 (7.6) 80 9 (11.3) 
          Mycoplasma/Chlamydia 128 8 (6.3) / 0 51 / 39 0 
          Legionella/Q-fever 0 0 50 / 42 0 
          Influenza A/B 158 1 (0.6) / 2 (1.2) 68 / 62 7 (10.3) / 0 
          RSV
*
/Adenovirus 158 2 (1.2) / 2 (1.2) 52 / 46 0 
          Epstein-Barr virus 1 0 0 0 
     Convalescent serology     
          ASOT 52 2 (3.8) 0 0 
          Mycoplasma/Chlamydia 14 3 (21.4) / 0 0 0 
          Influenza-A/B 101 1 (1.0) / 0 0 0 
          RSV/Adenovirus 101 6 (6.0) / 6 (6.0) 0 0 
          Epstein-Barr virus 1 1 (100) 0 0 
Respiratory secretions, overall 175 59 (33.7) 151 121 (80.1) 
     Viral screen 158 44 (27.9) 141 63 (44.7) 
     Bacterial culture 96 15 (15.6) 141 29 (20.6) 
     Pneumolysin RT (real-time)-PCR 0 0 121 76 (62.8) 
     H. influenzae RT-PCR 0 0 121 36 (29.8) 
     M. pneumoniae RT-PCR 0 0 121 5 (4.1) 
     C. pneumoniae/B. pertussis RT-PCR 0 / 1 0 / 1 (100) 121 0 
Urinary pneumococcal antigen 14 1 (7.1) 106 30 (28.3) 
Pleural fluids, overall 17 4 (23.5) 40 27 (67.5) 
     Bacterial culture 17 2 (11.8) 40 10 (25.0) 
     Pneumococcal antigen 17 2 (11.8) 30 7 (23.3) 
     Pneumococcal RT-PCR 0 0 30 18 (60.0) 
*RSV, respiratory syncytial virus. 
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5.1.1 Definite viral infections 
Table 5-2 shows the number of identified pathogens with age group distribution. Viral 
(31%) and mixed infections (12.5%) were significantly higher post-vaccine than pre-
vaccine; being respectively 19.5% (OR 0.6, 95% CI 0.35–0.90, p=0.021) and 5% (OR 
0.4, 95% CI 0.19–0.82, p=0.015). The detection of viruses using a combination of PCR 
and serological assays post-vaccine (57%, 85/149) was higher than that of testing with 
immunofluorescence and serology pre-vaccine (30.5%, 65/213). This improvement in 
viral detection was thought to be due to the application of PCR assays (44.7%) 
replacing immunofluorescence testing (27.9%) on respiratory secretions (OR 0.6, 95% 
CI 0.29–0.77, p=0.003). Post-vaccine, acute viral serological assays were only positive 
in seven with influenza A virus infection, whereas pre-vaccine, combined acute and 
convalescent serology identified infections with eight each of RSV and adenovirus, four 
influenza A/B viruses, and one Epstein-Barr virus. 
 
Post-vaccine, RSV was detected in 21% (31/147) of samples, of which 19 were type A 
with rhinovirus (8.5%), influenza (7%) and adenoviruses (7%). These figures were 
comparable with those pre-vaccine for adenovirus and influenza A/B (6% each); but 
higher than that for RSV (15%). Of the 142 definite pathogens post-vaccine, 71 (50%) 
viruses were detected among those aged under five years, compared to finding in the 
pre-vaccine study (36%, 54/149). hMPV was not detected in any of the 48 tested pre-
vaccine respiratory samples, but was identified in one child in the post-vaccine study. 
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Table 5-2 Detected definite pathogens by age group 
 2001–2002 study 2009–2011 study 
Pathogens n/N* n/N (%) n/N n/N (%) 
 < 5 y 5–16 y  < 5 y 5–16 y  
Bacterial       
     S. pneumoniae 28/180 7/58 35/238 (14.7) 14/93 10/45 24/138 (17.4) 
     M. pneumoniae 9/128 13/48 22/176 (12.5) 2/51 6/30 8/81 (9.9) 
     Group A Streptococcus 5/151 9/51 14/202 (7.0) 6/91 8/42 14/133 (10.5) 
     S. aureus 3/141 2/48 5/189 (2.6) 1/89 2/41 3/130 (2.3) 
     H. influenzae  0/141 2/48 2/189 (1.0) 3/89 0/41 3/130 (2.3) 
     Bordetella pertussis 1/1 0 1/1 (100) 0/85 0/36 0/121 
     M. catarrhalis 1/141 0/48 1/189 (0.5) 2/89 1/41 3/130 (2.3) 
     S. intermedius 1/141 0/48 1/189 (0.5) 0/89 1/41 1/130 (0.8) 
     Alpha haemolytic Streptococcus 1/141 0/48 1/189 (0.5) 0/89 0/41 0/130 
     K. pneumoniae 0/141 0/48 0/189 1/89 0/41 1/130 (0.8) 
Viral       
     RSV (not typed) 29/163 3/50 32/213 (15.0) 0 0 0 
     RSV type A 0 0 0 19/102 0/45 19/147 (13.0) 
     RSV type B 0 0 0 11/102 1/45 12/147 (8.2) 
     Influenza A and B viruses 9/163 4/50 13/213 (6.0) 7/103 4/44 11/149 (7.4) 
     Adenovirus 11/163 2/50 13/213 (6.0) 10/101 0/44 10/145 (6.9) 
     Parainfluenza 1-4   5/133 0/25 5/158 (3.2) 5/98 1/43 6/141 (4.3) 
     Human metapneumovirus 0/37 0/11 0/48 1/98 0/43 1/141 (0.7) 
     Epstein-Barr virus 0 1/1 1/1 (100) NT† NT – 
     Varicella zoster virus 0 1/1 1/1 (100) NT NT – 
     Rhinovirus  NT NT – 10/98 2/43 12/141 (8.5) 
     Pandemic influenza A H1N1 NT NT – 4/98 3/43 7/141 (5.0) 
     Bocavirus NT NT – 2/85 2/36 4/121 (3.3) 
     Coronavirus  (type OC43) NT NT – 2/85 1/36 3/121 (2.5) 
Total 103 46 149 100 42 142 
*N, total number of performed tests that their positive results classified as definite infections. 
†NT, not tested. 
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5.1.2 Definite bacterial infections 
There were no difference in the rates of bacterial infections between post-vaccine at 
17.5% of the total compared to 24% pre-vaccine (p=0.258). Identified overall 
pneumococcal infections as a definite cause were not different between both studies 
(p=0.557). They represent 17.4% among children tested post-vaccine (14/93 [15%] and 
10/45 [22.2%] in those aged under and over five years respectively). This was compared 
to 14.7% pre-vaccine (28/180 [15.6%] and 7/58 [12%] among those aged under and 
over five years respectively). In the post-vaccine study, diagnosis of pneumococcal 
infection improved when PCR assays were used (21/97, 21.6%) compared to culture 
(8/132, 6%) (p=0.0004). A serotype was identified in 75% (18/24) post-vaccine. These 
were serotypes 1 (44.4%), 3 (27.8%), 19A (22.2%) and 7A/F (5.6%). The rate of 
positive blood culture post-vaccine was almost double (5.6%) that in pre-vaccine 
(3.2%). Figure 5-2 shows Venn diagram distribution of different single and concordant 
identification sites of the overall pneumococcal infections.   
 
Group A streptococcal infections were confirmed in 10.5% of children tested post-
vaccine and 7% pre-vaccine. These infections were associated with severe disease, and 
in two-thirds of them with empyema. M. pneumoniae was identified from acute 
serology in 9.9% of children tested post-vaccine, with 4% (2/51) in those aged under 
five and 20% (6/30) over five years. The rate of detected mycoplasma infection in the 
pre-vaccine study was 12.5% when paired acute and convalescent samples were 
available, with 7% (9/128) in those aged under five and 27% (13/48) over five years 
old. Figure 5-3 shows Venn diagram distribution of different single and concordant 
identification sites of definite group A streptococcal infections. 
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Figure 5-2 A Venn diagram showing different single and concordant identification 
sites of the overall pneumococcal infections (2001 and 2009)  
 2001–2002 study 
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 2009–2011 study 
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Figure 5-3 A Venn diagram showing different single and concordant identification 
sites of group A streptococcal infections (2001 and 2009) 
 2001–2002 study 
 
 
 
 2009–2011 study 
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5.1.3 Bacteria from nasopharyngeal secretions 
Bacterial cultures of 96 samples of nasopharyngeal secretions yielded S. pneumoniae in 
4.2% and non-typeable H. influenzae in 9.4% in the pre-vaccine study. This is similar to 
7% and 7.8% respectively in the post-vaccine study. Detection rates increased 
considerably with the application of PCR assays on the samples to 62.8% and 29.8% for 
S. pneumoniae and H. influenzae respectively (Table 5-1). Mean (± SD) value of S. 
pneumoniae PCR was 38.2 ± 4.4 cycle threshold (Ct) with a median 38.6 (range, 28.5–
46), whereas for H. influenzae PCR it was 31.9 ± 4.9 Ct (median, 32.4; range, 19.5–
39.3). Where both bacterial culture and bacterial PCR for S. pneumoniae were 
performed on the same sample, there was no significant difference in the mean Ct levels 
between the positive and negative cultures [34.8 ± 6.5 versus 38.6 ± 4.2, p=0.072]. 
There was only one sample positive for H. influenzae by both culture and PCR. 
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5.2 Discussion 
This is the first study to describe the aetiology of CAP in UK children prior to and 
following the introduction of the pneumococcal conjugate vaccination programme. The 
timing of this comprehensive study three years after the introduction of PCV7 and 
during the first year of PCV13 provides a baseline for future comparative studies of the 
pneumonia aetiology in the same setting. The causative pathogens identified were 
predominately viruses in both studies with the detection of pneumococcal infections 
increasing from pre-to post-vaccine studies presumably as a consequence of the 
application of molecular diagnostic methods. 
 
The three previous UK studies investigating the aetiology of pneumonia in children 
prior to the introduction of the PCV7 were able to identify the aetiology of pneumonia 
in up to 54% of cases.[28, 29, 176] In addition to the blood culture, one tested blood for 
S. pneumoniae, Mycoplasma and Chlamydophila using PCR and identified 8% of 
children with pneumococcal pneumonia.[28] Another study identified 6% 
pneumococcal infection using pneumolysin ELISA on blood.[29] However, none of 
these studies investigated comprehensively the bacterial aetiology or evaluated the 
serotypes involved in pneumococcal pneumonia.  
 
In the post-vaccine study a likely pathogen was identified in 89% of children. This is 
comparable to detection rates around 80% in studies which used serological and/or 
molecular approaches,[11, 13, 15, 177] but is higher than the rates previously found 
prior to the introduction of the conjugate vaccine.[12, 178] The improved detection rate 
between the pre- and post-vaccine studies appears to be related to the different 
laboratory approaches used and compared to other studies likely to be related to 
methods, study duration and seasonality.   
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Whilst molecular diagnostic methods have improved respiratory virus detection and 
bacterial detection from normally sterile sites, the interpretation of results can be more 
problematic when it is applied to nasopharyngeal secretions and other respiratory 
samples. In the post-vaccine study most of the respiratory samples that were positive for 
S. pneumoniae (62.8%) and H. influenzae (29.8%) had higher Ct levels (>30) and 
therefore may represent nasopharyngeal carriage rather than definite infection.[1] This 
detection rate by PCR on nasopharyngeal secretions is similar to that previously 
reported 69%.[281] It has recently been recognised that the pneumolysin gene can be 
detected in non-pneumococcal Viridans-group streptococci, particularly S. 
pseudopneumoniae and S. mitis.[57] Therefore, this increased level of positivity may 
have also been caused by cross-reactivity with other Viridans-group streptococci. Hence 
the results of PCR-based approaches on nasopharyngeal secretions to diagnose 
pneumonia must be interpreted with caution particularly if such tests are used to inform 
decisions regarding clinical management.   
 
The rates of pneumococcal infection from the two data sets are lower than studies in 
other countries,[1] but are higher than previously described in the UK.[28, 29] 
Improvement of pneumococcal identification with the application of PCR assays when 
compared to culture alone is consistent with previous studies.[58, 188, 282, 283] This is 
similar to the reported increase in a recent Italian study (from 3.8% to 15.4%).[18] It is 
interesting that despite the overall decrease in the incidence and hospitalisation of 
pneumonia since the introduction of PCV7,[115, 144] the rates of pneumococcal 
infection were comparable between the two studies. Replacement with non-PCV7 
serotypes causing invasive pneumococcal disease is well recognised,[284] and this may 
explain our findings in the face of reduction in disease incidence. Where pneumococcal 
 103 
 
serotyping was possible with the majority being identified from pleural fluid samples, 
all serotypes recovered were non-PCV7 but covered in PCV13 (Chapter 6). This is 
similar to data from the USA on children with empyema where 98% were non-PCV7 
serotypes which are primarily similar to the serotypes in this study.[108] Despite the 
lack of comprehensive serotype data, this suggests that PCV13 could substantially 
reduce IPD.[125, 140, 285] 
 
Serological evidence of Mycoplasma infection was detected in 9.9% and 12.5% of 
children in both studies, rates that are similar to the published literature.[12, 29] M. 
pneumoniae is traditionally considered a pathogen of older children and in these studies 
was identified more frequently in those over five years of age. No other serological 
evidence was identified of other ‘atypical’ organisms although this may have been as a 
consequence of the lack of convalescent sera. S. aureus and GAS infections were often 
associated with severe pneumonia and empyema.[104, 286, 287] In keeping with 
previous findings, GAS can be found in up to 7% of children with pneumonia compared 
to 7% and 10.5% in the pre- and post-vaccine two data sets.[29, 288] With the 
introduction of PCV and decrease in pneumococcal pneumonia it is possible that the 
relative proportion of bacteria such as GAS and S. aureus as well as M. pneumoniae to 
cause severe pneumonia will increase.  
 
Viruses either alone or as co-pathogens were detected in 25% and 43% of children in 
the pre- and post-vaccination studies respectively, with RSV being the most commonly 
detected pathogen as previously reported.[1, 277, 278] This was followed by rhinovirus, 
influenza and adenovirus at approximately 7% each, similar to data previously 
described for the same region.[29] Diagnosis of viral infection was achieved mainly 
through the testing of respiratory secretions rather than by serology which was only 
 104 
 
positive in seven cases of influenza A virus. Most of the viruses detected were identified 
in those aged under five years, consistent with other studies.[13, 174] In the post-
vaccine study, viral screening was expanded to include eight viruses with their 
subgroups including pandemic H1N1 and to delineate their contribution in causing CAP 
in UK children. Considering the timing of the second recruitment period, pandemic 
influenza A H1N1 was not implicated in many cases of pneumonia as a single pathogen. 
The low isolation rates of bocavirus, coronavirus and hMPV highlight the minimal 
contribution of these viruses in the aetiology of pneumonia in UK children. The rates of 
mixed viral-bacterial infection were variable between the two studies and likely to be 
dependent on the screening methods used to identify the causative pathogens.[1] 
 
Although the source of referral of the enrolled children was statistically significant 
between the studies; being more from primary care than secondary care hospitals in the 
region in the pre- than post-vaccine study, it is unlikely that there would be sufficient 
bias in the aetiology data caused by the referral pathways. The change in epidemiology 
after the introduction of pneumococcal conjugate vaccination programme was not the 
focus of the aetiology study of the present research. The aetiology study was designed 
and focused to describe the proportion of pathogens in childhood CAP across a period 
of change in vaccination practice. In fact between the two study periods, the referral 
patterns have changed in the counties of Newcastle upon Tyne and Northumbria, such 
as primary care referrals from Ashington town were previously made to Royal Victoria 
Infirmary whereas after the pre-vaccine study this has changed the North Tyneside 
District General Hospital. When removed the children admitted at Royal Victoria 
Infirmary from Ashington town based on postcode in the pre-vaccine study and 
reanalysed the data, there was no statistical difference in the sources of referral between 
the pre- and post-vaccine study. 
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That this aspect of the aetiological studies was not designed to show incidence of 
pneumonia, in contrast to the observed substantial reduction in the annual incidence of 
lobar pneumonia following the conjugate vaccination programme in Canada,[79] the 
post-vaccine study reported increased lobar findings. This could be attributed to either 
the relative implication of non-PCV7 pneumococcal serotypes in the aetiology of 
pneumonia in children or due to the recognized variation in the interpretation of 
paediatric chest radiographs,[38, 210, 211] which in the pre- and post-vaccine study 
were reviewed and reported by two senior radiologists at the regional centres in 
Newcastle (designated as the “gold standard”) who were blinded to both the first reports 
by local radiologists at each site and specific clinical data. 
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5.2.1 Strengths and limitations 
There are several limitations to these data, such as potential seasonal bias to the data of 
post-vaccine study where the recruitment was carried out over 18 months which 
included two winter seasons (48% of enrolled children). Although the post-vaccine 
study covered two winter seasons, enrolled children were fewer than the pre-vaccine 
study which could be a true reflection of decreased disease incidence and 
hospitalisation. The findings from the post-vaccine study may have been hampered by 
the lack of convalescent sera which may have led to the underestimation of the role of 
atypical bacteria in childhood pneumonia. But this effect is probably minimal as 
mycoplasma infection was only detected in three children by paired serum samples pre-
vaccine. Another limitation is the variation between the two studies in the diagnostic 
methods used and the pathogens investigated. Lack of serotype data of the identified 
pneumococci from the pre-vaccine study limits the actual comparison with the serotype 
profile after the conjugate vaccine implementation. However, this research provides 
information on the changes of aetiology of pneumonia over two time periods. It also 
highlights the requirement of using multiple laboratory investigations in order to 
identify the likely causative pathogens. The improvement in the yield of several 
diagnostic approaches used in the post-vaccine study compared to the pre-vaccine study, 
particularly with more PCR-based assays used, is in line with recent studies over the last 
15 years.[1, 2, 20, 289] 
 107 
 
5.3 Conclusions 
Although viruses are the most common cause of pneumonia, around one fifth of 
children had bacterial infections. The combined use of culture, serology and PCR-based 
diagnostic tests significantly improved the identification of definitely causative 
pathogens in childhood pneumonia. Despite the widespread use of PCV7 and PCV13, 
infection with non-vaccine pneumococcal serotypes continued to be a significant cause 
of pneumonia in UK children. This requires continued surveillance for the emergence of 
serotype replacement. 
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Chapter 6 Identification and Typing of Pneumococci 
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6.1 Results 
A total of 225 children were enrolled, all of whom had at least one microbiological 
investigation performed. Of these, 60 with normal chest radiograph and 5 transferred 
from Cumbria region were excluded (three with empyema and two for intensive care 
management of complicated pneumonia with severe respiratory distress). Thus leaving 
160 children for final analysis; 56% males, 69% under five, median age 2.6 years. All 
children received antibiotics and none died. Based on age, pneumococcal vaccination 
uptake among 119 eligible children was 94% (89 had PCV7, 10 PCV13 and 13 received 
combinations of each) (Table 6-1). Lobar consolidation was the commonest radiological 
finding in 61%. Forty (25%) children had empyema, while pleural effusion was reported 
in 42.5% of the chest radiographs. 
 
Table 6-1 Number of received doses of PCV 
Received PCV
*
 doses n 
PCV7 (n=89)
‡
  
     1 dose 13 
     2 doses 19 
     3 doses 57 
PCV13 (n=10)
§
  
     1 dose 4 
     2 doses 5 
     3 doses 1 
Both PCV7 and PCV13 (n=13)  
     1 dose of each 1 
     2 PCV7 + 1 PCV13 doses 11 
     1 PCV7 + 2 PCV13 doses 1 
*PCV, pneumococcal conjugate vaccine 
‡Six children had partial schedule with one dose less for their age. 
§One child had one dose less for age. 
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6.1.1 Laboratory diagnostic testing 
A summary of the performed laboratory diagnostic procedures is presented in Table 6-2. 
Blood samples were obtained from 136 children and blood culture testing performed on 
126 samples. S. pneumoniae was isolated from five samples (4%) and single isolates of 
Staphylococcus aureus and group A Streptococcus (GAS) were also isolated from two 
additional samples. Of the 86 blood samples tested in the pneumococcal PCR assay, 
seven (8.1%) gave a positive signal in the test, whereas 16S rRNA PCR was only 
positive in one of 89 tested samples. Pleural fluid samples from 40 children were tested 
by culture with S. pneumoniae being isolated from three (7.5%) samples, as well as 
GAS from four samples, S. aureus from two samples and S. intermedius from one 
sample. Nucleic acid extracted from the thirty pleural fluid samples was tested in the 
pneumococcal PCR assay and 18 samples (60%) gave a positive signal in the test.  
 
For the 151 respiratory secretions analysed, S. pneumoniae PCR was positive in 62.8% 
(76/121, of which only four had cycle threshold [Ct] <30), and culture in 7% (10/141). 
Out of 12 samples cultured from tracheobronchial secretions one was positive (8.3%) 
for S. pneumoniae, 5 samples grew 7 other bacteria either singly or in multiples. For 
nasopharyngeal secretions, mean (± SD) Ct of pneumolysin PCR was 38.2 ± 4.4 with a 
median 38.6 (range, 28.5–46). Where both bacterial culture and PCR for S. pneumoniae 
were performed on the same sample, there was no significant difference in the mean Ct 
levels between the positive and negative cultures (34.8 ± 6.5 versus 38.6 ± 4.2, 
p=0.072). Pneumococcal antigen testing was performed on urine samples from 106 
patients and evidence of pneumococcal antigen in urine was detected in 28.3%. Overall 
presumptive pneumococcal infection was detected in 64% of children (103/160). 
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S. pneumoniae was the definite cause of pneumonia in 17.4% (24/138) of children; 15% 
(14/93) tested in those under five, 22.7% (10/44) tested among those over five. Twenty 
children of those with 24 identified definite pneumococcal infections had empyema. 
Definite pneumococcal infections among those who only had PCV7 was 19.8% (16/81), 
compared to 5.3% (1/19) for those who either had PCV13 only or both (OR 4.4, 95% CI 
0.55–35.70, p=0.182). Cultures from sterile sites (including blood, pleural fluids and 
tracheobronchial secretions) isolated S. pneumoniae in 6% (8/132) of cases; compared 
with pneumococcal PCR detection rate from sterile sites of 21.6% (21/97), p=0.0004. A 
serotype was identified in 18 (75%) of these; with serotype 1 (8, 44.4%), serotype 3 (5, 
27.8%), serotype 19A (4, 22.2%) and serotype 7A/F (1, 5.6%). Where a serotype was 
detected from a normally sterile sites (n=18), all but one case had empyema. Among 
these children with the identified 18 serotypes, 14 had pneumococcal antigen in urine 
tested with 11 (78.6%) being positive. Of the five pneumococcal isolates from blood 
cultures, only three were available and processed for serotyping which showed 
serotypes 1, 3 and 19A, of which two were concordantly identified in pleural fluids. 
Apart from one child who had 2 doses of PCV7 and a booster with PCV13, others with 
these non-PCV7 serotypes were either unvaccinated (n=7) or PCV7-vaccinated (n=10). 
 
Ten additional serotypes were identified from nasopharyngeal secretions and urine by 
xMAP assay. Of five pneumococcal isolates from nasopharyngeal secretions, only one 
serotype (23B) was identified. Out of the 17 assayed urinary Binax-positive samples, 9 
(53%) serotypes were identified. These included serotypes 1 and 7A/F (n=4 each) and 
one serotype 19A. Interestingly within this group of nine recovered urinary 
pneumococcal serotypes, four children had empyema and concordant identification of 
same serotypes from the pleural fluids (two were serotype 1, one each of serotypes 7A/F 
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and 19A). Figure 6-1 shows Venn diagram distribution of different single and 
concordant identification sites of definite pneumococcal infections by age group. 
 
The pneumococcal multiplex serotype-specific PCR was applied on culture-negative but 
pneumolysin PCR-positive nasopharyngeal secretions and blood. However, only those 
with Ct levels of ≤30 produced a discernible amplification product and samples with Ct 
levels above 30 were associated with multiple non-specific PCR products. The serotype-
specific PCR could not be fully applied to determine the serotype in the blood samples 
due to insufficient sample volume to perform all the multiple steps. However, the 
multiplex PCR assay was partially applied on four blood samples; two of these were 
positive but unable to proceed with identification due to insufficient volumes. 
 
Table 6-2 Detection rates of pneumococcal infection from the performed tests 
Tests Patients, n Positive (%) 
Overall definite infections 138 24 (17.4) 
Blood, overall 136 11 (8.0) 
     Culture (S. pneumoniae) 126 5 (4.0) 
     Pneumolysin real-time PCR 86 7 (8.1) 
     16S rRNA PCR 93 1 (1.1) 
Pleural fluids, overall 40 19 (47.5) 
     Culture (S. pneumoniae) 40 3 (7.5) 
     Pneumococcal antigen 30 7 (23.3) 
     Pneumolysin real-time PCR 30 18 (60.0) 
Respiratory secretions, overall 151 82 (54.3) 
     Nasopharyngeal secretions culture (S. pneumoniae) 141 10 (7.0) 
     Tracheobronchial secretions culture
*
 (S. pneumoniae) 12 1 (8.3) 
     Pneumolysin real-time PCR 121 76 (62.8) 
Urinary pneumococcal antigen 106 30 (28.3) 
*Tracheobronchial secretions, collected via bronchoalveolar lavage and/or endotracheal tube. 
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Figure 6-1 A Venn diagram showing different single and concordant identification 
sites of definite pneumococcal infections by age group 
 Children aged <5 years old 
 
 
 
 Children aged ≥5 years old 
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6.1.2 Correlation between pneumococcal diagnostic methods 
Positive blood pneumococcal PCR alone was associated with positive urinary 
pneumococcal antigen (OR 10.3, 95% CI 1.11–95.15, p=0.025). When compared with 
the overall definitely identified pneumococcal infections from normally sterile sites, 
positive urinary pneumococcal antigen was significantly associated with the 
pneumococcal detection by culture (OR 6.5, 95% CI 1.18–36.02, p=0.028) and PCR 
assays (OR 11.8, 95% CI 3.21–43.55, p=0.00008). However, there was no significant 
association between positive blood PCR and respiratory PCR (OR 1.0, 95% CI 0.20–
4.81, p=1.0), or urinary pneumococcal antigen and respiratory PCR (OR 1.2, 95% CI 
0.46–3.34, p=0.804). Figure 6-2 shows the ROC curve of urinary pneumococcal antigen 
test for identifying definite pneumococcal infection. The performance of diagnostic 
accuracy of urinary Binax test for definite pneumococcal infection was acceptable, with 
an area under the curve of 0.78 (95% CI, 0.65–0.90, p<0.001). The test corresponds to 
high sensitivity (75%) and low specificity (20%) on the ROC curve.     
 
None of the potential risk factors was significant in predicting positive status for PCR 
assays of blood and respiratory secretions or the collection of urine sample for the 
evidence of pneumococcal antigen during initial assessment at presentation. These 
tested risk factors included being male; aged under five; use of antibiotics or Ibuprofen 
prior to admission; referral to tertiary care; triage temperature >38
o
C; oxygen saturation 
<92%; dullness on chest examination; presence of lobar consolidation or pleural 
effusions on chest radiograph; and CRP >100 mg/L (67 [50.8%] of 132 performed). 
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Figure 6-2 Receiver operating characteristic curve of urinary pneumococcal antigen 
test for definite pneumococcal infection 
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6.2 Discussion 
This study describes diagnostic approaches to pneumococcal infections and provides the 
first information on serotype distribution of pneumococcal CAP in UK children after the 
introduction of the pneumococcal conjugate vaccination programme. The timing of the 
study towards the end of three years of PCV7 and during the first year of PCV13 gives a 
unique opportunity for future evaluation of the aetiology of pneumonia in the same 
setting. Non-PCV7 but PCV13 serotypes were the major contributor to the aetiology of 
pneumococcal pneumonia. 
 
There are only three previous UK studies investigating the aetiology of pneumonia in 
children before pneumococcal vaccination was introduced, finding a cause for 
pneumonia between 24% and 54%.[28, 29, 176] One of these studies utilised blood 
PCR for S. pneumoniae, Mycoplasma and Chlamydophila and identified 8% of children 
with pneumococcal pneumonia.[28] Another study identified 6% pneumococcal 
infection using pneumolysin ELISA on blood.[29] None of these studies 
comprehensively explored bacterial aetiology or evaluated the serotypes involved in 
pneumococcal pneumonia. 
 
Most of the nasopharyngeal secretion samples which were positive for S. pneumoniae 
by PCR had relatively high Ct levels (>30), which may represent nasopharyngeal 
carriage.[118, 290, 291] It has recently been recognised that the pneumolysin gene can 
be detected in non-pneumococcal Viridans-group streptococci, particularly S. 
pseudopneumoniae and S. mitis.[57] Therefore, this increased level of positivity may 
have also been caused by cross-reactivity with other Viridans-group streptococci. 
Definite pneumococcal infections were detected in approximately 18% of enrolled 
children. Although this is less than studies in other countries, it is more than previously 
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described in the UK.[28, 29] Diagnosis of pneumococcal infection was increased 
considerably when pneumolysin PCR was used,[58, 188, 282, 283] improving the 
detection rate of 6% by culture alone to 23%. This is similar to the increase (3.8% to 
15.4%) reported in a recent Italian study.[18] However in this population of children, 
16S rRNA PCR did not improve bacterial detection, with one only positive in a child 
who had proven pneumococcal empyema. The low positivity rate of this test may be 
related to prior use of antibiotics or pathogen viability, as tests were performed on 
batched samples. The cell wall of gram-positive bacteria is difficult to denature during 
DNA extraction which can make detection by 16S rRNA PCR lack sensitivity.[292-
294] 
 
Although the number of serotyped definite pneumococcal isolates was low with the 
majority being identified from pleural fluids, all were not covered within PCV7 
(serotypes 1, 3, 7, and 19A), but are included in the new PCV13 vaccine. This is similar 
to data from the USA on children with empyema where 98% were non-PCV7 serotypes 
and primarily similar to the serotypes in this study.[108] Despite the lack of 
comprehensive serotype data, this suggests that PCV13 could substantially reduce 
IPD.[125, 140, 285]  
 
It is acknowledged that the detection of antigen of S. pneumoniae in urine can represent 
nasopharyngeal carriage status.[191, 196] However, the significant association between 
this marker in the urine and the detection of pneumococci from normally sterile sites 
either by culture or PCR assays may suggest that despite its recognized low specificity, 
urinary pneumococcal antigen could still have a diagnostic role in the aetiological work 
up of CAP in children.[189] This is particularly helpful in resource-limited settings 
where PCR assays are not easily affordable or logistically possible. In this study, four of 
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the identified serotypes in urine had the same serotype detected in the blood and/or 
pleural fluids, which makes urine detection likely to represent a real infection. The lack 
of association between pneumococcal PCR assays in blood and respiratory secretions 
reflects the nasopharyngeal carriage which is common in children.[117, 118] 
 
6.2.1 Strengths and limitations 
This is the first study in the UK to explore serotype data in children with pneumococcal 
CAP. It illustrated the improvement in detection rate of S. pneumoniae by using a 
comprehensive range of diagnostic techniques including PCR-based assays. These 
provide important information for the public health policy makers for planning 
strategies to combat this infection in children and for the design of new generations of 
pneumococcal conjugate vaccines. An important limitation was the insufficient volume 
of the samples which limited progress with the steps of the pneumococcal multiplex 
serotype-specific PCR, despite efficient procedures taken towards its development and 
validation. I acknowledge that numbers of positive pneumococcal PCR assays were 
small and this could be underestimated by the application of only pneumolysin PCR on 
blood and respiratory secretions. However, the results provide useful information on the 
overall contribution of S. pneumoniae in pneumonia among children in this setting. 
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6.3 Conclusions 
Non-PCV7 serotypes were the major contributor to the aetiology of pneumococcal 
pneumonia in UK children in the period after the PCV7 was introduced. This suggests 
that the replacement of PCV7 with PCV13 likely to be associated with a significant 
reduction in the incidence of pneumococcal-related pneumonia. Continued surveillance 
is required to monitor for the emergence of serotype replacement.
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Chapter 7 Inter-observer Variability in the 
Interpretation of Chest Radiographs
 121 
 
7.1 Results 
A total of 169 children were identified and treated for pneumonia and/or empyema 
(53% males, 73% aged under five years, mean (± SD) age of 3.8 ± 3.72 years, and age 
range from 0.05 to 16.7 years). Of those, 46 had chest radiograph reported as normal on 
the first reports, but on the second reading six (13%) had abnormal changes (i.e. false 
negative); four lobar and two patchy. All of the false negative cases received antibiotic 
treatment (median, 7 days), and none developed any complication. Fourteen (11.4%) 
were initially reported as having radiological changes, were reported as normal 
radiographs on the second review (i.e. false positive) (Table 7-1). 
  
All radiologists agreed that all chest radiographs were suitable for interpretation. There 
was significant inter-observer variability in the interpretation of chest radiographs 
(k=0.70, p<0.001), with patchy (48.8%) and perihilar (28.1%) changes being the main 
components of this variability (Table 7-1). Although few (n=5) were first reported by 
radiology trainees, there was no difference in reporting when these were reported by the 
second radiologist. The two interpretations varied when the first reports were performed 
by senior radiologists, particularly consultant pediatric radiologists who had an overall 
26.7% disagreement with the reviewing cardiothoracic radiologist and lowest (15.8%) 
with consultant thoracic radiologists (Table 7-2).  Levels of disagreement were highest 
among children aged under five years compared to those aged over five years (26%, 
k=0.66 versus 11%, k=0.83, p<0.001). There was no disagreement on reporting lobar 
findings in the under five years age group, disagreement was mainly related to patchy 
and perihilar changes.       
 
Pleural effusion was present at first reading of the films in 10% (17/169) compared to 
22% (37/169) on review. Variation in reporting of pleural effusion was 11.8% (k=0.57, 
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p<0.001). However, if the presence of a pleural effusion was reported in the first report 
there was no disagreement about this in the second report. In contrast 13.2% of pleural 
effusions were reported only on the second report and not in the first report. Initial 
reporting of pleural effusion by radiology trainees was not different to reports at second 
reading (k=1, p=0.200).  In addition there was good agreement between first and second 
reports of pleural effusion when initially read by consultant thoracic radiologists 
(k=0.17, p=0.368). Whilst there were significant differences in first reporting of effusion 
by consultant paediatric radiologists (k=0.78, p<0.001) or consultant general 
radiologists (k=0.41, p=0.002) compared to second reading, the proportions of 
disagreement were respectively low of 5.8% and 15.3%. 
 
Table 7-1 Inter-observer variability and agreement in chest radiographs reporting 
First reading Second reading (gold standard) Disagreement
* 
Radiographic changes n (%) Lobar Patchy Perihilar Normal n (%) 
     Lobar 48 (28.4) 47 1 0 0 1 (2.1) 
     Patchy 43 (25.4) 7 22 5 9 21 (48.8) 
     Perihilar 32 (19.0) 4 0 23 5 9 (28.1) 
     Normal 46 (27.2) 4 2 0 40 6 (13.0) 
     Total 169 62 25 28 54 37 (22.0) 
*Fisher's exact test, p<0.001; Kappa=0.70 (proportion of cases on which readers would be expected to agree). 
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Table 7-2 Comparison of chest radiographs reporting by the grade of readers 
First reading Second reading (gold standard) Disagreement  
Radiographic changes n (%) Lobar Patchy Perihilar Normal n (%) Kappa (P) 
Radiology trainees 5 (3) 1 1 2 1 0 1.00 (0.105) 
     Lobar 1 1 0 0 0 0  
     Patchy 1 0 1 0 0 0  
     Perihilar 2 0 0 2 0 0  
     Normal 1 0 0 0 1 0  
Consultant general radiologists 59 (35) 18 12 9 20 11 (18.6) 0.75 (<0.001) 
     Lobar 16 15 1 0 0 1 (6.3)  
     Patchy 17 0 11 3 3 6 (35.3)  
     Perihilar 8 1 0 6 1 2 (25.0)  
     Normal 18 2 0 0 16 2 (11.1)  
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First reading Second reading (gold standard) Disagreement  
Radiographic changes n (%) Lobar Patchy Perihilar Normal n (%) Kappa (P) 
Consultant paediatric radiologists 86 (51) 35 7 13 31 23 (26.7) 0.63 (<0.001) 
     Lobar 26 26 0 0 0 0  
     Patchy 18 5 5 2 6  13 (72.2)  
     Perihilar 17 2 0 11 4 6 (35.3)  
     Normal 25 2 2 0 21 4 (16.0)  
Consultant thoracic radiologists 19 (11) 8 5 4 2 3 (15.8) 0.78 (<0.001) 
     Lobar 5 5 0 0 0 0  
     Patchy 7 2 5 0 0 2 (28.6)  
     Perihilar 5 1 0 4 0 1 (20.0)  
     Normal 2 0 0 0 2 0  
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7.2 Discussion 
There was a substantial inter-observer variability in the interpretation of chest 
radiographs for the diagnosis of pneumonia in children. This has been recognised since 
radiology reporting was initiated in the middle of last century,[210, 211] and continues 
despite the acceptance of the recommended WHO criteria for reporting chest 
radiographs of pneumonia in children.[150, 151] 
  
The diagnosis of pneumonia in children based on a combination of clinical and 
radiological features is important for prompt management.[159] Yet, subtle 
radiographic changes can be difficult to recognise or interpret and failure to diagnose 
pneumonia may result in inappropriate management.[212, 213] The initial interpretation 
of chest radiographs is usually performed by clinicians with the radiologists’ reports 
following later, often after the patient has been discharged from hospital.[212] 
Interpretation by clinicians could be biased by inadequate training in radiology and lack 
of clinical information may limit the accuracy of reporting by the radiologists.[214] For 
research purposes blinded interpretation of the chest radiograph may improve detection 
of subtle changes and differentiating normal biological variants.[215] Making clinical 
information available may reduce inter-observer variability but does not result in 
marked improvement in the overall accuracy.[216]  
 
This study shows that most inter-observer variability is related to the interpretation of 
patchy and perihilar changes, which need careful viewing and the availability of clinical 
information during interpretation.[217] It is well recognised that abnormal chest 
radiographs may be interpreted as normal,[217] but surprisingly four of the normal 
reports had lobar changes on review. Similarly, 13% had a previously undetected 
pleural effusion. The variation in reporting of chest radiographs for those aged under 
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five years confirms the particular challenge of making a radiological diagnosis of 
pneumonia in this age group.[213, 219] The overall inter-observer variation is in line 
with other previously reported findings on interpretation variability including pleural 
effusion.[38, 219] It is widely accepted in the literature that chest radiographs cannot 
reliably differentiate viral from bacterial aetiology of pneumonia.[1, 2] Therefore these 
variations on the interpretation of chest radiographs do not significantly affect the 
clinical outcomes and management decisions of pneumonia in children.[1, 2, 209, 220, 
221]   
 
It is interesting that irrespective of the level of experience there continues to be 
significant variability in interpretation between reporters, particularly senior 
radiologists.[213, 222] A previous study showed that qualified radiologists had less 
inter-observer variability on reporting of chest radiographs compared to radiology 
trainees and physicians.[223] Despite the specialized training in paediatric radiology 
and advanced technology, human error remains a likely factor.[211] The level of 
variability between the senior radiologists could be a reflection of inconsistency in the 
application of WHO criteria, as this has been shown to decrease inter-observer 
variability.[224] However, the rate of false negative reports between the two 
interpretations of chest radiographs is a well recognised problem [217] which may 
jeopardize the results of epidemiological studies by underestimating the true burden of 
pneumococcal pneumonia.[225] In previous pneumococcal vaccine efficacy studies the 
radiographic evidence of pneumonia was observed in up to 34% of the enrolled 
children.[226] It has been suggested that using the WHO criteria would make any 
differences in the results reflect geographical variations in disease epidemiology or 
vaccine effects rather than methodological factors.[151] Despite the application of this 
classification, the concordance rate between two trained reviewers was only 48% 
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(250/521).[227] The degree of variability of reporting chest radiographs from the 
present study demonstrates that methodological differences are still a problem in the 
epidemiological studies of pneumonia in children. 
7.2.1 Strengths and limitations 
The findings were limited by heterogeneity amongst a range of radiologists (general and 
specialized radiologists) involved in the first reporting, with only one radiologist 
performing second reporting together with differences in clinical information provided 
at first and second readings. However, having them agree mostly on the interpretation of 
lobar changes, with the main variability related to non-end-point changes as recently 
shown among a group of 13 paediatricians and two radiologists,[295] make the impact 
of these limitations is minimal. On the other hand the agreement between readers was 
improved when the WHO criteria [151] was modified to consider the presence of any 
lung infiltrate irrespective of its features as end-point pneumonia.[296] All of these 
reported findings highlight the importance to have defined diagnostic radiological 
criteria of pneumonia that can be universally used in epidemiological studies and 
clinical practice. 
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7.3 Conclusions 
There is substantial inter-observer variability in the reporting of chest radiographs 
particularly in young children with pneumonia which appears unrelated to the level of 
training and experience of those reporting. These findings add to the recognised 
variability in the literature demonstrating that there may be a need for evaluation of the 
WHO categorization of radiological pneumonia in children to improve the validity and 
encourage widespread adoption of the criteria.
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Chapter 8 Final Summary 
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8.1 Community-acquired pneumonia in children 
Community-acquired pneumonia is a common childhood infection and is a frequent 
cause of admission to hospital, particularly in the young age group.[1] It causes a 
substantial morbidity and mortality respectively in developed and low resource 
settings.[4, 9] This research provides invaluable epidemiological and aetiological data 
on this infection in children in the North East of England where the disease was 
investigated in a similar prospective study in 2001–2002.[59, 157] The annual incidence 
and management outcomes of CAP from the survey in 2001–2002 were previously 
published,[59, 157] while the aetiological data were analysed together with the new data 
from the repeated research. There were several public health interventions to combat 
this infection or standardise it management; such as the introduction of routine 
pneumococcal conjugate vaccination programme in the UK with PCV7 in 2006 [124] 
which subsequently replaced by PCV13 in 2010 [125] and the publication of the 
national management guidelines from the British Thoracic Society (BTS) in 2002 [160].  
 
Data from the epidemiological survey were the first UK published prospective 
evaluation of the effect of PCV7 on the incidence of childhood CAP. It reports an 18% 
reduction in both the annual incidence of CAP presenting to hospital and hospitalisation 
rate between 2001 and 2009. The major reduction in pneumonia admissions (38%) was 
observed in those aged under two years. There was also a lower incidence of pneumonia 
among PCV7-vaccinated children under five years old than those annual unvaccinated. 
Analyses of the presentation and management outcomes showed that clinical 
management of children with pneumonia has changed significantly between 2002 and 
2008. There has been a reduced number of investigations performed, a change in the 
type of antibiotics, a decrease in intravenous and a concomitant increase in oral 
antibiotics. Possible influencers on change of clinical practice include the introduction 
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of the 7-valent pneumococcal conjugate vaccine (PCV7) to the UK immunisation 
programme in 2006, the publication of the BTS management guidelines and an 
expanding literature on oral/IV antibiotic use.[161, 162, 270] 
 
This is the first study to describe the aetiology of CAP in UK children prior to and 
following the introduction of pneumococcal conjugate vaccination programme. The 
timing of this comprehensive study three years after the introduction of PCV7 and 
during the first year of PCV13 provides a baseline for future comparative studies of the 
aetiology of pneumonia in the same setting. The causative pathogens identified were 
predominately viruses in both studies with the detection of pneumococcal infections 
increasing from the pre- to post-vaccine studies as a result of the application of 
molecular diagnostic methods. This study also describes different diagnostic approaches 
to pneumococcal infections and provides the first information on serotype distribution 
of pneumococcal CAP in UK children after the introduction of the pneumococcal 
conjugate vaccination programme. S. pneumoniae was the definite cause of pneumonia 
in 17.4% of children; 15% in those under five and 22.7% among those over five years. 
Non-PCV7 but PCV13 serotypes were the major contributor to the aetiology of 
pneumococcal pneumonia. 
 
The observed substantial inter-observer variability in the interpretation of chest 
radiographs for the diagnosis of childhood pneumonia highlights the on going debate 
when defining the radiologically confirmed pneumonia as entry criteria to studies 
investigating the epidemiology and aetiology of pneumonia in children. 
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8.1.1 Overall strengths and limitations 
8.1.1.1 Epidemiology survey 
The strengths of this survey include the use of a multi-centre large scale approach, well-
validated disease definition and previously studied population allowing accurate 
historical comparisons. Its significant limitation is that while the introduction of PCV7 
is the major change between the two surveys, the ecological nature of the survey means 
that the decrease in disease incidence cannot be causally attributed to PCV7 alone.[50, 
266] Further potentially relevant factors include natural variations in disease incidence, 
other public health interventions such as anti-smoking campaigns,[267, 268] variation in 
national and local health policies, changes in admission criteria, referral pathways and 
threshold for radiological investigation, and the implementation of national guidelines 
for the management of CAP in children by the BTS in 2002.[160] The later factor might 
have resulted in more children being managed in primary care including accident and 
emergency departments. While cannot rule out these factors using the methodology in 
this survey, I feel it is unlikely that any of these factors would have reduced the 
incidence of pneumonia to the degree observed. Furthermore, it would be speculated 
that these factors would alter the overall incidence rate regardless of age group. The fact 
that no significant difference was found in the annual incidence of pneumonia in the 
over five age group, by definition non-vaccine recipients, therefore increases the 
likelihood that the observed changes were attributable to PCV7. 
 
It could be speculated that changes in the incidence of viral disease or vaccination may 
have contributed to the observed differences in the annual rates of pneumonia, though 
this is unlikely given that the neither age group (and specifically the under two age 
group) are routinely vaccinated against respiratory viral disease. No specific data were 
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collected on influenza vaccination status but it is most likely that the overwhelming 
majority of enrolled children were unvaccinated. It has also been hypothesised that a 
considerable proportion of viral pneumonia may in fact have co-infection with bacterial 
pathogens including S. pneumoniae as shown by Michelow and colleagues [11] which 
could potentially ameliorate the effect of variations in the incidence of seasonal 
influenza or other viral infections. 
  
The inclusion of a further group of the other infiltrates/abnormalities chest radiographic 
feature to the WHO definition of radiological pneumonia could have overestimated the 
incidence of pneumonia within our population. However, the number of such 
individuals was low and represented only 3% of all cases of pneumonia within the 
studied cohort. It would be therefore suggested that this should not have significantly 
influenced these findings, given the magnitude of the changes reported in this survey. In 
contrast to the observed substantial reduction in the annual incidence of lobar 
pneumonia following the conjugate vaccination programme in Canada,[79] this survey 
reported increased lobar findings. This could be attributed to either the relative 
implication of non-PCV7 pneumococcal serotypes in the aetiology of pneumonia in 
children or due to the recognized variation in the interpretation of paediatric chest 
radiographs,[38] which in this survey were reported by local radiologists that differed 
between sites and from the original survey. Although the diagnosis of end-point 
pneumonia was dependent on reading non-standardised chest radiograph reports by 
local radiologists, the application of standardised criteria provided by the WHO on 
defining the radiological end-point pneumonia would allow more accurate comparative 
data in epidemiological studies for assessment of the impact of pneumococcal 
vaccination.[150, 151] 
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Furthermore, this survey provides invaluable evaluation of the presentation and 
management of childhood CAP seen in hospital over a year period with particular focus 
on the investigations performed and use of antibiotics. Lack of data collection and 
interviewing of admitting clinicians about their decisions for performing investigations 
and selection of the type and administration route of antibiotics limited the 
interpretations of potential factors surrounding the observed changes on these areas. 
8.1.1.2 Aetiology study 
There are several limitations to these data, such as potential seasonal bias to the data of 
post-vaccine study where the recruitment was carried out over 18 months which 
included two winter seasons (48% of enrolled children). Although the post-vaccine 
study covered two winter seasons, enrolled children were fewer than the pre-vaccine 
study which could be a true reflection of decreased disease incidence and 
hospitalisation. The findings from the post-vaccine study may have been hampered by 
the lack of convalescent sera which may have led to the underestimation of the role of 
atypical bacteria in childhood pneumonia. But this effect is probably minimal as 
mycoplasma infection was only detected in three children by paired serum samples pre-
vaccine. Another limitation is the variation between the two studies in the diagnostic 
methods used and the pathogens investigated. Lack of serotype data of the identified 
pneumococci from the pre-vaccine study limits the actual comparison with the serotype 
profile after the conjugate vaccine implementation. However, this research provides 
information on the changes of aetiology of pneumonia over two time periods. It also 
highlights the requirement of using multiple laboratory investigations in order to 
identify the likely causative pathogens. The improvement in the yield of several 
diagnostic approaches used in the post-vaccine study compared to the pre-vaccine study, 
particularly with more PCR-based assays used, is in line with recent studies over the last 
15 years.[1, 2, 20, 289] 
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This is the first study in the UK to explore serotype data in children with pneumococcal 
CAP. It illustrated the improvement in detection rate of S. pneumoniae by using a 
comprehensive range of diagnostic techniques including PCR-based assays. These 
provide important information for the public health policy makers for planning 
strategies to combat this infection in children and for the design of new generations of 
pneumococcal conjugate vaccines. An important limitation was the insufficient volume 
of the samples which limited progress with the steps of the pneumococcal multiplex 
serotype-specific PCR, despite efficient procedures taken towards its development and 
validation. I acknowledge that numbers of positive pneumococcal PCR assays were 
small and this could be underestimated by the application of only pneumolysin PCR on 
blood and respiratory secretions. However, the results provide useful information on the 
overall contribution of S. pneumoniae in pneumonia among children in this setting. 
8.1.1.3 Radiology study 
The findings were limited by heterogeneity amongst a range of radiologists (general and 
specialized radiologists) involved in the first reporting, with only one radiologist 
performing second reporting together with differences in clinical information provided 
at first and second readings. However, having them agree mostly on the interpretation of 
lobar changes, with the main variability related to non-end-point changes as recently 
shown among a group of 13 paediatricians and two radiologists,[295] make the impact 
of these limitations is minimal. On the other hand the agreement between readers was 
improved when the WHO criteria [151] was modified to consider the presence of any 
lung infiltrate irrespective of its features as end-point pneumonia.[296] All of these 
reported findings highlight the importance to have defined diagnostic radiological 
criteria of pneumonia that can be universally used in epidemiological studies and 
clinical practice. 
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8.1.2 Overall conclusions 
The introduction of the pneumococcal conjugate vaccination programme was associated 
with a reduction in both the annual rates of pneumonia and hospitalisation. The 
identification rates of confirmed causes of CAP overall and pneumococcal infections 
have increased with application of more PCR assays when compared with data from 
2001–2002 study in the same setting. All identified pneumococcal serotypes being non-
PCV7 but PCV13 serotypes which make the introduction of PCV13 likely to be 
associated with a substantial reduction in the annual incidence of pneumococcal-related 
pneumonia.  
 
There is substantial inter-observer variability in the reporting of chest radiographs 
particularly in young children with pneumonia which appears unrelated to the level of 
training and experience of those reporting. These findings add to the recognised 
variability in the literature demonstrating that there may be a need for evaluation of the 
WHO categorization of radiological pneumonia in children to improve the validity and 
encourage widespread adoption of the criteria.   
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8.2 Research impacts and future studies 
The outcomes of this research have several potential impacts on informing healthcare 
workers and policymakers: 
1. Information on the changes of rates of CAP and hospitalisation, aetiology and 
pneumococcal serotypes provide important opportunity for epidemiologists and 
public health policymakers to design and plan future strategies and new 
generations of pneumococcal conjugate vaccine to combat this infection in 
children. 
2. Outcomes on the presentation and management of CAP in children following the 
publication of BTS guidelines provide figures that are useful for practice 
improvement. These outcomes were reflected to the hospitals involved. 
 
I would suggest the following areas to be investigated in future studies: 
1. Repeat the survey into the incidence of CAP and hospitalisation in the same 
hospitals every five years to evaluate the impact the introduction of new 
generation of pneumococcal conjugate vaccine. 
2. Continued surveillance is required to monitor for the emergence of serotype 
replacement in childhood pneumococcal-related pneumonia. 
3. Further studies are required to explore the clinical decision making to determine 
the reasons behind the wide variation in IV antibiotic use seen, as this is not 
explained fully by disease severity in this research. 
4. A cost-effectiveness analysis focusing on the impact of reduced hospitalisation, 
IV antibiotic use and preadmission antibiotics would provide useful economic 
information. 
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5. Future studies should not only aim to replicate the methodology used here, but 
also, in addition, be designed to take into account the impact of the following 
factors on the incidence of pneumonia as determined in these surveys [59, 297]: 
a. Variable reporting of chest radiographs between sites and across 
different study periods. 
b. Referral patterns for pneumonia (how many children seen only in 
primary care or by accident and emergency staff). 
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Appendix 1 Ethics Approval 
 
 
Newcastle & North Tyneside 2 Research Ethics Committee 
Room G14 
Dental School 
Framlington Place 
Newcastle upon Tyne 
NE2 4BW 
 
                                        Telephone: 0191 222 3581  
Facsimile: 0191 222 3582 
Email: gillian.mayer@ncl.ac.uk 
2 April 2008     
                                                                        
Dr Julia Clark 
Consultant Paediatric Infectious Disease COPD 
Newcastle General Hospital  
 
Dear Dr Clark 
 
Query re collecting data for research - full postcode for epidemiological data  
 
In response to your recent query the Chairman notes the following points: 
 
1.  The vaccine has been introduced on a population basis into the immunisation 
schedule across the UK, so there is no research intervention here. 
 
2.  If data will be gathered on children admitted with pneumonia and the researchers 
will gather clinical and demographic data prospectively, as previously done, on an 
anonymised basis, then providing this is the case, and they are just simply repeating 
what they did before the vaccine was introduced, I don't feel they need formal review by 
a REC.   
 
This is assuming that the full postcode is the method of collecting the socioeconomic 
data.  If this is the case, I don't think they need informed consent to collect this.  
 
 
Yours sincerely 
 
G Mayer 
 
 
Gillian Mayer 
Committee Co-ordinator 
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Newcastle & North Tyneside 1 Research Ethics Committee 
Newcastle Dental School 
Room G14 
Dental School 
Framlington Place 
Newcastle 
NE2 4BW 
 
Telephone: 0191 222 3581  
Facsimile: 0191 222 3582 
22 December 2008 
 
Dr Julia Clark 
Consultant in Paediatric Immunology and Infectious Diseases 
Newcastle upon Tyne Hospitals NHS Trust 
Newcastle General Hospital 
Westgate Road 
Newcastle upon Tyne 
NE4 6BE 
 
Dear Dr Clark 
 
Full title of study: The Impact of Pneumococcal Vaccine (Prevenar) 
on the epidemiology of Childhood Pneumonia in 
the North East of England 
REC reference number: 08/H0906/105 
 
The REC gave a favourable ethical opinion to this study on 09 December 2008. 
 
Further notification has been received from a local site assessor following site-specific 
assessment.  On behalf of the Committee, I am pleased to confirm the extension of the 
favourable opinion to the new site.  I attach an updated version of the site approval 
form, listing all sites with a favourable ethical opinion to conduct the research. 
 
R&D approval 
 
The Chief Investigator or sponsor should inform the local Principal Investigator at each 
site of the favourable opinion by sending a copy of this letter and the attached form.  
The research should not commence at any NHS site until approval from the R&D office 
for the relevant NHS care organisation has been confirmed. 
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees (July 2001) and complies fully with the Standard 
Operating Procedures for Research Ethics Committees in the UK. 
 
08/H0906/105  Please quote this number on all correspondence 
 
Yours sincerely 
 
 
Ms Anne Taylor 
Committee Co-ordinator 
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Email: anne.taylor7@nhs.net 
 
Enclosure: Site approval form 
 
Copy to: Ms A Tortice 
Joint Research Office 
(Research & Development) 
Newcastle upon Tyne Hospitals NHS Foundation Trust 
Research & Development 
4th Floor, Leazes Wing 
Royal Victoria Infirmary 
Newcastle upon Tyne 
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13
th
 November 2008 
 
 
Dr F J Hampton 
Consultant Paediatrician 
Paediatric Unit 
Women & Children Division 
The James Cook University Hospital 
 
 
Dear Dr Hampton 
 
ID:  2008075 - The Impact of Pneumococcal Vaccine (Prevenar) on the 
 epidemiology of Childhood Pneumonia in the North East of England 
 
Your project was reviewed at the Research Approval Board on 12th November 2008.    
I am happy to say that on this occasion your project was approved. 
  
Documents reviewed and approved were: 
  
 Protocol - Version 1 dated 29/07/2008 
 Parent Information Sheet - Version 1 dated 15/07/2008 
 Children's Information Sheet (11-16 years) - Version 1 dated 15/07/2008 
 Children's Information Sheet (10 years and younger) - Version 1 dated 15/07/2008 
 Assent Form for Children - Version 1 dated 15/07/2008 
 Consent Form (Child) - Version 1 dated 15/07/2008 
 Consent Form (Parent / Carer 1) - Version 1 dated 15/07/08 
 Consent Form (Parent / Carer 2) - Version 1 dated 15/07/08 
 GP Letter - no version number or date 
  
I would like to take this opportunity to remind you that STHNHS Trust manages all 
research in accordance with the requirements of the Research Governance Framework.  
As a researcher working in the Trust you must comply with all reporting requirements, 
systems and duties of action put in place by the Trust to deliver Research Governance.  
You will be expected to read and familiarise yourself with conditions of approval as 
well as incident reporting procedures in relation to your project. 
  
Please note it is the responsibility of all researchers to adequately cover the ongoing 
costs of their project.  If external funding is not available or becomes unavailable then 
these costs must be covered by their departmental budget.  There is at present no 
possibility of the R&D department covering any shortfall in these costings.   
  
Enclosed are labels which need to be affixed to the front of Patient notes to indicate they 
are taking place in a clinical trial/study/registry. These are the only labels that should be 
used and any issued from another source should be discarded.  This will indicate to 
Health Records that these notes should be kept for a minimum of 15 years. If you 
require additional labels, please contact Research & Development. 
If the R&D Department can be of any further assistance, please do not hesitate to 
contact myself or Trish Watson, R&D Administrator on (01642) 282585. 
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Yours sincerely 
 
 
Dr S Graham 
Chairman of Research Approval Board 
 
 
Cc Dr Katherine Eastham 
  Teaching & Education Fellow 
  Education Centre 
  North Tyneside General Hospital 
  Rake Lane 
  Tyne & Wear 
  NE29 8NH 
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Appendix 2 Questionnaire 
 
 
Completed by  Hospital  Study No.  
Date & time of admission        /       /       __ __:__ __  am / pm Date of discharge /        / 
Pre-admission duration of illness (days)  Postcode  
Seen by GP / A&E Y / N if yes, days since initial assessment  
Date of birth /      / Father’s occupation & age  
Sex M / F Weight (kg)  Mother’s occupation & age  
No. of bedrooms in the house  Household size (total no. living at the same house)  
Pre-admission antibiotics     Y / N 
Name Start Date End Date 
 /      / /        / 
 /      / /        / 
Received Prevenar  Y / N Doses  Pre-admission Ibuprofen Y / N Tamiflu Y / N 
RISK FACTORS () 
Prematurity  Gestation  Immunodeficiency  Chronic lung disease 
 
 
Cystic fibrosis  Sickle  Bronchiectasis  Steroids  Other  
Parental smoking  Child smoking  Nursery school  Childminding  
CLINICAL PRESENTATION 
 
Respiratory rate  Clinical findings (free text) 
Temperature   
SaO2 (in air)   %  
PERFORMED INVESTIGATIONS (circle) 
FBC BC CRP ESR Serum Na Secretions:  virology IF Secretions: m,c&s 
Other (specify): 
Radiologist’s chest x-ray report 
(report text or attach copy) 
 
CLINICAL PROGRESS () 
Home on antibiotics  Home without antibiotics  Transferred where: Died  
IF ADMITTED 
Oxygen Y / N No. of days   Ibuprofen  Y / N Confirmed H1N1 virus Y / N 
NG feeds Y / N No. of days  IV fluids Y / N No. of days  
Antibiotics Y / N 
IV / Oral Name  No. of days  
IV / Oral Name  No. of days  
IV / Oral Name  No. of days  
IV / Oral Name  No. of days  
Organism 
Isolated 
(any)  
Y / N 
Name: Site: blood culture / NPS / Sputum / other 
1. 
2. 
3. 
1. 
2. 
3. 
COMPLICATIONS 
Pleural effusion Y / N PICU admission Y / N if yes, duration (days)  
Empyema Y / N Fluid resuscitation Y / N IPPV Y / N if yes, duration (days)  
Other (specify)  
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Appendix 3 Information and Consent Forms   
 
 
CHILDREN’S INFORMATION SHEET (10 YEARS AND YOUNGER) 
 
 
Causes of Pneumonia in Children 
 
The child should be helped to read the following information please: 
 
What is the research study all about? 
We are asking you if you would like to take part in a research study to find out what 
bugs cause chest infections in children.  
 
Why am I being asked to take part? 
You are being seen in hospital because you have an infection in your chest which is 
making you feel unwell. We want to do a special study to try to find out more about the 
kinds of bugs that cause infections like yours in children. This will help us know the 
best medicines to give.  
 
Do I have to take part? 
You do not have to take part in the study if you don’t want to. If you decide to take part 
you can stop at any time. Just tell you parents, doctor or a nurse. They will not be cross 
with you. 
  
What will happen to me if I take part? 
We would like to take some special tests from you to look for the bugs causing your 
chest infection even if your doctor would not normally have done them.   
 
 The first test is to look for bugs from your chest.  To do this a nurse will suck some 
secretions (the runny stuff!) from the back of your nose with a small tube.  
 If you are able, you could cough some spit into a pot instead. 
 
 
 
 The second is to look for bugs in your blood.   
If your doctor has asked for a blood test anyway then a little extra blood will be 
taken at the same time.   
If your doctor did not ask for a blood test then a little blood test will be taken.  
This test is just for this study and would not be done otherwise.  It is not very sore, 
is very quick, and we can use a special cold spray or cream so you don’t feel the 
prick as much. 
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 We also need to test some urine – we will ask you to collect some wee in a potty 
or special pot.  We will show you what to do. 
 
 
 
What are the possible benefits of taking part? 
We cannot promise that the study will help you but the information we get may help 
treat children with chest infections better in the future  
 
What if there is a problem? 
If you have any questions or there is a problem during the study please talk to your 
parents or the doctors and nurses who will be able to help you.  
 
Will anyone else know that I’m doing this? 
We will only tell people who have a right or need to know that you are taking part. 
 
Did anyone else check the study is OK to do? 
Before any research is allowed to happen it has to be checked by a group of people 
called a Research Ethics Committee. They make sure that the research is fair. The study 
has been checked by the Research Ethics Committee.   
 
We hope you will let us do these extra tests. The doctors and nurses will look after you 
just the same whether these extra tests are done or not. Please have a think if you’d like 
to take part and talk to your family, doctors and nurses about the study if you’d like to. 
Thank you for reading this and we hope you soon feel better 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pneumonia young children’s information sheet version 2, 12/11/2008 
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CHILDREN’S INFORMATION SHEET (11–16 YEARS) 
 
 
Causes of Pneumonia in Children 
 
What is the research study all about? 
We are asking you if you would like to take part in a research study to find out what 
bugs cause chest infections in children.  
 
Why am I being asked to take part? 
You are being seen in hospital because you have an infection in your chest which is 
making you feel unwell. Lots of different kinds of bugs can cause this infection.  Some 
medicines are best for one bug, others for a different one and some do not need any 
medicine at all!  It is hard to know which bug you have. To try to find out some special 
tests are sometimes done. Sometimes we never know exactly which bug caused your 
infection. All children admitted to hospitals in the Newcastle and Middlesbrough 
between October 2008 and March 2010 will also be asked if they would like to take part 
in the study. 
 
Why are we doing the research study?  
We want to do a special study to try to find out more about the kinds of bugs that cause 
infections like yours in children. This will help us know the best medicines to give. It 
will also let us find out if a new vaccine for babies has helped stop chest infections in 
children. 
 
Do I have to take part? 
You do not have to take part in the study if you don’t want to. You can also stop taking 
part in the study at any time during the study without giving a reason and without it 
affecting how the doctors and nurses look after you. 
  
What will happen to me if I take part? 
We would like to take a number of tests from you to look for the bugs causing your 
chest infection even if your doctor would not normally have done them.   
 
 The first test is to look for bugs from your chest.  To do this a nurse will suck some 
secretions (the runny stuff!) from the back of your nose with a small tube.  If you 
are able, you could cough some spit into a pot instead. 
 
 The second is to look for bugs in your blood.   
If your doctor has asked for a blood test anyway then a little extra blood will be 
taken at the same time.   
If your doctor did not ask for a blood test then a little blood test will be taken.  
This test is just for this study and would not be done otherwise.  It is not very sore, 
is easy and quick to do, and we can use a special cold spray or cream so you don’t 
feel the prick as much. 
 
 We also need to test some urine – we will ask you to collect some wee in a special 
pot.  We will show you what to do. 
 
What are the possible benefits of taking part? 
We cannot promise that the study will help you but the information we get may help 
treat children with chest infections better in the future.  
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What if there is a problem? 
If you have any questions or there is a problem during the study please talk to your 
parents and either you or they can ask to speak to one of the Researchers who will do 
their best to help you.  
 
Contact 
Dr Julia Clark, Consultant in Paediatric Immunology and Infectious Diseases, NGH 
0191 2336161, extension 23116 
 
Will anyone else know that I’m doing this? 
We will keep your information in confidence. This means that we will only tell people 
who have a right or need to know. Any information sent out of the hospital will have 
your name and address removed so you cannot be recognised from it. 
 
Who is funding the study? 
This study is being funded by a company called Wyeth who make a vaccine (prevenar) 
which helps to protect children from pneumonia. The money is being used to pay for the 
extra tests and to pay a nurse’s salary to undertake the extra work involved. None of the 
doctors or nurses looking after you will make any extra money if you agree to take part. 
 
Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people called a 
Research Ethics Committee. They make sure that the research is fair. The study has 
been checked by the Research Ethics Committee.   
 
We hope you will let us do these extra tests. The doctors and nurses will look after you 
just the same whether these extra tests are done or not. Please have a think if you’d like 
to take part and talk to your family, doctors and nurses about the study if you’d like to. 
Thank you for reading this and we hope you soon feel better. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pneumonia children’s information sheet version 2, 12/11/2008 
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PARENT INFORMATION SHEET 
 
 
Title of Project:   The impact of pneumococcal vaccination on the 
epidemiology of childhood pneumonia 
 
 
Investigators:  Dr Julia Clark, Newcastle General Hospital 
  Dr Fiona Hampton, James Cook University Hospital  
 
 
Summary 
Together with doctors in Middlesbrough we are doing a study of the causes of 
pneumonia in children and how these might have changed since the introduction of 
pneumococcal vaccination into the national childhood immunisation schedule. We are 
inviting you, on behalf of your child, to take part in this research study.  Before you 
decide whether to take part it is important that you understand why the research is being 
done and what it involves for your child. This information sheet is to help you with this.  
If anything is not clear or you have any further questions after reading this sheet please 
talk to the doctors or nurses looking after your child.  
 
What is pneumonia? 
There are several types of pneumonia and pneumonia is one type of chest infection.  
Most children with pneumonia are not seriously ill and may get better by themselves or 
with antibiotic medicine.  Some children may need injections of antibiotics or other 
types of treatment that mean a stay in hospital. 
 
What causes pneumonia? 
Pneumonia may be caused by many different germs.  Some germs are viruses and some 
are bacteria.  Viruses do not need any treatment but bacteria need antibiotics.  In most 
children with pneumonia the germ causing the infection is never found.  Because we do 
not know which germs are causing the infections we have to judge whether the child 
needs antibiotics or not and which antibiotics would be best.  We judge this by 
examining the children and by using information about which germs caused similar 
infections in other children in earlier studies. 
 
Why do we need to do a study? 
We need to see if the causes of pneumonia in children have changed since the 
introduction of a pneumococcal vaccine into the national childhood immunisation 
schedule. We have information about causes of pneumonia in the North East of England 
before the vaccine was introduced and want see if these have changed. New tests that 
have been developed in the last few years mean we can now find more germs quite 
easily.  A study done now will therefore give us a lot of very useful information without 
too many tests for the children.  
 
Why have I been given this information? 
You have been given this information sheet because the doctors looking after your child 
think that your child has pneumonia.  They may think this because of what they see 
when examining your child or from the chest x-ray or both.  We are asking if you and 
your child will help us in our study of the causes of pneumonia.   
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What will happen if I agree to help in the study? 
 
If you agree to take part then these things will happen: 
1. Your child will have some secretions sucked from the nose with a small tube 
and sent to the laboratory. 
This is a test we do regularly on nearly all small children with poorly chests and some 
of the older ones, even when they are not helping with a study.  If you do not wish to 
take part in this study your child may still need to have this test done as part of routine 
care. 
The secretions will be tested for signs of viruses and bacteria. 
 
If your child is able to cough up some spit into a pot we will send this specimen to the 
laboratory instead of secretions from the nose. 
 
2. Your child will have some blood tests taken and sent to the laboratory. 
Many children with pneumonia need blood tests as part of their routine care. 
If your child needs blood tests then these will be taken to help with giving your child the 
best possible care. This will not depend on whether or not you decide to take part in this 
study. If you decide to take part in this study then that will mean that a little more blood 
is taken at the same time.   
If your child does not need blood tests as part of routine care then taking part in this 
study will mean blood tests especially for this study. We would use a special cold spray 
or local anaesthetic cream to numb the skin prior to the blood test.    
This blood will be tested for signs of viruses and bacteria living in the blood and also 
used as a baseline for the tests in “3”. 
 
3. Anonymous records will be kept of some parts of the examination of your child 
when he or she comes into hospital and throughout the hospital stay.   Records 
will also be kept of the treatment your child receives in hospital and any 
medicines your child takes home. 
These records of your child’s age, weight, temperature, breathing rate and so on will 
later be matched with any germs we find when doing our tests. In this way we can help 
build a picture of how each germ may affect children. The treatment records will help us 
to see if we are using the best treatment for the germs which affect most children. 
 
4. You and your partner will have a small swab taken from the back of the nose. 
It is not known how a particular type of the pneumococcus bug, responsible for many of 
the complicated pneumonias we see, is picked up by children. It is thought that it may 
be transmitted to the child from the nose of a parent / carer. We will be looking for this 
bug in the child’s specimens (1-3 above), and are keen to see if either parent / carer 
carries this bug up their nose too. This will involve taking a small swab (a cotton bud on 
the end of a stick) from the back of the nose. The swab will be introduced into each 
nostril. It only takes a few seconds to do and should not cause any discomfort, but some 
adults find that it tickles, causes them to sneeze, or makes their eyes water.  
 
Additional points: 
1. What possible effects are there on my child by taking part in this study? 
This study is looking at the causes of pneumonia not the treatment. Your own child will 
be monitored, his or her treatment will not be affected by you agreeing to take part in 
the study.  Your own child will therefore not benefit or be put at any risk by taking part 
in the study. Our hope is that we may benefit future children with pneumonia, but we 
cannot benefit those who help in this study. 
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2. Will the information about my child be kept confidential? 
All information collected about your child during this study will be kept strictly 
confidential. Any information which leaves the hospital will have your child’s name and 
address removed so that he or she cannot be recognised from it.  
 
3. Financial concerns. 
This study is being funded by a company called Wyeth who make a vaccine (prevenar) 
which helps protect children from pneumonia. The money is being used to pay for the 
extra tests on the children’s blood and nasal secretions which the hospital would not do 
as part of routine care. The money is also being used to pay a nurse’s salary to 
undertake extra work in collecting information and second blood tests. None of the 
doctors or nurses asking you to help with the study will make any extra money if you 
agree to take part. 
 
4. Will I learn the results? 
We will inform your GP that your child is taking part in the study and will send you and 
your GP a letter once we know the results for your child. This may not be until several 
months after your child has been ill.  Remember that even after all our tests it is possible 
we will not know the name of the germ in your child’s illness. 
 
5. What will happen to the results of the study? 
It is intended to publish the results of the study in a general paediatric journal. Your 
child’s details will not be identified in any publication. You can find out which journal 
the study will be published in by contacting the Study Team after March 2010. 
 
6. What will happen to the study samples? 
Specimens collected for research purposes, that are not part of routine clinical care, will 
be stored by the Research Team until the end of the project. The specimens may be used 
for future research, however this would require further approval by the Research Ethics 
Committee (see point 9). 
 
7. What if there is a problem? 
If you have any concern about any aspect of the study you should ask to speak to one of 
the Researchers who will do their best to answer your questions. If you remain unhappy 
you wish to complain formally you can do this through the NHS complaints procedure. 
Details can be obtained from the hospital. 
Contact: Dr Julia Clark, Consultant in Paediatric Immunology and Infectious Diseases, 
NGH 
0191 2336161 ext 23116 
8. What happens if I no longer want my child to participate in the study? 
You can withdraw from the study at any point without having to give a reason and 
without your child’s clinical care being affected in any way. Specimens provided for 
research purposes can also be withdrawn from the study at your request. 
 
9. Who has reviewed the study?  
All research in the NHS is looked at by an independent group of people called a 
Research Ethics Committee to protect your safety, rights, wellbeing and dignity. The 
study has been reviewed and given a favourable opinion by the Research Ethics 
Committee. 
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10. Other questions. 
If you have any further questions about the study then please talk to one of the doctors 
or nurses on the ward.  If they cannot answer your question directly they will ask one of 
the doctors or nurses organising the study to come and speak to you. 
 
11. What now? 
If you agree to take part in the study then please let the doctors and nurses know and 
sign the attached consent form. If you agree to take any part at all in the study you will 
be providing us with some very useful information for treating children with pneumonia 
in the future.  We will be very grateful for this, as will the children.  We would like to 
thank you very much for helping us with our study. If you do not agree to take part we 
would still like to thank you for reading this information sheet and thinking about 
helping us. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pneumonia information sheet version 2 date 12/11/2008
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ASSENT FORM FOR CHILDREN 
 
Title of Project:  The impact of pneumococcal vaccination on the 
epidemiology of childhood pneumonia 
 
Name of Researcher:  Dr Julia Clark 
 
Child (or if unable parent to circle on their behalf) / young person to 
circle all they agree with: 
 
Have you read (or had read to you) about this project?  Yes / No 
Has somebody else explained this project to you?   Yes / No 
Do you understand what this project is about?   Yes / No 
Have you asked all the questions you want to?   Yes / No 
Have you had your questions answered in a way you understand?  Yes / No 
Do you understand it’s OK to stop taking part at any time?  Yes / No 
Are you happy to take part?      Yes / No 
 
If any answers are ‘no’ or you don’t want to take part then don’t sign your name 
If you do want to take part can you sign your name below? 
 
Your name______________________________ 
 
Date___________________________________ 
 
The doctor who explained the project to you needs to sign too: 
 
Print Name_____________________________ 
 
Sign___________________________________ 
 
Date___________________________________ 
 
Thank you for your help.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pneumonia children’s assent form version 1, 15/07/2008 
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CONSENT FORM (CHILD) 
 
Title of Project:   The impact of pneumococcal vaccination on the 
epidemiology of childhood pneumonia 
 
Name of Researcher:  Dr Julia Clark 
 
 
Please initial 
box 
 
1. I confirm that I have read and understand the information sheet dated 12/11/2008 
 (version 2) for the above study and have had the opportunity to ask questions. 
 
 
2. I understand participation is voluntary and that I am free to withdraw at any time, 
 without giving any reason, without my child’s medical care or legal rights being  
 affected. 
 
 
3. I understand that sections of any of my child’s medical notes may be looked at by 
responsible individuals where it is relevant to my taking part in research.  
 I give permission for these individuals to have access to my child’s records. 
 
 
4.   I agree to my child taking part in the main part of the above study. 
 
 
5. I also agree to my child’s GP being informed of participation in the study 
 
 
             
 
------------------------------------------------- 
- 
Name of Patient     
 
--------------------------------------  -------------------  ---------------------------------- 
Name of Parent    Date   Signature 
 
--------------------------------------  -------------------  ---------------------------------- 
Name of Person taking consent  Date   Signature 
(if different from researcher)   
 
--------------------------------------  -------------------  ---------------------------------- 
Researcher    Date   Signature 
 
 
 
 
 
 
 
 
 
Pneumonia consent form version 2 date 12/11/08 
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ABSTRACT 
We describe the aetiology of community-acquired pneumonia in children before 
and after the introduction of the pneumococcal conjugate vaccination programme in 
2006.  
Prospective studies were conducted in 2001–2002 (pre-vaccine) and 2009–2011 
(post-vaccine) of children aged 0–16 years with radiologically-confirmed pneumonia 
seen in hospital. Investigations included culture, serology, immunofluorescence 
antibody and urine antigen testing; with an increased use of PCR assays and expanded 
panels of pathogens in the post-vaccine study.  
241 and 160 children were respectively enrolled in the pre- and post-vaccine 
studies (73% aged <5 years). Identification of a causative pathogen was higher post-
vaccine (61%) than pre-vaccine (48.5%) [p=0.019]. Rates of bacterial infections were 
not different between post- and pre-vaccine studies (17.5% versus 24%, p=0.258). Viral 
(31%) and mixed infections (12.5%) found more often post-vaccine than pre-vaccine 
(19.5% [p=0.021] and 5% [p=0.015] respectively). Rates of identified pneumococcal 
infections were comparable between pre- and post-vaccine studies (14.7% versus 
17.4%, p=0.557). Diagnosis of pneumococcal infection post-vaccine improved when 
PCR was used compared to culture (21.6% versus 6%, p=0.0004). Serotypes were 
identified in 75% (18/24) post-vaccine which are included in PCV13 but not PCV7.  
Infection with non-vaccine pneumococcal serotypes continued to be a significant 
cause of pneumonia in UK children. 
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INTRODUCTION 
The range of implicated pathogens in paediatric community-acquired pneumonia 
(PCAP) is wide and includes viruses, bacteria or co-infection with both [1, 2]. Studies 
of pneumonia frequently report low levels of pathogen identification although improved 
knowledge of pneumonia aetiology is essential for development of targeted 
management and effective public health strategies such as vaccination [3, 4]. In the UK, 
the 7-valent pneumococcal conjugate vaccine (PCV7) was introduced routinely in 
September 2006 and replaced by PCV13 from April 2010. The vaccine schedule is three 
doses administered at 2, 4 and 13 months of age. When introduced, those over and 
under one year of age received one and two doses respectively as part of a catch up 
programme for children aged under two years. 
 
Identifying the aetiology of PCAP is challenging with a large number of potential 
pathogens, some of which may also be carried as commensal organisms, which can 
complicate the interpretation of the results of testing nasopharyngeal samples [5]. 
Conventional methods such as blood culture and serology often have limited sensitivity 
due to inadequate sample volume or lack of convalescent sera [3]. Molecular 
diagnostics are now routinely used in the assessment of viral respiratory infections and 
similar techniques have been developed for the detection of bacterial respiratory 
infections [6, 7]. Resti and colleagues demonstrated a significant improvement in the 
identification of pneumococcal pneumonia in children by PCR on blood samples 
(15.4%) when applied simultaneously with blood culture (3.8%) [8]. In a recent study of 
Italian children aged under five years, overall bacteremic pneumococcal pneumonia was 
identified in 14.3%, which was established by PCR in 92%, blood culture 1% and both 
in 7% [9]. 
 
The introduction of PCV was expected to decrease the incidence of pneumonia in 
children,  and this is supported by a region-wide epidemiological prospective survey 
[10]. We present data from studies conducted over two periods before (2001–2002) and 
after (2009–2011) the addition of conjugate pneumococcal vaccination. These were 
designed to describe the proportion of causative pathogens in PCAP and describe how 
the identification of causative pathogens could be improved with the application of 
more PCR-based assays. As the disease incidence declined, we therefore planned a 
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longer recruitment period in the post-vaccine study in order to have a larger cohort with 
representative aetiological data. 
 
METHODS 
Participants 
Two prospective studies were undertaken from August 2001 to July 2002 and October 
2009 to March 2011. Enrolled children were from the North East England (excluding 
Cumbria) who were aged 0–16 years and presented with clinical and radiological 
features suggestive of pneumonia. They were admitted to the paediatric services at the 
Great North Children’s Hospital (formerly Newcastle General and Royal Victoria 
Infirmary), the regional cardiothoracic centre, Freeman Hospital Newcastle, or the 
James Cook Hospital in Middlesbrough. The cohort of 2001–2002 study was a 
proportion of children with pneumonia seen at these recruitment sites as part of a 
previously published regional epidemiological survey [11]. They were consented and 
enrolled in the aetiological study with an extended panel of investigations. Written 
informed consent was obtained from parents and assent from older children. Ethical 
approvals were granted by the Newcastle and North Tyneside Research Ethics 
Committee and Research Approval Board at South Tees Hospitals NHS Trust, 
Middlesbrough. Caldicott approvals were also obtained.  
 
Research teams of doctors and nurses led and ascertained the standardised diagnosis of 
pneumonia and the recruitment procedures. Recruitment methodology and enrolment 
criteria were consistent across the two studies and included children with any history, 
signs or symptoms suggestive of lower respiratory tract infection including any of fever, 
tachypnoea (defined age-specific respiratory rates), dyspnoea, cough, respiratory 
distress, chest wall retractions and auscultatory findings such as crackles, bronchial 
breathing or reduced breath sounds together with chest radiographic findings consistent 
with pneumonia as determined initially by the local paediatrician. Data on C-reactive 
protein and full blood count indices were used when clinically indicated by the 
admitting teams to inform the diagnosis of pneumonia. Exclusion criteria included 
resident outside of North East England; clinical diagnosis of bronchiolitis; 
hospitalisation in the preceding three weeks or normal chest radiograph after formal 
reporting by a radiologist.  
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All chest radiographs were reviewed by second consultant radiologists (one for each 
study) at the regional centre in Newcastle who were blinded to both clinical data and the 
first reports. Radiological findings were categorised into lobar, patchy or perihilar 
according to the WHO criteria [12]. Pneumococcal conjugate immunisation history 
including the valency of PCV was obtained from parents and cross-checked with the 
child’s parent held health records. General practice surgeries were contacted to clarify 
doses given if there was uncertainty. Immunisation history was not collected in the pre-
vaccine study. 
 
Laboratory procedures 
Blood samples were collected for serum, blood culture (BacT/ALERT
®
, bioMérieux, 
France) and pneumococcal PCR testing. Approximately four weeks later blood was 
collected for convalescent serology. Parents often declined returning for these 
convalescent samples (all in the post-vaccine study), contributing to the variability in 
the number of investigations performed. Nasopharyngeal secretions included aspirates 
(NPA) from infants, and/or swab (NPS) from older children. NPA sample was placed in 
0.9% sodium chloride transport solution or swabs (Medical Wire & Equipment Co Ltd, 
UK). Tracheobronchial secretions (collected via endotracheal tube or bronchoalveolar 
lavage) and pleural fluids were tested when obtained. The nature of collected samples 
were standardised across all ages and in both studies. Recovery of bacterial pathogens 
from nasopharyngeal secretions, sputum, or by urinary pneumococcal antigen was not 
considered evidence of definite infection due to the risk of physiological colonisation 
[3, 13]. We therefore only present and discuss positive results that were classified as 
likely causative pathogens of pneumonia according to defined diagnostic criteria (Table 
1). Any positive results from the potentially colonised above mentioned sites were 
added together separately and rates were grouped among “unknown causes” in Figure 1 
for reader’s information.     
 
Where tests were not part of routine clinical care, samples were stored at –20°C for 
subsequent analysis. Investigations were performed in the Microbiology Laboratory, 
Newcastle upon Tyne Hospitals NHS Trust and the Health Protection Agency (HPA) 
Public Health Laboratory, Newcastle. Apart from locally performed routine diagnostic 
tests, samples from Middlesbrough were transported to Newcastle via daily transport 
services. Pneumococcal isolates from blood and respiratory secretions including pleural 
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fluids were serotyped by multiplexed immunoassay using xMAP beads for detection of 
serotype-specific Streptococcus pneumoniae antigens at the national HPA Respiratory 
and Systemic Infection Laboratory in London [14]. 
 
Viral laboratory diagnostic tests 
Pre-vaccine, immunofluorescence antibody testing (IFAT) was applied to respiratory 
secretions using Chemicon SimuFluor FITC for respiratory syncytial virus (RSV), 
influenza A and B, parainfluenza 1-3, and adenovirus and human metapneumovirus 
(hMPV) was tested for using IFAT utilising an in-house pool of anti-hMPV monoclonal 
antibodies [15]. Viral screening was performed in the post-vaccine study using an in-
house multiplex real-time PCR assay. The target panel was expanded to include 
pandemic influenza A subtype H1N1, parainfluenza virus 4, rhinovirus, coronavirus 
(229E, OC43 and NL63), and bocavirus plus the viruses previously tested for by IFAT. 
Viral serological tests included respiratory syncytial virus (RSV), influenza A and B 
virus, and adenovirus. 
 
Bacterial laboratory diagnostic tests 
Total nucleic acid was extracted from blood samples from both studies and tested using 
a S. pneumoniae specific PCR assay targeting the pneumolysin (ply) gene [16]. An 
acute complement fixation test (CF) antibody screen for ‘atypical’ bacteria and 
respiratory viruses was also performed which included Mycoplasma IgM antibody, M. 
pneumoniae, C. pneumoniae and C. psittaci, as well as, Coxiella burnetii, and 
Legionella pneumophila serogroup 1-6 in the post-vaccine study. Antistreptolysin O 
titre (ASOT) was assayed in both studies by Rheumajet ASO kit (Launch Diagnostics, 
UK). 
 
Statistical analysis 
Data were analysed using Epi Info
TM
 7. Summary of the isolated pathogens was 
presented as frequencies and categorised as viral, bacterial or mixed viral-bacterial 
infections. Detection rates of pathogens are expressed as proportions of those tested, and 
results were compared in relation to age group. The age group classification was 
under/above five years as by the start of post-vaccine study; children in the under five 
age group should have been vaccinated with PCV. This would allow the investigation of 
the relative contribution of pneumococcal infection in causing pneumonia, as well as the 
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role of other pathogens. Where there was a common methodology for diagnosis 
between studies, identification rates of infections were compared using Fisher’s exact 
test with odds ratios (ORs) and 95% confidence intervals (CIs).  
 
A subgroup analysis within the post-vaccine study was performed on enrolled children 
before the PCV13 was introduced in April 2010. This is to compare the rates of 
infection groups in relation to the data from pre-vaccine study and all post-vaccine 
study (October 2009 to March 2011). 
 
RESULTS 
A total of 401 children were enrolled, 241 and 160 in the pre- and post-vaccine studies 
respectively. All had at least one microbiological investigation performed. There were 
similar demographic characteristics between the pre- and post-vaccine studies; 
including median age (2.5 versus 2.6 years), proportions of males (57% versus 56%) 
and aged under five years (75.5% versus 69%). Figure 1 summarises the aetiological 
and radiological classifications and Table 2 lists the results of the diagnostic tests 
performed. Lobar consolidation was more often present post-vaccine in 61% compared 
to 23% pre-vaccine (p<0.001). A likely causative pathogen was established in 61% of 
children post-vaccine, compared to 48.5% pre-vaccine (OR 0.6, 95% CI 0.41–0.92, 
p=0.019) when the results of all tests were combined.  
 
Forty-one children were not eligible for the pneumococcal conjugate vaccination due to 
age criteria whilst its uptake was 94% (112/119) among eligible children (89 had PCV7, 
10 PCV13 and 13 received combined doses of each with age-appropriate schedule). Of 
those vaccinated with PCV7 either routinely or according to the catch up programmes, 
83 of them received age-appropriate doses (57 had full schedule) whereas six children 
had partial schedule with one dose less for their age. Among those who had PCV13, one 
received full schedule, one child had one dose less for age, and eight had not completed 
but had appropriate doses for their age. 
  
Viral infections 
Table 3 shows the number of identified pathogens with age group distribution. Viral 
(31%) and mixed infections (12.5%) were significantly higher post-vaccine than pre-
vaccine; being respectively 19.5% (p=0.021) and 5% (p=0.015). The detection of 
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viruses using a combination of PCR and serological assays post-vaccine (57%, 85/149) 
was higher than that of testing with immunofluorescence and serology pre-vaccine 
(30.5%, 65/213). This improvement in viral detection was thought to be due to the 
application of PCR assays (44.7%) replacing immunofluorescence testing (27.9%) on 
respiratory secretions (p=0.003). Post-vaccine, acute viral serological assays were only 
positive in seven with influenza A virus infection, whereas pre-vaccine, combined acute 
and convalescent serology identified infections with eight each of RSV and adenovirus, 
four influenza A/B viruses, and one Epstein-Barr virus. 
 
Post-vaccine, RSV was detected in 21% (31/147) of samples, of which 19 were type A, 
with rhinovirus (8.5%), influenza (7%) and adenoviruses (7%). These figures were 
comparable with those pre-vaccine for adenovirus and influenza A/B (6% each); but 
higher than that for RSV (15%). Of the 142 identified causative pathogens post-vaccine, 
71 (50%) viruses were detected among those aged under five years, compared to the 
finding in pre-vaccine study (36%, 54/149). hMPV was not detected in any of the 48 
tested pre-vaccine respiratory samples, but was identified in one child in the post-
vaccine study. 
 
Bacterial infections 
There were no difference in the rates of bacterial infections between post-vaccine at 
17.5% of the total compared to 24% pre-vaccine (p=0.258). Identified overall 
pneumococcal infections were not different between both studies (p=0.557). They 
represent 17.4% among children tested post-vaccine (14/93 [15%] and 10/44 [22.7%] in 
those aged under and over fives respectively). This was compared to 14.7% pre-vaccine 
(28/180 [15.6%] and 7/58 [12%] among those under and over fives respectively). In the 
post-vaccine study, diagnosis of pneumococcal infection improved when PCR was used 
(21/97, 21.6%) compared to culture (8/132, 6%) (p=0.0004). A serotype was identified 
in 75% (18/24) in the post-vaccine study. These were serotypes 1 (44.4%), 3 (27.8%), 
19A (22.2%) and 7A/F (5.6%). The rate of positive blood culture post-vaccine was 
almost double (5.6%) that in pre-vaccine (3.2%).    
 
Group A streptococcal infections were confirmed in higher proportion of children 
(10.5%) post-vaccine than the pre-vaccine (7%). These infections were associated with 
severe disease, and in two-thirds of them with empyema. M. pneumoniae was identified 
 198 
 
from acute serology in 9.9% of children post-vaccine, with 4% (2/51) in those under 
five and 20% (6/30) over five years. The rate of detected mycoplasma infection was 
higher in pre-vaccine (12.5%) when paired acute and convalescent samples were 
available, with 7% (9/128) in those under five and 27% (13/48) over five years old. 
        
Subgroup analysis (October 2009 to March 2010) 
Among of 67 children enrolled during this period, the causative pathogen was identified 
in 37 (55%). S. pneumoniae was identified in 18.3% (11/60) compared to 16.7% (13/78) 
during the first year of PCV13 (p=0.824). Rates of infections were 22.4% bacterial, 
22.4% viral and 10.5% mixed with both. The rate of bacterial infection is similar to the 
figures from pre- and entire post-vaccine studies. There was no difference between the 
rates of viral infections before and after the introduction of PCV13 during the post-
vaccine study (p=0.079). 
 
DISCUSSION 
This is the first published study to describe the aetiology of CAP in UK children prior to 
and following the introduction of the PCV7. The timing of this comprehensive study 
three years after the introduction of PCV7 and during the first year of PCV13 provides a 
baseline for future comparative studies of the pneumonia aetiology in the same setting. 
The causative pathogens identified were predominately viruses in both studies with the 
detection of pneumococcal infections increasing from pre-to post-vaccine studies 
presumably as a consequence of the application of molecular diagnostic methods. 
 
Previous UK studies investigating the aetiology of pneumonia prior to the introduction 
of the PCV7 were able to identify the causative pathogens in up to 54% of children [17-
19]. In addition to the blood culture, one tested blood for S. pneumoniae, Mycoplasma 
and Chlamydophila using PCR and identified 8% of children with pneumococcal 
pneumonia [18]. Another study identified 6% pneumococcal infection using 
pneumolysin ELISA on blood [19].  The identification rate of 61% for the likely 
causative pathogens in the post-vaccine study is similar to that reported by Don and 
colleagues who used serological assays [20]. However, this is lower than detection rates 
around 80% from studies which used serological and/or molecular approaches [21-23]. 
But this is higher than the rates previously found prior to the introduction of the 
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conjugate vaccine [24, 25]. The improved detection rate between our two studies 
appears to be related to the different laboratory approaches used.   
 
Whilst molecular diagnostic methods have improved respiratory virus detection and 
bacterial detection from normally sterile sites, the interpretation of results can be more 
problematic when it is applied to nasopharyngeal secretions and other respiratory 
samples [3, 13]. Additionally, pneumococcal pneumolysin (ply) DNA can be detected in 
the blood of healthy children colonized with pneumococcus [26]. The pneumolysin gene 
can also be detected in non-pneumococcal Viridans-group streptococci, particularly S. 
pseudopneumoniae and S. mitis [5]. Potential confounders with using a pneumolysin 
PCR in this study therefore include false positives associated with pneumococcal 
carriage or cross-reactivity with other Viridans-group streptococci. Given the very low 
pneumococcal carriage rate in this population (7%) the former is unlikely. Although not 
well explored, viral carriage is also a clinical possibility, leading to positive PCR results 
which do not necessarily correlate to the observed pneumonia [27]. Hence the results of 
PCR-based approaches can be limited in making a definite diagnosis of causative 
pathogens in pneumonia.   
 
The rates of pneumococcal infection from the two data sets are lower than studies in 
other countries [3], but are higher than previously described in the UK [18, 19]. 
Improvement of pneumococcal identification with the application of PCR when 
compared to culture alone is consistent with previous studies [9, 28-30]. This is similar 
to the reported increase in a recent Italian study (from 3.8% to 15.4%) [8]. It is 
interesting that despite the overall decrease in the incidence and hospitalisation of 
pneumonia since the introduction of PCV7 [31, 32], the rates of pneumococcal infection 
were comparable between the two studies. Replacement with non-PCV7 serotypes 
causing invasive pneumococcal disease is well recognised [33], and this may explain 
our findings in the face of reduction in disease incidence. Where pneumococcal 
serotyping was possible with the majority being identified from pleural fluids, all 
serotypes recovered were non-PCV7 but covered in PCV13. This is similar to data from 
the USA on children with empyema where 98% were non-PCV7 serotypes and 
primarily similar to the serotypes in our study [34]. Despite the lack of comprehensive 
serotype data, this suggests that PCV13 could substantially reduce invasive 
pneumococcal disease [35, 36]. 
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Serological evidence of Mycoplasma infection was detected in 9.9% and 12.5% of 
children in both studies, rates that are similar to the published literature [19, 25]. M. 
pneumoniae is traditionally considered a pathogen of older children and in these studies 
was identified more frequently in those over five years of age. We identified no other 
serological evidence of other ‘atypical’ organisms although this may have been as a 
consequence of the lack of convalescent sera. S. aureus and GAS infections were often 
associated with severe pneumonia and empyema [37, 38]. In keeping with previous 
findings, GAS can be found in up to 7% of children with pneumonia compared to 7% 
and 10.5% in our two data sets [19, 39]. With the introduction of PCV and decrease in 
pneumococcal pneumonia it is possible that the relative proportion of bacteria such as 
GAS and S. aureus as well as M. pneumoniae to cause severe pneumonia will increase.  
 
Viruses either alone or as co-pathogens were detected in 25% and 43% of children in 
the pre- and post-vaccination studies respectively, with RSV being the most commonly 
detected pathogen as previously reported [3, 40]. This was followed by rhinovirus, 
influenza and adenovirus at approximately 7% each, similar to data previously 
described for the same region [19]. Diagnosis of viral infection was achieved mainly 
through the testing of respiratory secretions rather than by serology which was only 
positive in seven children with influenza A virus. The improvement in detection of 
viruses in the post-vaccine study was mainly achieved by the application PCR assays 
for respiratory viral screening. Most of the viruses detected were identified in those 
aged under five years, consistent with other studies [2, 23]. In the post-vaccine study, 
viral screening was expanded to include eight viruses with their subgroups including 
pandemic H1N1 and to delineate their contribution in causing CAP in UK children. 
Considering the timing of the second recruitment period, pandemic influenza A H1N1 
was not implicated in many cases of pneumonia as a single pathogen. The low isolation 
rates of bocavirus, coronavirus and hMPV highlight the minimal contribution of these 
viruses in the aetiology of pneumonia in UK children. The rates of mixed viral-bacterial 
infection were variable between the two studies and likely to be dependent on the 
screening methods used to identify the causative pathogens [3]. 
 
There are several limitations to our data, such as potential seasonal bias to the data of 
post-vaccine study where the recruitment was carried out over 18 months which 
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included two winter seasons (48% of enrolled children). Although the post-vaccine 
study covered two winter seasons, enrolled children were fewer than the pre-vaccine 
study which could be a true reflection of decreased disease incidence and 
hospitalisation. The findings from the post-vaccine study may have been hampered by 
the lack of convalescent sera which may have led to the underestimation of the role of 
atypical bacteria in paediatric pneumonia, but this effect is probably minimal as 
mycoplasma infection was only detected in three children by paired serum samples pre-
vaccine. Lack of serotype data of the identified pneumococci from the pre-vaccine study 
limits the true comparison with the serotype profile after the conjugate vaccine 
implementation. Another limitation is the variation between the two studies in the 
diagnostic methods used and the pathogens investigated which makes the interpretation 
of comparative findings guarded. The significant improvement in the identification by 
the application of more PCR assays adds further evidence on the importance of using 
these techniques to monitor changes in the epidemiology of PCAP and pneumococcal 
serotype replacement. 
 
In conclusion, although viruses are the most common cause of pneumonia, around one 
fifth of children had bacterial infections. The combined use of culture, serology and 
PCR-based diagnostic tests significantly improved the identification of causative 
pathogens in PCAP. Replacement of PCV7 with PCV13 was likely to be associated a 
significant reduction in pneumococcal disease as non-PCV7 but PCV13 serotypes 
predominated. This requires continued surveillance to monitor for the emergence of 
serotype replacement. 
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TABLE 1 Laboratory investigations and diagnostic criteria 
  Tests
* Diagnosis of causative pathogens 
Sample Pathogen/antigen 2001-02 study 2009-11 study Definite/probable 
Serum Respiratory viruses Complement fixation Complement fixation Acute titre ≥1/128 or  
4-fold rise between paired sera  Atypical bacteria 
 Mycoplasma  IgM antibody IgM antibody Positive 
 Group A Streptococcus ASOT (IU/mL) ASOT (IU/mL) Acute 2-fold rise or  
4-fold rise between paired sera 
Blood Bacteria Culture Culture Growth 
 S. pneumoniae Real-time PCR Real-time PCR Positive 
Nasopharyngeal secretions/sputum Respiratory viruses IFAT Real-time PCR Positive 
Bacteria Culture Culture/real-time PCR Not applicable 
Tracheobronchial secretions (bronchoalveolar 
lavage/endotracheal) 
Respiratory viruses IFAT Real-time PCR Positive 
Bacteria Culture Culture/real-time PCR Growth/Positive 
Pleural fluids Bacteria Culture Culture Growth 
 Pneumococcal antigen ELISA ELISA Positive 
 S. pneumoniae Not tested Real-time PCR Positive 
*ASOT, antistreptolysin O titre; IFAT, immunofluorescence antibody testing; ELISA, enzyme-linked immunosorbent assay. 
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TABLE 2 Results of the diagnostic tests performed 
 2001-02 study (n=241) 2009-11 study (n=160) 
Tests Tests, n Positive, n (%) Tests, n Positive, n (%) 
Blood and serology 238 75 (31.5) 138 32 (23.2) 
Blood, overall 236 36 (15.3) 136 13 (9.6) 
     Bacterial culture 185 6 (3.2) 126 7 (5.6) 
     S. pneumonia PCR 228 30 (13.2) 86 7 (8.1) 
Serology, overall 181 49 (27.0) 105 22 (21.0) 
     Acute serology     
          Mycoplasma IgM antibody 34 11 (32.4) 77 8 (10.4) 
          ASOT 158 12 (7.6) 80 9 (11.3) 
          Mycoplasma/Chlamydia 128 8 (6.3) / 0 51 / 39 0 
          Legionella/Q-fever 0 0 50 / 42 0 
          Influenza-A/B 158 1 (0.6) / 2 (1.2) 68 / 62 7 (10.3) / 0 
          RSV*/Adenovirus 158 2 (1.2) / 2 (1.2) 52 / 46 0 
     Convalescent serology     
          ASOT 52 2 (3.8) 0 0 
          Mycoplasma/Chlamydia 14 3 (21.4) / 0 0 0 
          Influenza A/B 101 1 (1.0) / 0 0 0 
          RSV/Adenovirus 101 6 (6.0) / 6 (6.0) 0 0 
Respiratory secretions, overall 175 59 (33.7) 151 121 (80.1) 
     Viral screen 158 44 (27.9) 141 63 (44.7) 
     Bacterial culture (TBS)† 14 5 (35.7) 12 7 (58.3) 
Pleural fluids, overall 17 4 (23.5) 40 27 (67.5) 
     Bacterial culture 17 2 (11.8) 40 10 (25.0) 
     Pneumococcal antigen 17 2 (11.8) 30 7 (23.3) 
     Pneumococcal Real-time PCR 0 0 30 18 (60.0) 
*RSV, respiratory syncytial virus; †TBS, tracheobronchial secretions. 
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TABLE 3 Detected likely causative pathogens by age group 
 2001-02 study 2009-11 study 
Pathogens < 5 y 5–16 y n/N* (%) < 5 y 5–16 y n/N (%) 
Bacterial       
     S. pneumoniae 28 7 35/238 (14.7) 14 10 24/138 (17.4) 
     M. pneumoniae 9 13 22/176 (12.5) 2 6 8/81 (9.9) 
     Group A Streptococcus 5 9 14/202 (7.0) 6 8 14/133 (10.5) 
     S. aureus 3 2 5/189 (2.6) 1 2 3/130 (2.3) 
     H. influenzae  0 2 2/189 (1.0) 3 0 3/130 (2.3) 
     Bordetella pertussis 1 0 1/189 (0.5) 0 0 0 
     M. catarrhalis 1 0 1/189 (0.5) 2 1 3/130 (2.3) 
     S. intermedius 1 0 1/189 (0.5) 0 1 1/130 (0.8) 
     Alpha-haemolytic Streptococcus 1 0 1/189 (0.5) 0 0 0 
     K. pneumoniae 0 0 0 1 0 1/130 (0.8) 
Viral       
     RSV (not typed) 29 3 32/213 (15.0) 0 0 0 
     RSV type A 0 0 0 19 0 19/147 (13.0) 
     RSV type B 0 0 0 11 1 12/147 (8.2) 
     Influenza A and B viruses 9 4 13/213 (6.0) 7 4 11/149 (7.4) 
     Adenovirus 11 2 13/213 (6.0) 10 0 10/145 (6.9) 
     Parainfluenza 1-4   5 0 5/158 (3.2) 5 1 6/141 (4.3) 
     Human metapneumovirus (hMPV) 0 0 0/48 1 0 1/141 (0.7) 
     Epstein-Barr virus 0 1 1/1 (100) Not tested Not tested – 
     Varicella zoster virus 0 1 1/1 (100) Not tested Not tested – 
     Rhinovirus  Not tested Not tested – 10 2 12/141 (8.5) 
     Pandemic influenza A H1N1 Not tested Not tested – 4 3 7/141 (5.0) 
     Bocavirus Not tested Not tested – 2 2 4/121 (3.3) 
     Coronavirus  (type OC43) Not tested Not tested – 2 1 3/121 (2.5) 
Total 103 46 149 100 42 142 
*N, total number of performed tests that their positive results classified as definite/probable infections. 
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Figure Legend 
 
FIGURE 1 Summary of the aetiological and radiological classifications 
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401 children with pneumonia 
(≥1 microbiological test performed) 
241 enrolled in 2001-02 study 
Unknown cause 
124 (51.5%) 
 Definite/probable 
infections 
117 (48.5%) 
Viral, 47 (19.5%) 
- 44 single 
- 3 multiple (≥2) 
- 7 lobar 
- 27 patchy 
- 13 perihilar 
Bacterial, 57 (24%) 
- 47 single 
- 10 multiple (≥2) 
- 22 lobar 
- 32 patchy 
- 3 perihilar 
Mixed, 13 (5%) 
- 9 patchy 
- 4 perihilar 
160 enrolled in 2009-11 study 
 Definite/probable 
infections 
97 (61%) 
 Viral, 49 (31%) 
- 38 single 
- 11 multiple (≥2) 
- 17 lobar 
- 12 patchy 
- 20 perihilar 
Bacterial, 28 (17.5%) 
- 24 single 
- 4 multiple (≥2) 
- 20 lobar 
- 3 patchy 
- 5 perihilar 
Mixed, 20 (12.5%) 
- 17 lobar 
- 3 patchy 
Unknown cause 
63 (39%)  
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Abstract 
An important challenge when undertaking clinical research in children is the consent 
procedure. Understanding the factors influencing this process is vital in improving 
children’s involvement in research. We report observed rates and reasons for 
recruitment refusal in two studies of childhood pneumonia and empyema, and describe 
the potential underlying factors contributing to refusal or recruitment facilitation. Each 
study team included a research nurse and medical registrar. Severity of child’s illness 
appeared to determine parent’s decision regarding participation in clinical research. We 
found that willingness of research teams to provide parents with adequate study 
information as well as the liaison of research team members with nursing and admitting 
medical staffs about suitable time to approach families were effective for successful 
recruitment. 
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Introduction 
It is recognised that children are under-represented in clinical research [1]. This has 
impacted on the evidence base available for the management of sick children (Medical 
Research Council [2]. The barriers for research in children are well documented [1, 3]. 
One such barrier is the problem of obtaining informed consent (National Research 
Ethics Service [4]. Assessing a child’s ability to understand and make decisions about 
participation in research is a challenge and varies between individuals [2]. It is a legal 
requirement that in young children, parents or guardians are asked to provide consent on 
their behalf before they can be enrolled in studies [2, 5, 6]. International good clinical 
practice guidelines provide unified standards in research governance that governments 
can adopt to protect human rights of participants and also to define the roles of funders, 
investigators and monitors (International Conference on Harmonisation [7].   
 
In a previous study of British parents consenting to an interventional trial, the major 
reasons for participation given were benefit to other children in the future, contribution 
to science and benefit to their own child [8, 9]. Conversely, parents may feel an 
obligation to protect their children from potential harm or painful procedures [3, 8]. 
These factors are likely to influence the way in which parents rank the risks and 
potential benefits for their child, before making decisions regarding their child's 
enrolment [3, 8, 10, 11]. Given the urgent need to increase the involvement of children 
in clinical research, greater understanding of the process of consent is vital to address 
potential knowledge, attitudinal and psychosocial barriers to this procedure [11-14].  
 
There is a considerable body of literature about children’s consent to participation in 
research, particularly clinical trials [9, 11, 14-16]. However, most studies address the 
recruitment outcomes with minimal emphasis on strategies to improve the recruitment 
process [17]. Evidence from pooled review data showed that barriers to participation in 
research such as time constraints and demand of additional study procedures are related 
to both participants and researchers [15]. Approaches such as taking time to establish 
rapport with children and their parents, short consent forms, the presence of the research 
team to discuss the study with families and giving them the opportunity to request 
further information were found to improve recruitment rates [17]. Several other factors 
described in the literature appear important; trained research staff can significantly 
increase success in obtaining consent [18, 19] and complex information sheets and 
difficulties in understanding the process can be significant barriers to consent [8].    
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We examined data from two studies outside vaccine trials investigating childhood 
pneumonia and empyema both conducted in the same setting, in order to describe the 
potential reasons for consent refusal. The aim was also to report our experience on 
approaches that facilitated the recruitment procedures. 
 
Methods  
Study procedures  
Data were collected prospectively from two studies investigating the impact of the 
routine introduction of pneumococcal conjugate vaccination programme in 2006 on the 
aetiology and epidemiology of childhood community-acquired pneumonia and 
empyema [20]. These studies were undertaken at the Newcastle upon Tyne Hospitals 
NHS Foundation Trust between April 2010 and March 2011. Informed consent was 
voluntarily obtained from a parent or guardian (person or authority who holds parental 
responsibility) [1, 2, 6, 7, 21]. If the consent was refused within that period then the 
following information was documented: reason for refusal if an explanation was offered 
(although parents were not asked to express their reasoning); who approached parents 
for consent; and the severity of pneumonia based on the national guidelines for the 
management of childhood pneumonia [22]. In line with this guidance all children with 
empyema were regarded as severe.  
 
The aims of these studies were to investigate the effect of a pneumococcal conjugate 
vaccination programme on the aetiology of childhood pneumonia, and the changing 
epidemiology of childhood empyema. Children were eligible for the pneumonia study if 
aged between 0–16 years and seen in hospital with clinical and radiological features of 
pneumonia. Similarly, children were eligible for the empyema study if had clinical and 
radiological diagnosis of empyema and underwent pleural drainage.   
 
A favourable ethical opinion by the Newcastle and North Tyneside Research Ethics 
Committee was obtained for the pneumonia study and by the Sunderland Research 
Ethics Committee for the empyema study. Approval was not granted to ask parents 
about the refusal, hence they were not asked directly and systematically about declining 
the enrolment. 
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Recruitment process 
During the time of hospital admission, usually after the diagnosis had been confirmed, a 
member of the research team would visit the ward. This was either the research nurse 
(KP) or research registrar (MAE) for pneumonia study, or the research nurse (CS) or 
research registrar (MFT) for empyema study. Written information on the pneumonia 
study consisted of a four-page sheet for parents and a separate two-page information 
document for children under and those over ten years of age. While for empyema study 
consisted of a three-page parent information sheet and a three-page age appropriate 
information document for the child.  
 
Before approaching the parents and child, liaison with medical and nursing staff helped 
to establish if it was a suitable time to speak to the family about the study. Consenting 
for the empyema study was generally delayed until the invasive procedures had been 
carried out. As all children with empyema were eligible for both studies, efforts were 
made to co-ordinate visits between the two separate research teams, to avoid multiple 
requests to families. Study information was then presented both verbally and in written 
format to the parents and unless the parents specifically requested to give consent 
immediately, a suitable time was established to return and complete the consent process 
if they wished to join the study. The verbal explanation took up to ten minutes, after 
which the parents were offered a chance to ask questions regarding the given 
information. Consents were obtained at the child’s bedside. Where it was age 
appropriate, children were involved in the consent process and they could themselves 
accept or decline the study. 
 
If written consent was obtained then children with pneumonia had a standard proforma 
completed for epidemiological, clinical and management characteristics, together with 
samples of nasopharyngeal secretions, urine and blood.  Three questions regarding 
medical history were asked on empyema patients and a saliva sample obtained either by 
expectoration or by use of soft-tipped oropharyngeal saliva swabs for those unable to 
expectorate. 
 
Results 
A total of 116 children were eligible for enrolment to the pneumonia study and 28 were 
also eligible for the empyema study giving a total of 144 consent procedures. Ten (7%) 
consents were refused, 8 of them had severe pneumonia or empyema. Of 10 refusals, 
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five were seen by a research nurses and the remaining by a research registrars (Table 1). 
Of those with severe disease, consent refusals were 5% and 11% for pneumonia and 
empyema studies respectively. Refusal was linked to not wanting the child to undergo 
further tests, research delaying discharge, and anxiety regarding written consent and 
length of information sheets. It was also observed that if the child and family were 
approached prior to surgery then they would be reluctant to discuss their involvement in 
research at that time. Approximately two days postoperatively when the child became 
clinically stable was the optimum time to discuss the study and consent. 
 
Often parents declined the option to read the information and felt able to give consent 
based on the verbal information offered together with discussion to answer questions 
that they might have. None asked for more information on either of the studies. Parents 
commented on the length of the information sheets as being long and complicated. 
Other reasons for parental refusals were related to lack of interest in participating in 
research or preventing their children from extra study procedures. Children were 
difficult to engage during the recruitment phase. Few were interested in the verbal 
explanation of the study and although age appropriate information was always offered 
not many looked at or read them. 
 
Discussion 
This paper reports consent refusal rates from two clinical studies, and describes the 
potential reasons contributing to the refusal. Although the acceptance rates for both 
studies were high, severity of a child’s illness appears to influence parental decision on 
enrolment in clinical research. The high number of enrolled participants suggests 
effective recruitment strategies. We found that willingness of research teams to provide 
parents with adequate study information as well as the liaison of research team members 
with nursing and admitting medical staffs about suitable time to approach families were 
effective for this successful recruitment.  
 
Informed consent and assent 
The main elements of informed consent include adequate information, freedom of 
decision and capacity to understand [3, 6, 7, 23]. Informed consent must be sought from 
parents or legal guardians before enrolling children in research in the UK according to 
the research guidelines from the Medical Research Council [2, 7, 21] and the European 
Ethics Working Group in Paediatrics [24]. This happens after both written information 
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sheets and verbal explanation are provided. Our findings suggest that there is a balance 
between providing adequate information and over-lengthy information sheets which can 
often appear time-consuming and intrusive. In fact one parent after reading the 
information sheet felt that it was too long and declined the study despite earlier 
acceptance upon verbal explanation of the study. We initially created a one-page 
information sheet but the Ethics Committee advised provision of comprehensive 
information covering essential facts about the studies. Essential information required 
within consent for research is governed by a legal and statuary framework, thus any 
changes to this can only be made within this framework [7].  
 
Assent is a concept that allows the participation of older children in the recruitment 
decision, which in turn encourages a sense of ownership and is defined as “positive 
agreement” [25, 26]. In the UK, assent is advocated if the researcher feels that the child 
is able to make a decision about participation in study [2]. It refers to “acquiescence and 
affirmative agreement to participate” as defined by the Royal College of Paediatric and 
Child Health and Medical Research Council respectively [1, 2]. Involving children in 
the initial discussion of consent process is important as children feel respected [27-30] 
and researchers should recognize that they are developing autonomous decision making 
capacity [31]. In practice, experience has highlighted that it is difficult to engage with 
children despite researchers’ explanations [32] and there are concerns that the 
distinction of consent and assent is confusing [33]. As in our study, children were often 
observed not to be interested in verbal explanation or written information [34, 35]. They 
frequently referred to their parents to sign the consent on their behalf. Hence in older 
competent children beside the assent form if provided, consent was also obtained from 
their parents. This is unsurprising in the context of tired and ill children who may also 
be socially wary of new people [17]. 
 
Taking into account how many families were approached by each member of the team, 
the results showed the individual refusal rate of consent did not vary between different 
team members, suggesting that the role of the team member who obtained consent did 
not determine the likelihood of agreement to participation. Consent refusal was also not 
related to the role of the person seeking consent when research nurses were compared 
with medical registrars despite a variable knowledge and skills, a finding supported in a 
recent study [36]. Hence, our data supports the increasing role of nurses in the field of 
research. The research nurses (KP and CS) started their research careers with these 
  220 
pneumonia and empyema studies respectively. Joining medical teams during the ward 
round following admission and having the research team introduced by them to the 
families was found to be helpful as we did not observe any refusal in such situations. 
This may show that both admitting and research staffs appear as a single team. 
Furthermore coordination with the ward-based non-research nursing staff was useful by 
building bridges between families and research teams as well as supporting the research 
teams to collect study samples. These overall factors facilitated the achievement of high 
enrolment rates to both studies.  
 
Timing and environment 
When a child is admitted to hospital with an illness and consent is sought soon after 
diagnosis, parents will be making decisions when they are stressed and vulnerable, 
whilst simultaneously trying to comfort their child [37]. The pneumonia and empyema 
research teams used approaches in accordance with the guidance on how to seek 
consent provided by the Royal College of Paediatrics and Child Health [1]. We 
provided parents with the study information sheets either before or at the same time of 
interview for consent. If at the initial meeting with parents it was felt to be an 
inappropriate time due to previous events, the child’s condition or parental anxiety then 
information sheets were left with the parents and an appointment made to come back at 
a later time. It did not appear that more of these parents read the information than those 
given the information at time of interview. Parents reported not reading the information 
leaflets and the information provided did not appear to influence the questions that were 
asked by them. This would reflect the trust in person obtaining consent as previously 
reported [38]. Due to the nature of acute illness, when the admission period is often 
minimal, obtaining informed consent usually occurs during one meeting. 
  
Ideally informed consent should be presented in a relaxed and non-coercive 
environment [2]. The environment in which we delivered study information and 
obtained consent was often at the child’s bedside. This allowed the parent to stay with 
their child and the child to continue with their activity should they not want to listen to 
the researcher. Confidentiality may be a consideration when the child is on a bay with 
other children and families. From our experience on children with empyema or severe 
pneumonia timing is equally important as the environment chosen when gaining 
consent, highlighting the challenges when seeking consent for severely unwell children 
[39]. We found that if the child and family were approached prior to decortication 
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surgery then they would be reluctant to discuss their involvement in research at that 
time. At this time parents would often be distressed and vulnerable whilst 
simultaneously trying to comfort their sick child. Postoperatively when the child was 
less critical appeared to be the optimum time to gain consent and related specimens. It 
was interesting from the documented seven children of refusal that five of them had 
severe pneumonia. It could be argued therefore that parental anxiety and the parental 
role to protect their child from further harm was heightened, resulting in refusal. 
 
There are limitations of the reported findings such as parents in this study were not 
directly asked why they did not want to participate. This could affect the conclusions on 
factors influencing consent as these may not have been uncovered. The research team 
reported the parental response and their personal experience which are subject to self 
report bias. These limitations highlight the tensions and barriers involved in trying to 
improve the consent process [11]. 
  
In conclusion, reasons for refusal of enrolment of children into research are complex, 
influenced by illness severity and study procedures. Consent forms should be simple for 
easy understanding. Our findings and observations suggest that increasing the research 
awareness within the department and involvement of non-research nursing and medical 
staffs are important elements for improvement of the recruitment outcomes in clinical 
research. Therefore this warrants a systematic evaluation of the role of non-research 
departmental staff in recruitment procedures.  
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Table 1 Summary of consent refusals  
Staff obtaining consent Refusals (%) 
Research Nurses 5/68 (7.3%) 
     Pneumonia (KP) 4/52 (7.7%) 
     Empyema (CS) 1/16 (6.2%) 
Research Registrars 5/76 (6.6%) 
     Pneumonia (MAE) 3/64 (4.7%) 
     Empyema (MFT) 2/12 (16.7%) 
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SUMMARY 
In epidemiological studies, chest radiograph remains a major criterion for the 
classification of pneumonia in children and yet considerable variation in its 
interpretation is still happening. We aimed to report inter-observer variability in the 
interpretation of 169 chest radiographs in children suspected of having pneumonia. An 
18-month prospective study was undertaken at two centres in Northern England. Chest 
radiographs were performed on eligible children aged ≤16 years with clinical features of 
pneumonia. The initial radiology report was compared with a subsequent assessment by 
a consultant cardiothoracic radiologist. Chest radiographic changes were categorised 
according to the World Health Organization (WHO) criteria. There was significant 
disagreement (22%) between the first and second reports (kappa=0.70, P<0.001), 
notably in those aged <5 years (26%, kappa=0.66, P<0.001). The most frequent sources 
of disagreement were the reporting of patchy and perihilar changes. The levels of 
disagreement between the two interpretations varied when the first reports were 
performed by consultant general, paediatric or cardiothoracic radiologists. Pleural 
effusion was present in first reading in 10% compared to 22% on review of these films. 
Variation in reporting of effusion was 11.8% (kappa=0.57, P<0.001). In conclusion, 
there is substantial inter-observer variability without apparent link to the level of 
training and experience. This highlights the need for experts from different countries to 
create a consensus to review and improve the wider applicability of the WHO 
radiological classification criteria which form the basis for recruitment in 
epidemiological studies of pneumonia in children. 
 230 
 
INTRODUCTION 
Chest radiograph is frequently performed when managing pneumonia in children [1], 
but usually does not affect the clinical outcome [2]. In epidemiological studies, the chest 
radiograph remains a major criterion in classification of pneumonia [3, 4]. Variability in 
the interpretation of chest radiographs for the diagnosis of pneumonia in children is a 
recognised problem [5]. It has been suggested that if all radiologists followed the 
standardised World Health Organization (WHO) radiological criteria for classifying 
pneumonia [3], this would allow more accurate comparative data in epidemiological 
studies for assessment of the impact of pneumococcal vaccination [4]. Broadly four 
categories are defined: “End-point consolidation”, “Other (non end-point) infiltrate”, 
“Pleural effusion” and “No pneumonia”. 
   
We conducted a study to explore the effect of the implementation of pneumococcal 
conjugate vaccine on the aetiology of childhood community-acquired pneumonia. 
Radiological findings were part of the study entry criteria. The aim of this analysis was 
to characterise inter-observer variability in the interpretation of chest radiographs for the 
diagnosis of pneumonia in children according to the WHO radiological classification 
[3]. 
 
METHODS 
Study design and participants 
A prospective study to investigate the aetiology of pneumonia in children was 
undertaken from October 2009 to March 2011 in two teaching hospitals in North of 
England. Caldicott approval was granted and the study was ethically approved by the 
Newcastle and North Tyneside Research Ethics Committee (No: 08/H0906/105), and 
the Research Approval Board at South Tees Hospitals NHS Trust (No: 2008075).  
 
Children aged ≤16 years who presented to paediatric services with signs and symptoms 
suggestive of lower respiratory tract infection including any of fever, tachypnoea, 
dyspnoea, cough, respiratory distress and auscultatory chest crackles, with chest 
radiographic findings consistent with pneumonia as determined initially by the 
admitting paediatrician were enrolled. Paediatricians were not asked to give specific 
radiological interpretations which were provided by radiologists. As this study was on 
the community-acquired pneumonia (CAP) aetiology, exclusions included being 
resident outside of North East England, clinical bronchiolitis, or hospitalization in the 
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preceding three weeks. Children with recent hospitalization were excluded in order to 
eliminate the potential risk of having hospital rather than community-acquired 
pneumonia. Children with underlying chronic chest diseases (such as cystic fibrosis) 
were also excluded to avoid any ambiguity in the interpretation of acute and chronic 
changes on chest radiographs. Research teams of doctors and nurses led and ascertained 
the standardised diagnosis of pneumonia and the recruitment process across the two 
sites. All enrolled children irrespective of the chest radiographic findings received 
treatment for pneumonia according to the management guidelines from the British 
Thoracic Society [6]. 
 
Radiology 
All chest radiographs were anteroposterior views and first reported by radiologists 
locally as per routine clinical care and viewed electronically via the Picture Archiving 
and Communications System (PACS). There were uniform and regular quality 
assessments performed on the system performance including display characteristics. All 
reporters used similar workstations of radiological standards when reporting the chest 
radiographs. Using the full text written first reports, each radiograph was categorised 
into lobar (end-point consolidation), patchy, perihilar (non end-point 
consolidation/infiltrate) or normal (no pneumonia) according to the WHO criteria [3, 4]. 
Effusion with fluid in the pleural space between the lung and chest wall was considered 
as primary end-point and classified simply as either present or absent [4]. This does not 
include fluid in the horizontal or oblique fissures. First reports were generated with the 
benefit of clinical information, a standard institutional requirement for routine reporting. 
All radiographs were reviewed by a second consultant cardiothoracic radiologist (MM) 
at the regional centre (designated as the “gold standard”) who was blinded to both the 
first report and specific clinical data. However, this radiologist knew the radiographs 
were from a child enrolled in the CAP study, thus clinically pneumonia had been 
suspected. Radiologists involved in performing the first and second reporting received 
the same training in radiology including the classification of radiological pneumonia. 
Those involved in first reporting included five radiology trainees, three consultants 
general, two paediatric and two cardiothoracic radiologists.   
 
A workshop including MAE, MM, DAS and JEC was carried out before the application 
of WHO criteria [3] on the first reports and performing the second reading in order to 
discuss and refine the potential definitions which could be a source of disagreement 
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such as interstitial infiltrates of patchy or perihilar changes. The study team agreed that 
if more than one radiographic change were reported, then in line with WHO 
recommendations the most significant one is reported [3]. The WHO criteria were 
prioritised according to the clinical significance, as follows: lobar (end-point 
consolidation) in favour of other changes (non-end-point infiltrates) if both were present 
[3]. When more than one radiographic change was reported then the radiograph was 
classified overall according to the most significant category. Grouping of the first 
reports was carried out by MAE and there was no ambiguity on the wording of first 
reports that might cause confusion on categorization. Inter-observer variability in the 
interpretation of chest radiographs was measured by the comparison of first reports with 
their second reading. The intra-observer variation was not calculated because all 
radiologists read the radiographs only once. 
 
Statistical analysis 
Data analysis was performed using the PASW Statistics 19 program. The significance 
of inter-observer variability was assessed using fisher's exact test because there were 
small values <5 in the tables. Cohen's kappa index (k) was calculated to measure the 
agreement between the first and second readers above that which would be expected by 
chance. 
 
RESULTS 
A total of 169 children were identified and treated for pneumonia and/or empyema 
(53% males, 73% aged <5 years, mean age 3.8±3.72 years, and age range from 0.05 to 
16.7 years). Of those, 46 had chest radiograph reported as normal on the first reports, 
but on the second reading six (13%) had abnormal changes (i.e. false negative); four 
lobar and two patchy. All of the false negative cases received antibiotic treatment 
(median, 7 days), and none developed any complication. Fourteen (11.4%) were 
initially reported as having radiological changes, were reported as normal radiographs 
on the second review (i.e. false positive) (Table 1). 
  
All radiologists agreed that all chest radiographs were suitable for interpretation. There 
was significant inter-observer variability in the interpretation of chest radiographs 
(k=0.70, P<0.001), with patchy (48.8%) and perihilar (28.1%) changes being the main 
components of this variability (Table 1). Although few (n=5) were first reported by 
radiology trainees, there was no difference in reporting when these were reported by the 
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second radiologist. The two interpretations varied when the first reports were performed 
by senior radiologists, particularly consultant pediatric radiologists who had an overall 
26.7% disagreement with the reviewing cardiothoracic radiologist and lowest (15.8%) 
with consultant thoracic radiologists (Table 2).  Levels of disagreement were highest 
among children aged <5 years compared to those aged ≥5 years (26%, k=0.66 versus 
11%, k=0.83, P<0.001). There was no disagreement on reporting lobar findings in the 
<5 years age group, disagreement was mainly related to patchy and perihilar changes.       
 
Pleural effusion was present at first reading of the films in 10% (17/169) compared to 
22% (37/169) on review. Variation in reporting of pleural effusion was 11.8% (k=0.57, 
P<0.001). However, if the presence of a pleural effusion was reported in the first report 
there was no disagreement about this in the second report. In contrast 13.2% of pleural 
effusions were reported only on the second report and not in the first report. Initial 
reporting of pleural effusion by radiology trainees was not different to reports at second 
reading (k=1, P=0.200).  In addition there was good agreement between first and second 
reports of pleural effusion when initially read by consultant thoracic radiologists 
(k=0.17, P=0.368). Whilst there were significant differences in first reporting of 
effusion by consultant paediatric radiologists (k=0.78, P<0.001) or consultant general 
radiologists (k=0.41, P=0.002) compared to second reading, the proportions of 
disagreement were respectively low of 5.8% and 15.3%. 
 
DISCUSSION  
We found substantial inter-observer variability in the interpretation of chest radiographs 
for the diagnosis of paediatric pneumonia. This has been recognized since radiology 
reporting was initiated in the middle of last century [7, 8], and continues despite the 
acceptance of the recommended WHO criteria for reporting chest radiographs of 
pneumonia in children [3, 4]. 
  
The diagnosis of pneumonia in children based on a combination of clinical and 
radiological features is important for prompt management [9]. Yet, subtle radiographic 
changes can be difficult to recognise or interpret [10] and failure to diagnose pneumonia 
may result in inappropriate management [11]. The initial interpretation of chest 
radiographs is usually performed by clinicians with the radiologists’ reports following 
later, often after the patient has been discharged from hospital [11]. Interpretation by 
clinicians could be biased by inadequate training in radiology and lack of clinical 
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information may limit the accuracy of reporting by the radiologists [12]. For research 
purposes blinded interpretation of the chest radiograph may improve detection of subtle 
changes and differentiating normal biological variants [13]. Making clinical information 
available may reduce inter-observer variability but does not result in marked 
improvement in the overall accuracy [14].  
 
This study shows that most inter-observer variability is related to the interpretation of 
patchy and perihilar changes, which need careful viewing and the availability of clinical 
information during interpretation [15]. It is well recognised that abnormal chest 
radiographs may be interpreted as normal [15], but surprisingly four of the normal 
reports had lobar changes on review. Similarly, 13% had a previously undetected 
pleural effusion. The variation in reporting of chest radiographs for those aged <5 years 
confirms the particular challenge of making a radiological diagnosis of pneumonia in 
this age group [10, 16]. The overall inter-observer variation is in line with other 
previously reported findings on interpretation variability including pleural effusion [5, 
16]. It is widely accepted in the literature that chest radiographs cannot reliably 
differentiate viral from bacterial aetiology of pneumonia [6, 17]. Therefore these 
variations on the interpretation of chest radiographs do not significantly affect the 
clinical outcomes and management decisions of pneumonia in children [2, 6, 17-19].   
 
It is interesting that irrespective of the level of experience there continues to be 
significant variability in interpretation between reporters, particularly senior radiologists 
[10, 20]. A previous study showed that qualified radiologists had less inter-observer 
variability on reporting of chest radiographs compared to radiology trainees and 
physicians [21]. Despite the specialized training in pediatric radiology and advanced 
technology, human error remains a likely factor [8]. The level of variability between the 
senior radiologists could be a reflection of inconsistency in the application of WHO 
criteria, as this has been shown to decrease inter-observer variability [22]. However, the 
rate of false negative reports between the two interpretations of chest radiographs is a 
well recognized problem [15] which may jeopardize the results of epidemiological 
studies by underestimating the true burden of pneumococcal pneumonia [23]. In 
previous pneumococcal vaccine efficacy studies the radiographic evidence of 
pneumonia was observed in up to 34% of the enrolled children [24]. It has been 
suggested that using the WHO criteria would make any differences in the results reflect 
geographical variations in disease epidemiology or vaccine effects rather than 
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methodological factors [4]. Despite the application of this classification, the 
concordance rate between two trained reviewers was only 48% (250/521) [25]. The 
degree of variability of reporting chest radiographs from the present study demonstrates 
that methodological differences are still a problem in the epidemiological studies of 
pneumonia in children. 
 
Our findings were limited by heterogeneity amongst a range of radiologists (general and 
specialized radiologists) involved in the first reporting, with only one radiologist 
performing second reporting together with differences in clinical information provided 
at first and second readings. However, having them agree mostly on the interpretation of 
lobar changes, with the main variability related to non-end-point changes as recently 
shown among a group of 13 paediatricians and two radiologists [26], make the impact 
of these limitations is minimal. On the other hand the agreement between readers was 
improved when the WHO criteria [4] was modified to consider the presence of any lung 
infiltrate irrespective of its features as end-point pneumonia [27]. All of these reported 
findings highlight the importance to have defined diagnostic radiological criteria of 
pneumonia that can be universally used in epidemiological studies and clinical practice.      
 
In conclusion, there is substantial inter-observer variability in the reporting of chest 
radiographs particularly in young children with pneumonia which appears unrelated to 
the level of training and experience of those reporting. These findings add to the 
recognized variability in the literature demonstrating that there may be a need for 
evaluation of the WHO categorization of radiological pneumonia in children to improve 
the validity and encourage widespread adoption of the criteria. 
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Table 1 Inter-observer variability and agreement in the chest radiographs reporting 
First reading Second reading (gold standard) Disagreement* 
Radiographic changes n (%) Lobar Patchy Perihilar Normal n (%) 
Lobar 48 (28.4) 47 1 0 0 1 (2.1) 
Patchy 43 (25.4) 7 22 5 9 21 (48.8) 
Perihilar 32 (19.0) 4 0 23 5 9 (28.1) 
Normal 46 (27.2) 4 2 0 40 6 (13.0) 
Total 169 62 25 28 54 37 (22.0) 
*Fisher's exact test, P<0.001; Kappa=0.70 (proportion of subjects on which readers would be expected to agree). 
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Table 2 Comparison of chest radiographs interpretation by the grade of reporters 
First reading Second reading (gold standard) Disagreement  
Radiographic changes n (%) Lobar Patchy Perihilar Normal n (%) Kappa (P) 
Radiology trainees 5 (3) 1 1 2 1 0 1.00 (0.105) 
     Lobar 1 1 0 0 0 0  
     Patchy 1 0 1 0 0 0  
     Perihilar 2 0 0 2 0 0  
     Normal 1 0 0 0 1 0  
Consultant general radiologists 59 (35) 18 12 9 20 11 (18.6) 0.75 (<0.001) 
     Lobar 16 15 1 0 0 1 (6.3)  
     Patchy 17 0 11 3 3 6 (35.3)  
     Perihilar 8 1 0 6 1 2 (25.0)  
     Normal 18 2 0 0 16 2 (11.1)  
Consultant paediatric radiologists 86 (51) 35 7 13 31 23 (26.7) 0.63 (<0.001) 
     Lobar 26 26 0 0 0 0  
     Patchy 18 5 5 2 6  13 (72.2)  
     Perihilar 17 2 0 11 4 6 (35.3)  
     Normal 25 2 2 0 21 4 (16.0)  
Consultant thoracic radiologists 19 (11) 8 5 4 2 3 (15.8) 0.78 (<0.001) 
     Lobar 5 5 0 0 0 0  
     Patchy 7 2 5 0 0 2 (28.6)  
     Perihilar 5 1 0 4 0 1 (20.0)  
     Normal 2 0 0 0 2 0  
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Abstract 
Rationale and aim: To compare clinical features and management of paediatric 
community-acquired pneumonia following the publication of UK pneumonia guidelines 
in 2002 with data from a similar survey at the same hospitals in 2001–2002 (pre-
guidelines). 
Methods: A prospective survey of 11 hospitals in Northern England was undertaken 
during 2008–2009. Clinical and laboratory data were recorded on children aged ≤16 
years who presented with clinical and radiological features of pneumonia. 
Results: 542 children were included. There was a reduction in investigations performed 
(P<0.001) except C-reactive protein (P=0.448) between surveys. These included full 
blood count (76% to 61%); blood culture (70% to 53%) and testing of respiratory 
secretions for viruses (24% to 12%) and bacteria (18% to 8%). Compared to pre-
guidelines, there was a reduction in the use of intravenous antibiotics as a proportion of 
the total prescribed from 47% to 36% (P<0.001) and a change in the route of antibiotic 
administration with increasing preference for oral alone (16% pre- compared to 50% 
post-guidelines, P<0.001).  
Conclusion: Apart from the collection of blood culture which is encouraged and acute 
phase reactants that should not be measured routinely, these changes are in line with the 
guideline recommendations. Improvements in antibiotic use are possible and have 
implications for future antimicrobial stewardship programmes. 
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Introduction 
Paediatric community-acquired pneumonia (PCAP) is a frequent cause of admission to 
hospital [1, 2]. Clinical features of pneumonia are often non-specific in young children 
[3, 4]. Management decisions are generally based on a combination of clinical signs, 
symptoms and radiological changes [3, 5]. National UK clinical guidelines for 
management of PCAP were published in 2002[6] and updated in 2011[1] by the British 
Thoracic Society (BTS). They synthesized evidence and expert opinion to produce best 
practice national standards, which included statements on investigations and antibiotics 
use (box 1) [6]. 
 
In the UK, the 7-valent pneumococcal conjugate vaccine (PCV7) was introduced 
routinely from September 2006. It was associated with a reduction in the incidence of 
PCAP and rate of hospitalisation [7]. We therefore aimed to explore changes in the 
management of children with pneumonia seen in hospital in the context of the national 
guidelines. Presentation and management outcomes of pneumonia in children in the 
present survey were compared to those previously described in a similar survey 
conducted in the same region in 2001–2002 [3], prior to the publication of the BTS 
management recommendations for PCAP in 2002 [6]. Such findings are important for 
doctors involved in the management of this infection and for experts updating these 
guidelines. 
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Box 1 Selected standards from 2002 BTS management guidelines of PCAP [6] 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Methods 
Participants 
A prospective survey of children aged ≤16 years who presented with clinical and 
radiological features of pneumonia at 11 hospitals (sites) was conducted in Northern 
England (excluding Cumbria) from August 2008 to July 2009 “post-guidelines”. 
Exclusions included being resident outside the geographical study area; clinical 
bronchiolitis; hospital admission within three weeks of pneumonia admission; or normal 
chest radiograph. Disease severity was classified according to the BTS criteria [6]. 
Chest radiographic changes from the local radiologists’ reports were classified into 
patchy, lobar or perihilar consolidations according to the WHO criteria [8]. ‘Non-end-
point changes’ such as increased bronchovascular markings, peribronchial thickening, 
bronchial wall thickening, or peribronchial cuffing were grouped together in an 
additional category “other infiltrates/abnormalities”. This cohort was included in a 
region-wide survey investigating the impact of PCV7 on the incidence of pneumonia 
confirmed on chest radiograph [9].  
 
 Blood cultures should be performed in all children suspected of having bacterial 
pneumonia. 
 Nasopharyngeal aspirates from all children under the age of 18 months should be sent 
for viral antigen detection with or without viral culture.  
 Acute phase reactants should not be measured routinely. 
 Amoxicillin is first choice for oral antibiotic therapy in children under the age of 5 
years and macrolide antibiotics may be used as first line empirical treatment in 
children aged 5 and above. 
 Antibiotics administered orally are safe and effective for children presenting with 
CAP. 
 Intravenous antibiotics should be used in the treatment of pneumonia in children when 
the child is unable to absorb oral antibiotics (for example, because of vomiting) or 
presents with severe signs and symptoms. 
 Appropriate intravenous antibiotics for severe pneumonia include Co-amoxiclav, 
Cefuroxime, and Cefotaxime. 
 If clinical or microbiological data suggest that S. pneumoniae is the causative 
organism, Amoxicillin, Ampicillin, or Penicillin alone may be used. 
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Results were compared with those from an identically performed survey, using the same 
recruitment methods and diagnostic criteria in 2001–2002 “pre-guidelines” [3]. Hospital 
reconfigurations reduced the number of units admitting children from 13 to 11 during 
the pre- and post-guidelines surveys respectively. The catchment population and referral 
pathways from primary care or accident and emergency departments to paediatric 
services remained the same. Ethical approval was obtained from the Newcastle and 
North Tyneside Research Ethics Committee with Caldicott approval granted from all 
sites. 
 
Data collection and case ascertainment 
A family doctor/general practitioner or medical staff at the accident and emergency 
departments saw children before referral for further assessment by the paediatric team. 
Children were managed entirely by their local paediatric team. Data were recorded on 
standard form and validated by reviewing ward admission diaries for children admitted 
with respiratory symptoms (eight sites), or by obtaining hospital coding data on 
pneumonia where admissions are carried out electronically (three sites). Hard copy and 
electronic records were reviewed to ascertain the data and resolve any missing or 
inconsistent data. Duplicates or those who did not fulfil the enrolment criteria were 
removed. 
 
Statistical analysis 
Descriptive analysis was performed using Epi Info
TM
 7. Fisher’s exact test was used to 
compare categorical variables between groups and with those from the pre-guidelines 
survey [3]. A comparison of treatment approaches, clinical and radiological features for 
severe versus mild/moderate CAP was performed using logistic regression. 
 
Results 
A total of 542 were eligible for inclusion (58% males; 74% <5 years old). Similar to 
pre-guidelines (89%), 84% children were admitted. Ten children required admission to 
the intensive care for assisted ventilation; eight were under five. An underlying co-
morbidity was present in 15% and asthma in 7%. No children died during either survey 
periods. The epidemiological outcomes for this cohort were described in a separate 
publication [9].  
 
  246 
Table 1 summarises the clinical features at presentation across both surveys. Comparing 
post- with pre-guidelines surveys; fewer children presented with severe disease 
(P=0.023). Among those with pleural effusion, reported lobar changes were present in 
77% post-guidelines compared to 42% pre-guidelines (OR=0.2; 95% CI 0.09 to 0.48; 
P=0.0002). Logistic regression analysis of the post-guidelines data suggested that 
children over two not given preadmission antibiotics were more likely to develop severe 
disease (P=0.010). Hospitalisation was associated with disease severity (P<0.001), but 
not with pyrexia (triage temperature >38
o
C) or chest radiographic changes. 
 
Investigations 
There was an association between the collection of blood samples for investigation(s) 
and use of intravenous (IV) antibiotics pre-guidelines (P<0.001), but not post-guideline. 
There was a reduction in the number of investigations performed (P<0.001) except C-
reactive protein (CRP) (P=0.448) between pre- and post-guidelines. Full blood count 
(FBC) decreased from 76% to 61%; blood culture from 70% to 53%; testing respiratory 
secretions for viruses from 24% to 12% and bacteria from 18% to 8%. The yield of 
blood culture was the same in both surveys (4% and 4.9%). Post-guidelines, viral PCR 
assays (immunofluorescence test in pre-guidelines) were performed on respiratory 
secretions from 66 children with 26 (39%) positive. Obtaining a viral respiratory screen 
was age-dependent and more frequently performed in those aged <2 (22%) than ≥2 
years, but less often when compared with pre-guidelines (34%) [OR=0.5; 95% CI 0.33 
to 0.75; P=0.001]. 
 
CRP was obtained in 322 (59%). Of which, 27% were >100 mg/L; 9% of infants, 58% 
of under five years old and 42% in the above five. Pleural effusion was associated with 
higher CRP greater than 100 mg/L (P<0.001). Lobar and patchy changes were 
associated with a CRP more than 150 mg/L (P<0.05). Mean values of CRP, total white 
cell count (WCC) and neutrophils were higher with lobar changes (P<0.001). 
 
Management 
Between the pre- and post-guidelines, IV antibiotics as a proportion of the total 
prescribed antibiotics decreased from 47% (501/1065) to 36% (318/891) [OR=1.6; 95% 
CI 1.33 to 1.93; P<0.001], and oral antibiotics alone increased from 16% to 50% 
[OR=4.4; 95% CI 3.37 to 5.71; P<0.001]. There was also a reduction in the use of IV 
route only from 8% to 5% [OR=1.8; 95% CI 1.08 to 2.86; P=0.025] and the use of both 
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oral and IV routes (P<0.001) between the pre- and post-guidelines respectively. Post-
guidelines, Amoxicillin prescription both orally and intravenously increased (P<0.001) 
with a decrease in IV cephalosporins (Cefuroxime and Cefotaxime) (P<0.001) and total 
oral macrolides (Erythromycin, Azithromycin and Clarithromycin) (P<0.001). 
However, the individual use of Azithromycin or Clarithromycin remained the same, 
whilst decreased for Erythromycin (P<0.001).  
 
 
Pre-guidelines, initial IV antibiotics were associated with severe disease, lobar changes, 
pleural effusion, or pyrexia (P<0.05), but not with oxygen saturation <93%. These 
associations were replicated in post-guidelines with the initial use of IV antibiotics 
being associated with severe disease (P=0.0003), lobar changes (P=0.018), or pleural 
effusion (P=0.041), but not with oxygen saturation <93% or pyrexia. Comparing post- 
with pre-guidelines; IV antibiotics were more likely to be given to those with lobar 
changes (35% versus 25%) [OR=0.6; 95% CI 0.45 to 0.85; P=0.004], but less likely to 
be given to children presenting with low oxygen saturations (25% versus 34%) 
[OR=0.6; 95% CI 0.45 to 0.89; P=0.009].  
 
Mean duration of hospitalisation decreased from pre- to post-guidelines (4.7±7.16 
versus 3.2±3.02 days, P<0.001). Those with severe disease, lobar changes or pleural 
effusion had a longer stay (P<0.001). All children irrespective of their age group who 
received any IV antibiotics (alone or in combination with oral) had a longer average 
duration of hospitalisation than those who had only oral (4.1±3.4 versus 2.0±1.9 days, 
P<0.001). Figure 1 shows the probability of discharge from hospital in relation to the 
duration of admission. Approximately 75% of children were likely to be discharged 
within two days of hospital admission, whilst hospital stay for up to five days was 
required for nearly 20% of children. Approximately 5% of children stayed for nearly 
three weeks because of complications and presence of pre-morbid medical illnesses. 
 
Discussion 
This survey provides invaluable evaluation of the presentation and management of 
PCAP seen in hospital over a year period. Clinical management of children with 
pneumonia has changed significantly between 2002 and 2008. There have been a 
reduced number of investigations performed, a change in the type of antibiotics, a 
decrease in IV and a concomitant increase in oral antibiotics. Reasons for these changes 
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are likely to be multifactorial such as the publication of the BTS management guidelines 
[6], an expanding literature on oral/IV antibiotic use [10-12], and the routine 
introduction of PCV7 in the UK in 2006.   
 
Drivers of change are complex. Some are likely to be literature driven. Others probably 
reflect the complex relationships around perceived benefits and risks of IV cannulation, 
venepuncture and differing usefulness of investigations. It is interesting that fewer blood 
tests in terms of FBC and blood cultures were taken, but just as many CRP samples 
were ordered. The BTS guidelines including the recently updated version [1] made no 
specific recommendations around FBC, but blood cultures were (and are) specifically 
encouraged, whilst CRP is not [6]. In this survey, the correlation between high CRP of 
>100 mg/L with pleural effusion demonstrates the usefulness of CRP in differentiating 
between uncomplicated and complicated pneumonia of bacterial aetiology [13]. The 
reduction in collecting blood cultures perhaps reflects the feeling that bacterial 
pneumonia is less likely given the introduction of PCV7, which in the same population 
was associated with decreased disease incidence and rate of hospitalisation [9]. 
Although clinicians were not asked directly, the shift towards less testing of respiratory 
secretions for either viruses or bacteria could reflect the feeling that the results would 
not affect the decision on antibiotic use. 
 
More positive changes are seen with antibiotic usage, encouraging for developing 
antimicrobial stewardship programmes. These included a significant reduction in the 
use of antibiotics prior to admission. This is in line with the observed substantial decline 
since 1990s in the prescription of antibiotics in primary care for lower respiratory tract 
infection in children [14]. This fall in antibiotic prescriptions predate the published BTS 
management guidelines of pneumonia in 2002 [6]. They reflect a continued fall in the 
use of antibiotics despite a marginal increase in antibiotic prescription during the period 
between 2003 and 2006, primarily for non-specific upper respiratory tract infections, for 
which national guidance aimed at primary care was introduced in 2008 [14, 15]. 
Intravenous antibiotics were used far less frequently than oral, with a substantial 
increase in the use of Amoxicillin overall and orally, at the expense of IV Cefuroxime 
and oral cephalosporins, which decreased from one fifth to 2%. In contrast, oral 
macrolides remain frequently prescribed particularly to those aged under five, similar to 
previous data [3], although not recommended as first line treatment [6]. Evidence for 
the safety and efficacy of oral antibiotics even in severe pneumonia in children 
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accumulated over the six years period between surveys, including a Cochrane review in 
2006[11] and the PIVOT trial in 2007[12].  
 
The selection of initial antibiotic route was influenced by disease severity and lobar 
changes, possibly reflecting that these criteria were considered markers of bacterial 
infection. The fact that lobar changes were associated with high mean value of 
inflammatory markers may support this. Other factors that could have influenced the 
decision to give IV antibiotics, such as the level of training of admitting medical staff or 
the knowledge of the published guidelines, could not be ascertained with the data 
collected.  
 
In conclusion, there has been a positive change in the management practices of PCAP 
reflected by reduced number of overall investigations performed and an increased 
preference for oral antibiotic use. 
 
 
 
 
  250 
Authorship 
JEC developed the survey concept and with KME and MAE were responsible for the 
survey logistics and facilitation of data collection. MAE managed and validated the 
data. All authors were involved in the interpretation of the results and writing of this 
article. 
 
Funding and conflict of interest 
This survey was supported by a grant from Pfizer Vaccines UK (No: 0887X1-4479). 
The sponsor had no role in the survey design and data analysis or interpretation. JEC 
and DAS received unconditional research support from the Pfizer. 
 
Acknowledgements 
We thank Kerry Pollard, research nurse for the assistance with data validation. We are 
grateful to the support from the paediatric staff in the following hospitals: Queen 
Elizabeth Gateshead, James Cook Middlesbrough, North Tyneside, South Tyneside, 
Sunderland Royal, North Tees, North Durham, Darlington Memorial, Freeman 
Newcastle, Newcastle General and Royal Victoria Infirmary.  
  251 
References 
1. Harris, M., Clark, J., Coote, N., Fletcher, P., Harnden, A., McKean, M. & 
Thomson, A. (2011) British Thoracic Society guidelines for the management of 
community acquired pneumonia in children: update 2011. Thorax, 66 Suppl 2, ii1-23. 
2. McIntosh, K. (2002) Community-acquired pneumonia in children. New England 
Journal of Medicine, 346 (6), 429-437. 
3. Clark, J. E., Hammal, D., Spencer, D. & Hampton, F. (2007) Children with 
pneumonia: how do they present and how are they managed? Archives of Disease in 
Childhood, 92 (5), 394-398. 
4. Van den Bruel, A., Haj-Hassan, T., Thompson, M., Buntinx, F. & Mant, D. 
(2010) Diagnostic value of clinical features at presentation to identify serious infection 
in children in developed countries: a systematic review. Lancet, 375 (9717), 834-845. 
5. Neuman, M. I., Scully, K. J., Kim, D., Shah, S. & Bachur, R. G. (2010) 
Physician assessment of the likelihood of pneumonia in a pediatric emergency 
department. Pediatric Emergency Care, 26 (11), 817-822. 
6. British Thoracic Society. (2002) Guidelines for the management of community 
acquired pneumonia in childhood. Thorax, 57 Suppl 1, i1-24. 
7. Koshy, E., Murray, J., Bottle, A., Sharland, M. & Saxena, S. (2010) Impact of 
the seven-valent pneumococcal conjugate vaccination (PCV7) programme on childhood 
hospital admissions for bacterial pneumonia and empyema in England: national time-
trends study, 1997-2008. Thorax, 65 (9), 770-774. 
8. Cherian, T., Mulholland, E. K., Carlin, J. B., Ostensen, H., Amin, R., de Campo, 
M., Greenberg, D., Lagos, R., Lucero, M., Madhi, S. A., O'Brien, K. L., Obaro, S. & 
Steinhoff, M. C. (2005) Standardized interpretation of paediatric chest radiographs for 
the diagnosis of pneumonia in epidemiological studies. Bulletin of the World Health 
Organization, 83 (5), 353-359. 
9. Elemraid, M. A., Rushton, S. P., Shirley, M. D., Thomas, M. F., Spencer, D. A., 
Eastham, K. M., Hampton, F., Gorton, R., Pollard, K., Gennery, A. R. & Clark, J. E. 
(2012) Impact of the 7-valent pneumococcal conjugate vaccine on the incidence of 
childhood pneumonia. Epidemiology and Infection, 1-8. 
DOI:10.1017/S0950268812002257. 
10. Addo-Yobo, E., Chisaka, N., Hassan, M., Hibberd, P., Lozano, J. M., Jeena, P., 
MacLeod, W. B., Maulen, I., Patel, A., Qazi, S., Thea, D. M. & Nguyen, N. T. (2004) 
Oral amoxicillin versus injectable penicillin for severe pneumonia in children aged 3 to 
  252 
59 months: a randomised multicentre equivalency study. Lancet, 364 (9440), 1141-
1148. 
11. Kabra, S. K., Lodha, R. & Pandey, R. M. (2006) Antibiotics for community 
acquired pneumonia in children. Cochrane Database of Systematic Reviews, (3), Art. 
No. CD004874. 
12. Atkinson, M., Lakhanpaul, M., Smyth, A., Vyas, H., Weston, V., Sithole, J., 
Owen, V., Halliday, K., Sammons, H., Crane, J., Guntupalli, N., Walton, L., Ninan, T., 
Morjaria, A. & Stephenson, T. (2007) Comparison of oral amoxicillin and intravenous 
benzyl penicillin for community acquired pneumonia in children (PIVOT trial): a 
multicentre pragmatic randomised controlled equivalence trial. Thorax, 62 (12), 1102-
1106. 
13. Van den Bruel, A., Thompson, M. J., Haj-Hassan, T., Stevens, R., Moll, H., 
Lakhanpaul, M. & Mant, D. (2011) Diagnostic value of laboratory tests in identifying 
serious infections in febrile children: systematic review. British Medical Journal, 342, 
d3082. 
14. Thompson, P. L., Spyridis, N., Sharland, M., Gilbert, R. E., Saxena, S., Long, P. 
F., Johnson, A. P. & Wong, I. C. (2009) Changes in clinical indications for community 
antibiotic prescribing for children in the UK from 1996 to 2006: will the new NICE 
prescribing guidance on upper respiratory tract infections just be ignored? Archives of 
Disease in Childhood, 94 (5), 337-340. 
15. Tan, T., Little, P. & Stokes, T. (2008) Antibiotic prescribing for self limiting 
respiratory tract infections in primary care: summary of NICE guidance. British Medical 
Journal, 337, a437. 
 
  253 
Table 1 Clinical features at presentation  
 2001 survey (n=711) [3] 2008 survey (n=542)   
Characteristics n (%) n (%) OR (95% CI) P-value 
Pre-admission antibiotics 214 (30.0) 119 (22.0) 0.7 (0.50 to 0.85) 0.001 
Triage temperature >38oC 333/702 (47.4) 266/531 (50.0) 1.1 (0.89 to 1.39) 0.358 
Oxygen saturation <93% 213/689 (31.0) 145/529 (27.4) 0.8 (0.66 to 1.08) 0.204 
Disease severity     
     Mild/moderate  293 (41.2) 259 (47.8) 1.3 (1.04 to 1.64) 0.022 
     Severe  418 (58.8) 283 (52.2) 0.8 (0.61 to 0.96)  0.023 
Chest radiographic findings     
     Lobar 145 (20.4) 162 (29.9) 0.6 (0.46 to 0.78) 0.0001 
     Patchy 436 (61.3) 296 (54.6) 0.8 (0.61 to 0.95) 0.019 
     Perihilar 130 (18.3) 67 (12.4) 1.6 (1.15 to 2.18) 0.006 
     Other infiltrates  – 17 (3.1)  – 
Pleural effusion 65 (9.0) 52 (9.6) 1.1 (0.72 to 1.55) 0.845 
OR, odds ratio; CI, confidence interval. 
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Figure Legend 
 
FIGURE 1 Survival curve showing probability of discharge from hospital in relation 
to duration of admission 
 
Abbreviations in figure 1:  
Solid line, probability of discharge from hospital; broken lines, 95% CIs  
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ABSTRACT 
We investigated prospectively the association of urinary pneumococcal antigen with 
pneumococcal pneumonia in children aged ≤16 years). Control urine samples were 
collected from children undergoing investigation of urinary tract infection. Urinary 
antigen was detected in more cases than controls (P=0.00003). Among cases with 
identified pneumococcal infections, 75% (15/20) had positive urinary antigen 
(P=0.000008). 
 
LETTER TO THE EDITOR 
Urinary pneumococcal antigen is a rapid non-invasive test which may indicate recent 
invasive pneumococcal infection (Elemraid et al., 2013) or carriage (Hamer et al., 
2002), and guide appropriate antibiotic therapy (Charkaluk et al., 2006; Neuman & 
Harper, 2003). We investigated the association of urinary pneumococcal antigen with 
pneumococcal infection in childhood pneumonia.  
 
A prospective aetiological study of childhood pneumonia was conducted from October 
2009 to March 2011. Enrolled cases were children aged ≤16 years with clinical and 
radiological features suggestive of pneumonia. Patients were resident in North East 
England (excluding Cumbria) who presented or were transferred to the paediatric 
services at the Great North Children’s Hospital (GNCH), the regional cardiothoracic 
centre at Freeman Hospital, Newcastle or the James Cook University Hospital, 
Middlesbrough. Exclusion criteria included clinical diagnosis of bronchiolitis, 
hospitalisation in the preceding three weeks or normal chest radiograph after formal 
reporting by a radiologist. For cases, informed written consent was obtained from 
parents as well as assent from older children. Control urine samples were collected from 
children who attended the paediatric renal service at the GNCH during March to May 
2010 for routine follow up or investigations of previous urinary tract infection. Controls 
had no clinical evidence of concurrent infectious illness and urine microscopy 
performed to exclude acute infection.  
 
Extensive microbiological and virological testing informed the aetiology of pneumonia 
using defined diagnostic criteria and positive results were classified as definite/probable 
or possible (online supplement). Urine samples were tested for pneumococcal antigen 
using Binax NOW (Inverness Medical Innovations Ltd, Galway, Ireland). Investigations 
were performed in the Microbiology Laboratory, Newcastle Hospitals NHS Trust and 
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the Health Protection Agency Public Health Laboratory Newcastle. Epi Info
TM
 7 was 
used for data analysis. Fisher’s exact test was used to evaluate group differences.  
 
A total of 160 children were enrolled with a median age of 2.6 years (56% males and 
69% aged <5 years). All of whom had at least one microbiological investigation 
performed. Control urine samples were collected from 122 children with a median age 
of 4.7 years (37% males and 52% aged <5 years). Urinary pneumococcal antigen was 
detected in 28.3% (30/106) of cases, compared to 7.4% (9/122) in controls (OR=0.2, 
95% CI 0.09–0.45, P=0.00003). Among those aged <5 years, the urine antigen was 
positive in 23.5% (16/68) cases and 9.5% (6/63) in controls (OR=0.3, 95% CI 0.12–
0.94, P=0.037). S. pneumoniae was the definite cause of pneumonia in 17.4% (24/138) 
of children; 15% (14/93) and 22.7% (10/44) tested among those aged < and ≥5 years 
respectively. Among those children with identified pneumococcal infections, 75% 
(15/20) had positive urinary pneumococcal antigen (OR=12.0, 95% CI 3.76–38.26, 
P=0.000008). 
 
Our study has shown that in children with radiologically confirmed pneumonia the 
urinary pneumococcal antigen is more likely to be positive than in healthy 
asymptomatic children. This indicates that positive urinary Binax test could be highly 
suggestive of this infection in healthy children including young age group who had no 
recent infections. Although previous findings showed poor utility of urine antigen test in 
distinguishing pneumococcal pneumonia from nasopharyngeal colonisation in children 
(Dominguez et al., 2003; Dowell et al., 2001), our findings showed significantly 
positive results of urinary pneumococcal antigen between children with pneumococcal 
infections and those with other causes pneumonia. Urinary pneumococcal antigen 
testing may be a useful investigation to help establish the diagnosis of invasive 
pneumococcal disease, particularly in low-resource countries where expensive PCR-
based assays are not readily available. Used in this way this test may also prove a useful 
tool in studies of the epidemiology of childhood pneumonia.       
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Abstract 
Pneumococcal serotype 1 was isolated from adult’s nasopharynx during a school 
outbreak with this infection. We therefore tested the hypothesis that parents may be 
involved in the transmission of this serotype in children with pneumonia. 212 parental 
nasopharyngeal swabs were obtained from 144 children with pneumonia. Serotype 1 
was identified in the parent of one child with invasive pneumococcal serotype 1 disease. 
This accumulating evidence warrants the hypothesis investigation in a larger 
community-based study. 
 
Letter to the Editor 
Asymptomatic carriage of Streptococcus pneumoniae is common in the human 
nasopharynx, but invasion of the mucosal barrier can lead to local or systemic 
infections.
1
 Transmission of pneumococcal carriage within the household and 
community is common, and is particularly prevalent in young children.
2
 Paediatric 
pneumococcal empyema has increased dramatically in many countries in recent years, 
and this problem has predominantly been related to infection with serotype 1.
3
 The 
mode of transmission of this serotype is uncertain as it does not frequently colonise the 
nasopharynx.
4
 We previously found serotype 1 in the nasopharynx of an adult during 
the investigation of a school outbreak of serotype 1 disease.
5
 We therefore tested the 
hypothesis that parents and family members may be involved in the transmission of this 
serotype in children with pneumonia. 
 
A prospective aetiological study of radiologically-confirmed pneumonia in children 
aged ≤16 years was conducted from October 2009 to March 2011.6 They were resident 
in North East England and admitted to the Great North Children’s Hospital, the regional 
cardiothoracic centre at Freeman Hospital, Newcastle or the James Cook Hospital, 
Middlesbrough. Informed written consents were obtained for children and parents 
participation. A nasopharyngeal swab (NPS) was collected from parents. Aliquots of 
NPS were inoculated into plates of Columbia agar (Oxoid) supplemented with 5% horse 
blood (CBA) and Oxoid brain-heart infusion broth with 10% serum (Oxoid). Broths 
were incubated overnight at 37°C and sub-cultured (10 µL) onto CBA plates for 
incubation at 37°C in 5% carbon dioxide for 48 hr. Isolates of S. pneumoniae and group 
A Streptococcus (GAS) were identified by standard methods including latex 
agglutination and API 32 STREP (bioMérieux) and stored in STGG medium (skim 
milk-tryptone-glucose-glycerol). 
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At least one parental NPS was obtained from 144 children with pneumonia (57% males, 
70% aged <5 years); 136 from mothers and 76 fathers. From parents, 212 NPSs were 
collected and four pathogens were isolated; one GAS and three S. pneumoniae. There 
were four cases of pneumonia whose parents had a positive swab culture. Firstly, a 13-
month-old who had GAS grown from the blood culture as well as mother’s NPS. 
Secondly, a 6.3-year-old who had S. pneumoniae serotype 1 isolated from blood culture 
and also mother’s NPS. Thirdly, a 20-month-old whom her father’s NPS grew non-
typeable pneumococcus. Fourthly, a 26-month-old with father’s NPS positive for S. 
pneumoniae but typing was not carried out. 
 
This is the first published study to investigate the parental pneumococcal 
nasopharyngeal carriage in a selected group of children with pneumonia in North East 
England. The established carriage rate was low. Although the findings are limited, they 
still provide information for future surveillance of pneumococcal carriage in our 
population. Limiting testing to parents might not fully reflect the complete pattern of 
pneumococcal carriage within the family. The finding of serotype 1 in the parent of one 
child with invasive serotype 1 disease in this series adds to our previous findings,
5
 and 
this hypothesis now warrants investigation in a larger community-based study.  
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